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ABSTRACT 
Maternal obesity is associated to increased fetal risk of obesity and other 
metabolic diseases. Human amniotic mesenchymal stem cells (hA-MSC) have not 
been characterized in obese women. The aim of this study was to isolate and 
compare hA-MSC immunophenotypes from obese (Ob-) and normal weight 
control (Co-) women to identify alterations possibly predisposing the foetus to 
obesity. We enrolled 16 Ob- and 7 Co-women at delivery (mean/SEM pre-
pregnancy BMI: 40.3/1.8 kg/m
2
 and 22.4/1.0 kg/m
2
, respectively). hA-MSCs were 
phenotyped by flow cytometry; several maternal and newborn clinical and 
biochemical parameters were also measured.  
The expression of membrane antigen CD13 was higher on Ob-hA-MSCs 
than on Co-hA-MSCs (P=0.0043). Also serum levels of CD13 at delivery were 
higher in Ob- versus Co-pregnant women and correlated with CD13 antigen 
expression on Ob-hA-MSCs (r
2
=0.84, P<0.0001). Adipogenesis induction 
experiments revealed that Ob-hA-MSCs had a higher adipogenic potential than 
Co-hA-MSCs as witnessed by higher PPARγ and aP2 mRNA levels (P=0.02 and 
P=0.03, respectively) at post-induction day 14 associated with an increase of 
CD13 mRNA from baseline to day 4 post-induction (P<0.05). Adipogenesis was 
similar in the two sets of hA-MSCs after CD13 silencing, whereas it was increased 
in Co-hA-MSCs after CD13 overexpression. Pretreatment of Co- and Ob-hA-
MSCs with IFN-γ (12.5 ng/mL) for 24 h induced upregulation of CD13 
expression.  
In conclusion, antigen CD13, by influencing the adipogenic potential of 
hA-MSCs could be an in-utero risk factor for obesity. Our data strengthen the 
hypothesis that high levels of serum and MSC CD13 are obesity markers.  
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BACKGROUND 
Epidemic Obesity and Definition   
Obesity is an epidemic health problem worldwide that affects virtually all 
age and socioeconomic groups and threatens to overwhelm both developed and 
developing countries. In 1995, there were an estimated 200 million obese adults 
worldwide and another 18 million under-five children classified as overweight. As 
of 2000, the number of obese adults has increased to over 300 million. Contrary to 
conventional wisdom, the obesity epidemic is not restricted only to industrialized 
societies but also in developing countries, when it is estimated that over 115 
million people suffer from obesity-related problems [WHO. Fact sheet No 311].  
Obesity causes morbidity and mortality associated with increased risk of 
cardiovascular disease, metabolic syndrome, and cancer [Maury et al. 2010, Gesta 
et al. 2006]. It is a multifactorial disease caused by a complex interaction between 
environmental, genetic and behavioral factors. The environment is likely the major 
contributor to the obesity epidemic. It is certain that obesity develops when there is 
an altered imbalance between energy intake and energy expenditure, but the 
underlying mechanism is poorly understood, even if it is known that both excess 
energy intake and decreased energy expenditure contributed in the obesity 
insurgence. In addition to environment, also genetic factors play an important role 
in the predisposition to obesity. In fact, it is known that gene mutations are 
responsible for monogenic or polygenic forms of obesity [Dang et al. 2010, 
Choquet and Meyre 2011]. 
The obesity is characterized by an increased body weight. The body mass 
index (BMI), defined as the weight in kilograms divided by the height in meters 
squared (kg/m
2
), is the more used index from the World Health Organization 
(WHO) for the definition of obesity grade. This classification provides that a 
person is overweight when the BMI is greater or equal to 25 and obese when the 
BMI is greater or equal to 30 [WHO. Fact sheet No 311]. Waist circumference can 
be used in combination with a BMI value to evaluate health risk for individuals 
[Mitchell et al. 2011].
The overweight and obesity consist in an adipose tissue expansion, 
increased adipocyte size and number, and increased macrophage infiltration that, 
together, lead to increased free fatty acid release, dysregulated secretion from 
adipocytes of a variety of adipokines, including adiponectin, leptin, resistin, and 
retinol binding protein 4 (RBP4), and increased release from resident macrophages 
of the inflammatory cytokines, tumor necrosis factor α (TNFα) and interleukin 6 
(IL6). Dysregulated secretion of these adipokines elicits a variety of adverse 
effects on numerous tissues including the hypothalamus, liver, skeletal muscle, 
pancreas, and vasculature [Harwood et al. 2012]. 
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Table 1: International Classification of adult underweight, overweight and obese according to 
BMI.
Classification BMI (kg/m²) 
Underweight <18.50 
Normal Range 18.50 - 24.99 
Overweight 25.00 
Obesity 30.00 
Type I 30.00 - 34-99 
Type II 35.00 - 39.99 
Type III 40.00 
Obesity in pregnancy 
The incidence of obesity and overweight is increasing worldwide also 
during pregnancy, in fact recent data show that ~30% of American women of 
reproductive age are obese and 8% have reached extreme obesity [Ogden et al. 
2006]. Maternal obesity is associated with adverse consequences both in mother 
and child. [Catalano et al. 2007, Huda et al. 2010]. The related risks include 
infertility, fetal anomalies, gestational hypertensive diseases, gestational diabetes, 
intrauterine fetal death, cesarean birth, macrosomia, and long-term risks of adult 
disease for the foetus. [Nodine et al. 2012] 
Normally, the pregnancy is characterized by marked increases in plasma 
lipid concentrations, due to the strong lipolytic activity, to meet the feto-placental 
and maternal demands of late gestation and lactation. In normal weight women the 
majority of fat is accumulated centrally in the subcutaneous compartment. Instead, 
obese women, who will have more saturated subcutaneous fat stores, tend to 
accumulate fat more centrally (visceral) than lean women, an observation which 
may reflect their more insulin-resistant state. Visceral adiposity, in pregnancy,  
appears to be strongly correlated with adverse metabolic outcomes in pregnancy 
including gestational diabetes mellitus, gestational hypertension and pre-eclampsia 
[Huda et al. 2010]. 
Furthermore, the hyperlipidemia of pregnancy is exaggerated in obesity with 
higher serum triglyceride and very low density lipoprotein cholesterol 
concentrations than those observed in lean women. Maternal obesity is also 
accompanied by alterations in glucose metabolism and by perturbations in 
inflammatory markers, adipokines and vascular dysfunction [Huda et al. 2010]. 
Interestingly, the mother, placenta and foetus interact to modulate fetal 
growth during pregnancy. Maternal obesity appears to induce modifications in 
adipose tissue and in placenta, in fact both showed to have increased expression of 
proinflammatory cytokines and a marked accumulation of a heterogeneous 
macrophage population. Additionally, placenta from obese women compared with 
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that from lean women demonstrated a significant increase in the expression of the 
placental lipoprotein lipase, leptin and TNF-. How this might impact placental 
function is not well established, however, the activation of phospholipase activity 
suggests that the inflammation may be one mechanism by which excess fat 
accumulates in obese neonates (Figure1). [Heerwagen et al. 2010]. 
The placenta maintains fetal homeostasis by carrying out a wide range of 
physiological functions. Therefore, placental perturbations, by affecting one or 
more aspects of placental structure and function, may determine long-term health 
outcomes into adulthood [Murphy et al. 2010]. For example, placental weight 
correlates with fetal weight, and since fetal growth is related to adult outcomes, 
placental weight and low birth weight could predict adult diseases as obesity, 
diabetes 2 and hypertension [Barker et al. 2005, Godfrey et al. 2002, Osmond et al. 
2000, Lewis et al. 2006]. In addition, changes in placental structure (thicker 
placental exchange barrier and increased placental vascular resistance) are directly 
involved in the fetal programming of cardiovascular diseases [Thornburg and 
Louey 2010]. The placenta could act as a nutrient sensor, in fact it could modify 
nutrient and hormone availability to foeto-placental tissues in relation to 
environmental conditions in a manner that maximises fetal growth [Jansson et al. 
2007]. Intrauterine growth retardation induced in animal models by a variety of 
methods (including over- and under-nutrition, isocalorific manipulation of the 
macro- and micro-nutrient content of the diet, maternal stress, hypoxemia, 
glucocorticoid administration, and restriction of uterine blood flow) has been 
shown to cause abnormalities in postnatal physiological functions [Fowden et al. 
2006, Fowden et al. 2006, McMillen et al. 2005]. The exaggerated inflammatory 
response demonstrated in the placenta during obesity appears have critical 
consequences for the short- and long-term programming of obesity. [Challier et al. 
2008]. The above observations led to the concept that adult disease can originate in 
utero as a result of changes in development during suboptimal intrauterine 
conditions that lead to permanent changes in tissue morphology and function - this 
process is called "intrauterine or fetal programming" [Fowden et al. 2008]. 
Fetal programming involves developmental plasticity that allows the foetus 
to respond to present or predicted environmental influences, by adaptive 
mechanisms (that is, by changing its metabolism and growth). The process 
whereby a developing individual makes permanent changes to its physiology or 
anatomy that could be advantageous in later life, is known as "predictive adaptive 
response". However, the predictive adaptive response of the foetus may be 
inappropriate if postnatal conditions are different from those expected, and this 
mismatch may result in adult life disease [Gluckman et al. 2008]. Because the 
placenta is the active interface between the maternal and fetal blood circulations, 
perturbation in the maternal compartment, such as altered nutrition, cytokine and 
hormonal levels and reduced utero-placental blood flow must be transmitted across 
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the placenta in order to affect the foetus. The mechanisms linking an adverse 
intrauterine environment to adult disease are under investigation, however studies 
in animal models have shown that epigenetic regulation of fetal genes in key 
metabolic pathways is an important mechanism in fetal programming [Pham et al. 
2003, Lillycrop et al. 2005]. 
Figure 1. Maternal metabolism undergoes profound adjustments to meet the nutrient needs 
of the developing foetus. Obesity is associated with adipose tissue inflammation and systemic 
insulin resistance, resulting in increased adipose tissue lipolysis and hepatic very-low-density 
lipoprotein (VLDL) secretion. When combined with pregnancy, this leads to an increase in 
maternal circulating lipids with advancing gestation. Subsequent hydrolysis of maternal 
triglycerides (TGs) by placental lipoprotein lipase (LPL) and increased free fatty acid (FFA) uptake 
and transport by the placenta results in excess lipid transfer to the developing foetus. This increase 
in fetal lipid exposure may impact the liver, skeletal muscle, adipose tissue, brain, and pancreas to 
increase the risk for metabolic disease in childhood. MCP-1, monocyte chemotractant protein-1; 
CM, chylomicron; NAFLD, nonalcoholic fatty liver disease. [Heerwagen et al. 2010] 
Placenta  
The placenta is the site of exchange between mother and foetus and 
regulates fetal growth. Placenta, fetal membranes and umbilical cord are fetal 
adnexa. The term placenta is discoid in shape with a diameter from 15 cm to 20 
cm and a thickness from 2 cm to 3 cm. The fetal component, which includes the 
amniotic and chorionic fetal membranes, separates the foetus from the 
endometrium. The amniochorionic membrane forms the outer limits of the sac that 
encloses the foetus, while the innermost layer of the sac is the amniotic membrane 
(AM). The AM thickness varies from 0.02 mm to 0.5 mm and consists of an 
epithelial monolayer, a thick basement membrane, and an avascular stroma (Figure 
2). 
The innermost layer, nearest to the foetus, is the amniotic epithelium and 
consists of a single layer of cells uniformly arranged on the basement membrane. 
The basement membrane is one of the thickest membranes found in all human 
tissue. The support provided to the foetus by the basement membrane throughout 
gestation stands testimony to the structural integrity of this remarkable membrane. 
The compact layer of stromal matrix adjacent to the basement membrane forms the 
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main fibrous skeleton of the AM. The collagens of the compact layer are secreted 
by mesenchymal cells situated in the fibroblast layer. Interstitial collagens (types I 
and III) predominate and form parallel bundles that maintain the mechanical 
integrity of AM. Collagens type V and VI form filamentous connections between 
interstitial collagens and the epithelial basement membrane. The intermediate layer 
(spongy layer or zona spongiosa) of the stromal matrix sits adjacent to the 
chorionic membrane. Its abundant content of proteoglycans and glycoproteins 
produces a spongy appearance in histologic preparations, and it contains a 
nonfibrillar meshwork of mostly type III collagen. The spongy layer is loosely 
connected to the chorionic membrane; hence, the AM is easily separated from the 
chorion by means of blunt dissection.
Figure 2: Schematic presentation of the structure of the fetal membrane at term. The Extracellular 
matrix components of each layer are shown [NiKnejad et al. 2008]. 
AM is not just a simple avascular structure (no blood vessels or nerves); it 
has multiple metabolic functions such as the transport by diffusion out of the
amniotic fluid and/or from the underlining decidua of water and soluble materials 
and the production of bioactive factors, including vasoactive peptides, growth 
factors and cytokines [NiKnejad et al. 2008]. The AM provides protection to the 
developing embryo against desiccation and an environment of suspension, in 
which the embryo can grow free from pressures of the structures that surround its 
body. Furthermore, the presence of interstitial collagens, one of the important 
properties of AM is its resistance to proteolytic factors [NiKnejad et al. 2008]. AM 
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also has an important role during birth, because the substances produced by the 
epithelium of AM allow the initiation and maintenance of uterine contractility. 
Placental Stem Cells 
Mesenchymal stem cells (MSCs) have been thoroughly studied for over 40 
years, ever since Friedenstein’s initial description in 1966 [Klein and Fauza 2011]. 
MSCs were initially identified in the bone marrow of adult subjects. The plasticity, 
self-renewal and multi-lineage potential of MSCs have generated growing interest 
in their use in a constantly expanding variety of experimental regenerative 
applications [Klein and Fauza 2011]. A number of reports have identified diverse 
sources of MSCs, i.e. fat tissue, placental, amniotic fluid [Mihu et al. 2008]. 
Furthermore, it is accepted that these cells have the capacity to regenerate 
mesenchymal tissue and blood cells.  
Human placenta, besides playing a fundamental and essential role in fetal 
development, nutrition, and tolerance, may also represent a reserve of 
progenitor/stem cells. Four regions of fetal placenta can be distinguished: amniotic 
epithelial, amniotic mesenchymal, chorionic mesenchymal, and chorionic 
trophoblastic. From these regions can be isolated: human amniotic epithelial cells 
(hA-EC), human amniotic mesenchymal stromal cells (hA-MSC), human 
chorionic mesenchymal stromal cells (hC-MSC), and human chorionic 
trophoblastic cells (hC-TC) [Parolini et al. 2008]. Cells from each layer 
demonstrate variable plasticity. Because of their plasticity, the term stem cell has 
been used in the literature to describe a number of cells isolated from placenta. 
Self renewal and “hierarchy,” which are normally considered a hallmark of stem 
cells, have not been clearly demonstrated in the different placenta derived cell 
types, and therefore the term “stem cell” at this time is not always appropriate. 
However, it may be interesting to mention that recent reports propose an 
alternative stem cell concept whereby plasticity is essential to define stemness, and 
self renewal and hierarchy are optional characteristics [Parolini et al. 2008]. 
According to criteria recently proposed by Dominici et al. for bone 
marrow-derived mesenchymal stromal cells [Parolini et al. 2008], mesenchymal 
cells isolated from fetal membranes should be termed mesenchymal stromal cells 
(hA-MSC and hC-MSC). Minimal criteria for defining hA-MSC are as follows: 
• Adherence to plastic; 
• Formation of fibroblast colony-forming units; 
• A specific pattern of surface antigen expression (CD90+, CD73+, CD105+ and 
CD45-, CD34-, CD14-, HLA-DR-); 
• Differentiation potential toward one or more lineages, including osteogenic, 
adipogenic, chondrogenic, and vascular/endothelial;
• Fetal origin. 
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AIMS OF THE STUDY 
Experimental observations and epidemiological studies led to the concept 
that adult disease can originate in utero as a result of changes in development 
during suboptimal intrauterine conditions that lead to permanent changes in tissue 
morphology and function - this process is called "intrauterine or fetal 
programming". 
The aim of this study is to determine whether human amniotic 
mesenchymal stromal cells (hA-MSCs) of obese pregnant women, at delivery, 
differed from those of control pregnant women in term of clinical/biochemical 
parameters, cell morphology, immunophenotypes, adipogenic differentiation 
potential.  
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MATERIALS AND METHODS
Patients and controls 
Sixteen Ob- (age range: 26–39 years) and seven Co-pregnant women, (age 
range: 26–38 years), pre-pregnancy BMI (mean/SEM) 40.3/1.8 kg/m2 and 22.4/1.0 
kg/m
2
, respectively and thirty-two not pregnant women (16 obese and 16 normal 
weight, BMI >30 kg/m
2 
and <25 kg/m
2
, respectively) were recruited at the 
Dipartimento of Neuroscienze and Scienze Riproduttive and 
Odontostomatologiche, University of Naples Federico II. The clinical, personal 
and family history of the 23 women was recorded during a medical interview 
conducted by an expert upon hospitalization. Data relative to each pregnancy 
follow-up and delivery were also recorded. The general characteristics of the 
newborn and clinical data (birth weight, length, head circumference, Apgar score) 
were recorded at birth. 
Sample collection  
Two fasting peripheral blood samples were collected in the morning from 
not pregnant women and from Ob- and Co-pregnant women, immediately before 
delivery. One sample was used for DNA extraction, whereas the other was 
centrifuged at 2,500 rpm for 15 min and serum was stored at -80°C until further 
processing. At delivery, placentas were collected by C-section from each enrolled 
women and immediately processed. 
All patients and controls gave their informed consent to the study and both parents 
gave consent for their newborns. The study was performed according to the 
Helsinki II Declaration and was approved by the Ethics Committee of our Faculty.  
Biochemical evaluations  
The main serum biochemical parameters were evaluated by routine assays. 
Leptin and adiponectin were measured in maternal serum with Luminex xMAP 
Technology on a BioRad Multiplex Suspension Array System (Bio-Rad, Hemel 
Hempstead, Herts., UK), according to the manufacturer’s instructions. The ratio 
leptin/adiponectin (L/A) was also calculated.  
Aminopeptidase N/CD13 ELISA assay  
Aminopeptidase N (APN)/CD13 serum levels were measured by ELISA 
(Life Science, Houston). Briefly, the microtiter plate was pre-coated with a 
specific anti-CD13 antibody. Standards or samples were then added to the 
appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody 
preparation specific for CD13. Next, avidin conjugated to horseradish peroxidase 
was added to each microplate well and incubated for 15 min at room temperature. 
A TMB substrate solution (3,3´,5,5´-tetramethylbenzidine) was then added to each 
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well. The enzyme-substrate reaction was terminated by the addition of a sulphuric 
acid solution and the color change was measured spectrophotometrically at a 
wavelength of 450 nm. The amount of CD13 in each sample was determined by 
comparing the absorbance of the sample to a standard curve. 
Cell isolation from placenta tissue 
Placentas were collected and immediately processed, according to Parolini 
et al. [2008]. After removal of the maternal decidua, the amnion was manually 
separated from the chorion and extensively washed 5 times in 40 mL of 
phosphate-buffered saline (PBS) containing 100 U/mL penicillin, 100 g/mL 
streptomycin and 250 g/mL amphotericin B (all from Sigma-Aldrich) after which 
it was mechanically minced into small pieces [Parolini et al. 2008]. Amnion 
fragments were digested overnight at 4°C in ACCUMAX
®
 reagent (Innovative 
Cell Technology, San Diego), a combination of DNase, protease and 
collagenolytic enzymes [Grant et al. 2005], containing 100 U/mL penicillin, 100 
g/mL streptomycin and 250 g/mL amphotericin B. The next day, digestion 
enzymes were inactivated with complete culture medium constituted by low 
glucose D-MEM (Sigma-Aldrich) supplemented with 10% of heat-inactivated 
bovine serum (FBS), 1% of non-essential amino acids and 2% of Ultraglutamine 
(all from Lonza, Basel, Switzerland). After centrifugation at 300g for 10 min, cell 
pellets and digested tissue fragments were seeded in a cell culture dish (BD 
Falcon, New York) in complete culture medium and incubated at 37°C in 5% CO2. 
One week later, digested tissue pieces were removed from the dish and discarded, 
and isolated cells formed distinct fibroblast colony-forming units. When the 
colonies reached 70% confluence, they were washed with PBS and detached with 
trypsin/EDTA (Sigma-Aldrich), counted and reseeded in complete medium for 
expansion at a concentration of about 5,000/cm
2 
[Parolini et al. 2008]. 
Cell preparation  
hA-MSCs were expanded for several passages. Absence of mycoplasma 
contamination was assessed as described previously [Mariotti et al. 2008]. The 
population-doubling level was calculated for each subcultivation with the 
following equation: population doubling= [log10 (NH)  log10 (NI)]/ log10 (2), 
where NI is the cell inoculum number and NH is cell harvest number [Bieback et 
al. 2004]. The increase in population doubling was added to the population 
doubling levels of the previous passages to yield the cumulative population 
doubling level. When 70%-80% confluent cultures reached about 4 population 
doublings they were detached with trypsin/EDTA, resuspended in PBS with 10% 
FBS, and processed for flow cytometry, and DNA, RNA and protein extraction. 
Cellular viability was assessed by both Trypan blue dye exclusion and the analysis 
of light scatter proprieties in flow cytometry, and it was never lower than 90%.  
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DNA typing  
The fetal origin of both amnion and hA-MSCs was verified by DNA 
typing. Genomic DNA was extracted from the mother’s peripheral blood, from 
amnion samples and from hA-MSCs using the Nucleon BACC2 extraction kit 
(Illustra DNA Extraction Kit BACC2, GE Healthcare, Calfont St. Giles, Bucks., 
UK). DNA concentration was evaluated using the NanoDrop® ND-1000 UV-Vis 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). Genomic DNA (1 
ng) was amplified in a final volume of 25 µL using the AmpFlSTR® Identifiler™ 
PCR Amplification Kit (Applied Biosystems, Foster City). The AmpFlSTR® 
Identifiler™ PCR Amplification Kit is a short tandem repeat (STR) multiplex 
assay that amplifies 15 repeat loci and the Amelogenin gender determining marker 
in a single PCR amplification using a primer set labeled with four fluorescent 
molecules. The amplification was performed with the GeneAmp PCR System 
9700 (Applied Biosystems) instrument. PCR products were then analyzed by 
capillary electrophoresis on the ABI Prism 3130 Genetic Analyzer (Applied 
Biosystems) together with an allelic ladder that contained all the most common 
alleles for the analyzed loci that were present in Caucasian populations and both a 
negative- and a positive-quality control sample. Typically, 1µL of each sample 
was diluted in 18.7µL of deionized formamide; each sample was supplemented 
with 0.3µL of an internal size standard (LIZ 500 Applied Biosystems) labeled with 
an additional fluorophore. The samples were denatured at 95 °C for 4 min and then 
placed in the auto sampler tray (maximum of 96 samples) on the ABI Prism 3130 
for automatic injection in the capillaries. The data were analyzed by Gene Mapper 
Software (Applied Biosystems). 
Immunophenotyping of hA-MSCs by flow cytometry 
We analyzed the expression of 38 hematopoietic, mesenchymal, 
endothelial, epithelial and no-lineage membrane antigens on the surface of hA-
MSCs by four-color flow cytometry (Table 2). 
The antibody cocktails contained in each tube are detailed in Table 3. All 
monoclonal antibodies (MoAbs) were from Becton Dickinson (San Jose) except 
anti-CD338-APC, which was from R&D (Minneapolis), anti-CD-133-PE and anti-
CD271-APC MoAbs, which were from Milenyi Biotec (Bergisch Gladbach, 
Germany). For all antibody staining experiments, at least 1x10
5 
hA-MSCs isolated 
from each placenta sample were incubated at 4°C for 20 min with the appropriate 
amount of MoAbs, washed twice with PBS and finally analyzed with an 
unmodified Becton-Dickinson FACSCanto II flow cytometer (Becton-Dickinson, 
San Jose), that was set up according to published guidelines [Perfetto et al. 2006]. 
For each sample the respective control was prepared in order to determine the 
level of background cellular autofluorescence without antibody staining. 
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CaliBRITE beads (Becton-Dickinson, catalog no. 340486) were used as 
quality controls across the study as described elsewhere [Lmoreaux et al. 2006, 
Maeker et al. 2006], according to the manufacturer’s instructions. Daily control of 
CaliBRITE intensity showed no change in instrument sensitivity throughout the 
study. The relative voltage range for each detector was assessed una tantum using 
the “eight-peak” technology (Rainbow Calibration Particles, Becton-Dickinson, 
catalog no. 559123) at the beginning of the study. 
Compensation was set in the FACS-DiVa (Becton-Dickinson) software, and 
compensated samples were analyzed. Samples were acquired immediately after 
staining using the FACSCanto II instrument, and at least 10,000 events were 
recorded for each monoclonal combination. Levels of CD antigen expression were 
displayed as median fluorescence intensity (MFI). The FACS-DiVa software 
(Becton-Dickinson) was used for cytometric analysis. 
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Table 2. Surface immunophenotypic profile investigated in hA-MSCs by flow cytometry 
Fluorochrome CD Antigen Other Names Molecular Weigth (kDa) Cell expression Function 
FITC CD9 Tspan-29 24-26 Platelets, pre-B, activated T 
Adhesion, migration, platelet 
activation 
APC CD10 CALLA 100 B/T precursors, stromal cells Endopeptidase 
PE CD13 APN 150 
Granulocytes, monocytes and their 
precursors, endothelial, epithelial 
cells, mesenchymal stem cells 
Metalloproteinase 
PE CD14 LPS-R 53-55 Monocytes, macrophages Receptor for LPS/LPB complex  
APC CD15 Lewis X _ 
Granulocyte, monocyte, epithelial 
cells 
Cell adhesion 
PE CD16 FCRIIIa 50-65 Neutrophils, NK, macrophages 
Low affinity with FC receptor, 
mediates phagocytosis 
APC CD19 Bgp95 95 B, not on plasma cells Signal transduction
FITC CD26 DPP IV 110 Mature thymocytes, T, B, NK cells Exoprotease, costimulation  
APC CD28 Tp44 44 
Most T, thymocyte,NK and plasma 
cells 
Costimulation 
APC CD29 VLA 1-chain 130 
T, B, Granulocytes, monocytes, 
fibroblast, endothelial, NK , platelet 
Adhesion activation, 
embryogenesis and development 
FITC CD31 PECAM-1 130-140 
Monocytes, platelets, granulocytes 
and endothelial cells 
Cell adhesion 
APC CD33 My9 67 
Monocytes, granulocytes, masocytes 
and myeloid progenitors 
Cell adhesion 
APC CD34 My10 105-120 
Hematopoietic stem cells and 
progenitors, endothelial cells 
Cell adhesion 
APC CD36 Platelet GPIV 85 
Platelets, monocytes, macrophages, 
endothelial cells, erythroid precursors 
Adhesion and phagocytosis 
FITC CD40 Bp50 48 
Monocytes, macrophage, B, 
endothelial, fibroblast cells, 
keratinocytes 
Costimulation to B cells, growth, 
differentiation and isotype 
switching 
APC CD44 H-CAM 90 
Leukocytes, erythrocytes and 
epithelial cells 
Rolling, homing and aggregation 
Per Cp CD45 LCA 180-220 
hematopoietic cells, except 
erythrocyte and platelet 
Critical for T and B cell receptor 
mediated activation 
FITC CD47 IAP I 50-55 
Hematopoietic, epithelial, endothelial, 
brain mesenchymal cells 
 Adhesion 
FITC CD49d VLA-4 150 
B and T , monocytes, eosinophils, 
basophils, NK, dendritic cells 
Adhesion, migration, homing, 
activation 
APC CD54 ICAM-1 80-114 
Epithelial and endothelial cells 
monocyte. Low on resting 
lymphocyte, upregulate on activated 
T cell activation 
PE CD56 NCAM 175-220 
Neural,  tumors, embryonic tissue, 
NK 
Homophilic and heterophilic 
adhesion 
PE CD58 LFA-3 40-70 
Leucocyte, erythrocyte, epithelial 
endothelial cells and fibroblast 
Costimulation 
FITC CD71 Transferrin recepor 95 Reticulocytes, erythroid precursor 
Controls iron intake during cell 
proliferation 
APC CD81 TAPA-1 26 B, T, monocytes, endothelial cells Signal transduction 
FITC CD90 Thy-1 25-35 
Hematopoietic stem cells, neurons, 
mesenchymal stem cells 
Inhibition of hematopoietic stem 
cells and neurons differentiation 
PE CD99 MIC2 32 
Leucocyte, NK, monocytes, 
endothelial and epithelial cells 
Leucocyte migration, T cell 
activation,cell adhesion 
PE CD105 Endoglin 90 
Endothelia and  mesenchymal stem 
cells erythroid precursors, monocytes  
Angiogenesis, modulates cellular 
response to TGF1 
PE CD117 c-kit 145 
Hematopoietic stem cells and 
progenitors 
Crucial for hematopoietic stem 
cells  
PE CD133 Prominin-1 120 
Hematopoietic stem cell, endothelial, 
epithelial and neural precursors 
Unknown function, stem cells 
marker 
PE CD151 PETA-3 32 
Endothelial and epithelial cells, 
megakaryocye, platelets 
Adhesion 
PE CD166 ALCAM 100-105 
Neurons, activated T cells, epithelial 
cells, MSC 
Adhesion, T cells activation 
PE CD200 OX-2 33 
B , activated T, Thymocytes, neurons 
endothelium 
Down regulatory signal for 
myeloid cell functions 
FITC CD243 MDR-1 170 
Stem cells, multi drug resistant 
tumours 
Influences the up-take, 
distribution, elimination of drugs  
APC CD271 NGFR 75 
Neurons, stromal and dendritic 
follicular cells 
Low affinity for NGF receptor 
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APC CD324 E-cadherin 120 Epithelial, keratinocytes, platelet Adhesion, growth, differentiation 
APC CD338 ABCG-2 72 
Hematopoietic stem cells, liver, 
kidney, intestine, side population of 
stem cells 
Absorbition and excretion of 
xenobiotics 
FITC HLA-ABC Class I MHC 46 All nucleated cells and platelets Antigen presentation   
FITC HLA-DR Class II MHC 30 
B cells, monocytes, myeloid 
progenitors, activated T and dendritic 
cells  
Antigen presentation   
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Table 3: Antibody cocktails contained in each tube for hA-MSCs immunophenotyping by flow 
cytometry.
Tube CD Antigens 
1 Anti-CD90-FITC (clone 5E10)/anti-CD13-PE (clone L138)/anti-CD45-PerCP (clone 
2D1)/anti-CD34-APC (clone 8G12) 
2  Anti-HLA-DR-FITC (clone l243)/anti-CD14-PE (clone MP9)/anti-CD45-PerCP (clone 
2D1)/anti-CD29-APC (clone MAR4) 
3 Anti-CD243-FITC (clone17F9)/anti-CD56-PE (clone MY31)/anti-CD45-PerCP (clone 
2D1)/anti-CD44-APC (clone g44-26) 
4  Anti-CD324-FITC (clone 36)/anti-CD105-PE (clone 266)/anti-CD45-PerCP (clone 
2D1)/anti-CD338-APC (clone 5D3) 
5 Anti-CD71-FITC (clone L01.1)/anti-CD56-PE (clone MY31)/anti-CD45-PerCP (clone 
2D1)/anti-CD28-APC (clone CD28.2) 
6 Anti-CD90-FITC (clone 5E10)/anti-CD200-PE (clone MRC OX-104)/anti- CD45-PerCP 
(clone 2D1)/anti-CD33-APC (clone p67.6) 
7  Anti-HLA-A,B,C-FITC (clone G46-2.6)/anti-CD16-PE (clone B73.1)/anti-CD45-PerCP 
(clone 2D1)/anti-CD36-APC (clone CB38 NL07) 
8 Anti-CD90-FITC (clone 5E10)/anti-CD200-PE (clone MRC OX-104)/anti-CD45-PerCP 
(clone 2D1)/anti-CD34-APC (clone 8G12) 
9 Anti-CD9-FITC (clone ML-13)/anti-CD133-PE (clone ACC133/1)/anti-CD45-PerCP 
(clone 2D1)/anti-CD10-APC (clone HI10A) 
10 Anti-49d-FITC (clone R1-2)/anti-CD58-PE (clone L306.4)/anti-CD45-PerCP (clone 
2D1)/anti-CD271-APC (clone ME20.4-1.H4) 
11 Anti-CD31-FITC (clone WM59)/anti-CD117-PE (clone 104D2)/anti-CD45-PerCP (clone 
2D1)/anti-CD81-APC (clone JS-81) 
12 Anti-CD26-FITC (clone L272)/anti-CD99-PE (clone TU12)/anti-CD45-PerCP (clone 
2D1)/anti-CD19-APC (clone SJ25C1) 
13 Anti-CD40-FITC (clone 53C)/anti-CD151-PE (clone 14A.H1)/anti-CD45-PerCP (clone 
2D1)/anti-CD54-APC (clone HA58) 
14 Anti-CD47-FITC (clone B6H12)/anti-CD166-PE (clone 3A6)/anti-CD45-PerCP (clone 
2D1)/anti-CD15-APC (clone HI98) 
FITC: fluorescein isothiocyanat; PE: R-Phycoerythrin; PerCP: peridinin-chlorophyll-protein 
complex; APC: allophycocyanin  
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Differentiation potential towards the adipogenic lineage 
hA-MSCs were cultured in low glucose D-MEM (Sigma-Aldrich) 
supplemented with 10% of FBS, 2% of ultraglutamine and 1% of non-essential 
amino acids at 37°C in 5% CO2 (all from Lonza, Basel, Switzerland). The cells 
were passaged twice before the addition of differentiation medium composed of 
DMEM with the addition of 10% FBS, 1 µM dexamethasone, 0.5 mM 3-isobutyl-
1-methylxhantine, 200 µM indomethacin and 10 µg/mL insulin. Media were 
changed every two days and cells were either stained or collected for RNA 
extraction. 
CD13 RNA interference and overexpression 
hA-MSCs plated at a density of 5,000 cells/cm
2
 were transfected using 20 
µL Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen, 
Paisley, UK) with 8 µg short hairpin RNAs (shRNAs)-expressing plasmids (Open 
Biosystem, Huntsville) or with 8 µg pCMV-Sport 6 Vector (Invitrogen, Paisley, 
UK), to silence or to overexpress CD13 mRNA, respectively. Transfected cells 
were induced to differentiate towards the adipogenic lineage up to 4 days.  
Effect of IFN-γ on the expression of CD13 on the surface of hA-MSCs 
The expression of CD13 on the surface of Co- and of Ob-hA-MSCs was 
measured after exposure of cells to 0.8 and 12.5 ng/mL IFN-γ at 37° C for 24 h, 
using untreated Co- and Ob-hA-MSCs as controls. At the end of incubation, the 
cells were harvested by trypsin, washed in PBS, counted, and adjusted to the same 
concentrations of 1x10
5 
hA-MSCs. Subsequently, their immunophenotype was 
examined by flow cytometry.
Adipocyte staining 
After 14 days of differentiation, the adipocyte cultures were stained for 
lipid droplets, which are an index of differentiation. The cells were washed in PBS 
and fixed in 10% formalin for 1 h. Then they were washed in PBS and the lipids 
were stained for 15 min with Oil-red-O prepared by mixing vigorously three parts 
of stock solution (0.5% Oil-red-O in 98% isopropanol) with two parts of water and 
then eliminating undissolved particles with a 0.4-µm filter. Cells were then washed 
with water and the number of adipocytes was evaluated with a microscope. 
Relative lipid levels were assessed by redissolving the Oil-Red-O present in 
stained cells in 98% isopropanol and then determining absorbance at 550 nm. 
RNA isolation 
Total RNA was purified from hA-MSCs isolated from term placentas of 
Co- and of Ob-pregnant women using the mirVanaTM miRNA isolation kit 
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(Ambion, Austin) and its concentration was evaluated with the NanoDrop® ND-
1000 UV-Vis spectrophotometer (NanoDrop Technologies, Wilmington).  
Quantitative real-time polymerase chain reaction (qRT-PCR) of mRNAs 
Real-time quantitative PCR was carried out on the Applied Biosystems 
7900HT Sequence Detection system (Applied Biosystems). cDNAs were 
synthesized from 2 µg of total RNA using hexamer random primers and M-MuLV 
Reverse Transcriptase (New England BioLabs, Beverly). The PCR reaction was 
performed in a 20 µL final volume containing cDNA, 1X SYBR Green PCR mix, 
10 µM of each specific primer. Table 4 lists the oligonucleotide primers used for 
PCR of selected genes: peroxisome proliferator-activated receptor gamma 
(PPARγ), CD13, protein homologous to myelin P2 (aP2), and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The PCR conditions for reverse transcription 
were: stage 1: 50°C, 2 min; stage 2: 95°C, 10 min; stage 3: 95°C, 15 s; 60°C, 1 
min/40 cycles; and stage 4: 95°C, 15 s; 60°C, 1 min. Levels of target genes were 
quantified using specific oligonucleotide primers and normalized for GAPDH 
expression. 
Table 4: PCR oligonucleotide primers  
Statistical analysis  
The parameters investigated were expressed as mean and standard error of 
the mean (SEM) (parametric distributions) or as median value and 25
th
 and 75
th
percentiles (non parametric distributions). Student’s “t” and Mann-Whitney tests 
were used to compare parametric and nonparametric data, respectively. P values 
<0.05 were considered statistically significant. Correlation analysis was performed 
with the SPSS package for Windows (ver. 18; SPSS Inc., Headquarters, Chicago). 
Primers Sequence 
CD13 Forward GGACAGCGAGTTCGAGGGGGA 
CD13 Reverse AGTGGCCACCACCTTTCTGACA 
PPARγ  Forward CATACATAAAGTCCTTCCCGCTG 
PPARγ Reverse CGAATGGTGATTTGTCTGTTGTCT 
aP2 Forward GGTGGTGGAATGCGTCATG 
aP2 Reverse CAACGTCCCTTGGCTTATGC 
GAPDH Forward GTCGGAGTCAACGGATTTGG 
GAPDH Reverse AAAAGCAGCCCTGGTGACC 
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RESULTS 
The clinical and biochemical characteristics of the mothers and their 
newborns are reported in Table 5 (A and B, respectively). Weight gain was lower 
(P=0.025) and diastolic blood pressure was higher (P=0.039) in Ob- than in Co-
pregnant women. Both leptin concentration (P<0.0001) and the L/A ratio 
(P<0.0001) were higher in Ob- than in Co-pregnant women at delivery. Biometric 
characteristics did not differ significantly between Ob- and Co-newborns. 
Table 5. Clinical and biochemical characteristics of obese (Ob-) and normal weight control (Co-) 
pregnant women at delivery and their newborns. 
Data are expressed as mean (SEM) (parametric distributions). 
Statistically significant difference at “t Student” test: 
a
 P<0.0001, 
b
 P =0.025 and 
c
 P=0.039. 
d
 median value and 25
th
 – 75
th
 percentiles (non parametric distributions). 
A     
Mother’s parameters Ob-pregnant women (n=16) Co-pregnant women (n=7) 
Age (years) 32.6 (0.9) 30.7 (1.5) 
Weight (kg)
a
 110.1 (5.4) 65.2 (3.6) 
Height (m) 163.3(1.6) 169.0 (1.7) 
BMI pre-pregnancy (kg/m
2
) 
a
 40.3 (1.8) 22.4 (1.0) 
Weight gain in pregnancy 
b
 8.4 (1.3) 14.3 (1.8) 
Systolic blood pressure (mmHg)  124.3 (2.7) 117.1 (5.1) 
Diastolic blood pressure (mmHg) 
c
 82.5 (2.2) 74.2 (2.0) 
Frequency cardiac. 79.6 (1.7) 79.0 (3.7) 
Gestational age 38.4 (0.3) 38.7 (0.2) 
Glucose (mmol/L)  4.3 (0.1) 4.0 (0.3) 
Total cholesterol (mmol/L) 6.9 (0.4) 7.3 (0.1) 
Triglycerides (mmol/L) 2.8 (0.2) 2.3 (0.3) 
AST (U/L) 15
d
  (12.2-26.5
d
) 14.8 (0.7) 
ALT (U/L) 13
d
 (9.2-17.7
d
) 12.1 (1.1) 
ALP (U/L) 124.2 (11.1) 115.0 (12.6) 
GGT (U/L) 11.0 (1.7) 8.8 (1.5) 
Leptin (L)(ng/ml) 
a
 38.5 (2.2) 15.2 (3.3) 
Adiponectin (A)(mg/ml) 6.0 (0.7) 7.5 (1.4) 
L/A 
a
7.7 (0.6) 2.6 (0.5) 
B     
Newborn’s parameters Ob-newborns (n=16) Co-newborns (n=7) 
Birth weight (kg) 3162 (0.1)  3401 (0.1) 
Length (cm) 49.6 (0.7)  50.8 (0.7) 
Head circumference (cm) 34.0 (0.4)  34.8 (0.3) 
Apgar 1’ 7.0
d
 (7.0-8.0 
d
) 7.8 (0.2) 
Apgar 5’ 9.0
d
 (8.5-9.0 
d
) 8.7 (0.1) 
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Isolation of hA-MSCs 
We isolated hA-MSCs from the mesenchymal layer of amniotic 
membranes obtained from our Ob- and Co-pregnant women at delivery. The fetal 
origin of all isolated hA-MSCs was confirmed by STR typing of DNA of the 
mother and of the hA-MSCs. Mycoplasma contamination of cultures was checked 
and excluded (data not shown). All isolated hA-MSCs were characterized by a 
high proliferation potential and collected after 4 population doublings. 
Morphologically, cultured Ob- and Co-hA-MSCs showed a similar fibroblastic-
like morphology after 4 population doublings (Figure 3).  
Figure 3: Morphology of hA-MSCs isolated from pregnant women. A similar fibroblastic-like 
shape was observed in three Ob- (A) and three Co- (B) hA-MSCs  after 4 population doublings by 
phase contrast light microscopy (magnification 10x). 
Immunophenotyping of placental hA-MSCs 
The antigenic mosaic displayed by Ob- and Co-hA-MSCs is shown in 
Table 5. Seventeen of the 38 antigens investigated were not expressed on the 
surface of hA-MSCs (hematopoietic antigens: CD14, CD15, CD16, CD19, CD28, 
CD33, CD34, CD45 and CD117; the endothelial marker PECAM-1/CD31; and no-
lineage markers: thrombospondin receptor/CD36, Bp50/CD40, Prominin-
1/CD133, MDR-1/CD243, NGFR/CD271, ABCG-2/CD338 and HLA-DR). Both 
Ob- and Co-hA-MSCs were positive for the following mesenchymal markers: 
CD9, CD10, CD13, CD26, CD29, CD44, CD47, CD49d, CD54, CD56, CD58, 
CD71, CD81, CD90, CD99, CD105, CD151, CD166, CD200 and HLA-ABC. A 
very weak positivity for the epithelial antigen E-cadherin/CD324 was also 
observed. Interestingly, CD13 expression was significantly higher in Ob-hA-
MSCs than in Co-hA-MSCs, i.e., MFI: 9,802.0 and 3,950.0, respectively 
(P=0.0043) (Table 6 and Figure 4A).  
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Table 6. Immunophenotyping of hA-MSCs isolated from obese (Ob-) and control (Co-) pregnant 
women 
Ob-hA-MSCs  Co-hA-MSCs  
Not expressed antigens  
Fluorochrome  Antigen  MFI 25th-75th Percentiles MFI 25th-75th  Percentiles p Value
FITC CD31 364.0 278.3-511.3  306.5 286.8-368.0 0.3254 
  CD40 444.0 336.5-568.3 388.0 357.0-457.8 0.4824 
  CD243 363.0 292.3-528.3 307.5 274.0-378.3 0.2061 
  HLA-DR 355.0 283.8-530.0 297.0 272.5-374.8 0.2415 
  NC  325.0 250.0-516.3  279.0 218.8-418.8 0.4260 
PE CD14 166.5 125.5-197.8  134.5 124.5-157.8 0.2815 
  CD16 36.0 11.5-71.7 65.5 50.5-72.0 0.2407 
  CD117 142.5 109.5-189.3 121.0 116.0-176.8 0.6065 
  CD133 95.5 80.5-112.8 87.5 76.50-110.5 0.5423 
  NC  115.5 91.75-181.5  102.5 93.25-135.0 0.5427 
APC CD15 122.0 91.0-283.5  122.5 80.0-162.5 0.6065 
  CD36 241.5 194.0-388.5 200.5 145.5-267.3 0.2417 
  CD271 208.0 127.0-296.5 170.0 127.5-233.3 0.6065 
  CD338 200.5 106.5-373.0 107.5 101.8-146.8 0.1223 
  CD19 192.0 154.0-241.3 144.0 120.3-182.2 0,1012 
  CD28 91.0 5.2-228.5 85.5 0-122.0 0.1722 
  CD33 147.5 10.0-189.5 105.5 90.0-132.3 0.6734 
  CD34  186.5 105.0-241.5 133.0 17.5-206.0 0.4250 
  NC  169.0 99.5-244.8  92.0 64.0-204.0 0.2061 
Per Cp CD45 215.5 133.8-251.3  167.0 146.0-208.0 0.6734 
  NC  305.0 252.0-483.3  288.5 261.3-348.8 0.7431 
Expressed antigens  
Fluorochrome  Antigen  MFI 25th-75th Percentiles MFI 25th-75th  Percentiles p Value
FITC CD9 3,538.0 2,172.0-6,871.0  2,156.0 1,743.0-3,495.0 0.2417 
  CD26 1,287.0 651.8-3,235.0 1,308.0 742.3-1,920.0 0.9626 
  CD47 1,339.0 980.3-2,312.0 1,287.0 1,106.0-1,344.0 0.4824 
  CD49d 1,185.0 946.8-1,393.0 941.0 708.3-1,140.0 0.2061 
  CD71 1,271.0 796.5-2,147.0 1,093.0 897.0-1,538.0 0.7431 
  CD90 37,140.0 22,740.0-52,690.0 36,210.0 21,640.0-50,260.0 0.8149 
  CD324 517.0 463.0-551.0 436.0 375.0-545.0 0.3027 
  HLA-ABC 9,363.0 4,033.0-14,180.0  5,424.0 3,987.0-6,539.0 0.1223 
 NC  325.0 250.0-516.3  279.0 218.8-418.8 0.4260 
PE CD13 9,802.0 6,786.0-17,130.0  3,950.0 3,634.0-4,961.0 0.0043
a
  CD56 496.0 293.8-711.0 528.0 151.0-1,048.0 0.9626 
  CD58 2,432.0 1,723.0-2,792.0 2,009.0 1,798.0-2,459.0 0.5427 
  CD99 405.0 296.5-586.3 467.5 360.5-651.0 0.3736 
  CD105 652.0 507.0-1,329.0 790.0 746.0-847.8 0.6734 
  CD151 16,010.0 10,970.0-21,430.0 19,410.0 11,090.0-23,690.0 0.4260 
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  CD166 5,215.0 3,551.0-7,382.0 4,634.0 3,962.0-5,608.0 0.6734 
 CD200 722.5 205.8-1,699.0  1,137.0 631.5-1,444.0 0.3736 
  NC  115.5 91.7-181.5  102.5 93.2-135.0 0.5427 
APC CD10 1,247.0 999.3-2,319.0  1,890.0 1,122.0-3,031.0 0.3736 
  CD29  45,150.0 25,130.0-54,610.0 24,240.0 17,660.0-40,000.0 0.0832 
  CD44 11,440.0 8,186.0-16,290.0 7,259.0 6,613.0-9,753.0 0.0678 
  CD54 9,910.0 5,404.0-14,260.0 10,660.0 9,486.0-24,670.0 0.3736 
 CD81  31,240.0 19,110.0-55,050.0  38,890.0 24,500.0-44,640.0 0.8149 
  NC  169.0 99.5-244.8  92.0 64.0-204.0 0.2061 
MFI, Median fluorescence intensity; a significant P value at Mann-Whitney test. 
APN/CD13 serum levels  
We first measured baseline serum levels of CD13 in a small group of not 
pregnant obese and normal weight women and found significantly higher values in 
the obese subset (medians: 6.00 U/L and 1.00 U/L, P=0.02, respectively) (Figure 
4B). The serum levels of CD13 were also significantly higher in Ob- than in Co-
pregnant women at delivery (medians: 24.00 U/L and 7 U/L, P=0.002, 
respectively), (Fiure 4B). CD13 levels were significantly higher in Ob- and Co-
pregnant women than in not pregnant Ob- and Co-women: 4 (P=0.0003) and 7 
times (P=0.003), respectively. Furthermore, in Ob-pregnant women, serum CD13 
levels were significantly correlated to the levels of CD13 on the surface of hA-
MSCs (r2=0.84; P<0.0001) (Figure 4C).  
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Figure 4. Expression of CD13 antigen in control (Co-) and obese (Ob-) pregnant women. A: 
Ob-hA-MSCs expressed significantly higher amounts (at Mann-Whitney test) of CD13 surface 
antigen compared with Co-hA-MSCs (P=0.0043); B: serum levels of CD13 were significantly 
higher in Ob-women than in Co-women at delivery (P=0.002); C: Serum CD13 levels were 
correlated with CD13 surface expression levels in Ob-pregnant women (r
2
=0,84; P<0.0001). The 
box plots provide a vertical view of the data expressed as median, 25th percentile, 75th percentile 
and extreme values. 
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CD13 hA-MSC expression during adipogenic differentiation 
To investigate whether CD13 is involved in adipogenesis, we cultured 
Ob- and Co-hA-MSCs for 14 days in adipogenic induction medium. At the end of 
incubation, the adipogenic potential, as measured by PPARγ and aP2 mRNA 
levels, was higher in Ob- than in Co-hA-MSCs. In fact, as shown in Figure 5A and 
5B, the mean RQs at day 14 were  0.04 and 0.02, respectively for PPAR (P=0.02), 
and 0.02 and 0.01, respectively for aP2 (P=0.03). The same results were obtained 
by Oil-Red staining, this latter being higher incorporated in Ob- than in Co-hA-
MSCs at day 14 of differentiation [Abs (550 nm) = 0.6 and 0.4, P=0.02, 
respectively] (Figure 5C).  
Figure 5. Adipogenic potential in Ob-hA-MSCs and in Co-hA-MSCs. The statistically 
significant higher mRNA expression levels of PPARγ (P=0.02) (A) and of aP2 (P=0.03) (B) 
measured 14 days  after the adipogenic induction, indicated increased adipogenesis in Ob- versus 
Co-hA-MSCs. The higher adipogenesis in Ob- than in Co-hA-MSCs was also confirmed by Oil-
Red staining [Abs (550 nm) = 0.6 and 0.4, P=0.02, respectively] (C). 
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During adipogenesis, CD13 mRNA levels remained higher in Ob- than in 
Co-hA-MSCs. When we silenced CD13 by shRNA in Ob-hA-MSCs we observed 
a switch-off of CD13 mRNA expression, as evaluated by RT-PCR (Figure 6A), 
and at the same time, the adipogenic potential of these cells did not differ from that 
observed in Co-hA-MSCs, as shown by similar PPARγ mRNA levels measured in 
silenced Ob-hA-MSCs and in Co-hA-MSCs (P=0.71) (Figure 6B). In agreement to 
CD13 involvement in adipogenesis, we overexpressed CD13 in Co-hA-MSCs 
(mRNA CD13 mean RQ=7.23) and observed at day 4 of differentiation higher 
PPARγ mRNA levels in treated (mean RQ=0.015) than in untreated (mean 
RQ=0.001) Co-hA-MSCs. 
Figure 6. Role of CD13 in adipogenesis. (A) mRNA expression levels of CD13 were significantly 
higher in Ob- than in Co-hA-MSCs at day 0 (P=0.02), day 2 (P=0.02) and day 4 (P=0.04) when 
cultured with adipogenic medium. CD13 mRNA expression was switched-off in Ob-hA-MSCs 
after CD13 silencing with shRNA. (B) At day 4 of adipogenic induction, PPARγ mRNA 
expression levels that were significantly higher in Ob-hA-MSCs than in Co-hA-MSCs (P=0.01), 
decreased to the levels detected in Co-hA-MSCs after CD13 silencing (P=0.71), which indicates 
that CD13 enhances adipogenesis in hA-MSCs. n.s.: not statistically significant difference. 
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Upregulation of CD13 hA-MSC expression by IFN-γ
We next evaluated if CD13 expression could be upregulated in h-MSCs 
by IFN-γ as occurs in murine cellular models [Gabrilovac et al. 2011]. To this aim, 
we treated the Co- and Ob-hA-MSCs with 0.8 ng/mL or 12.5 ng/mL IFN-γ for 24 
h. We found that CD13 expression was significantly higher on membranes of Co-
hA-MSCs treated with 12.5 ng/mL IFN-γ (P=0.04) than in untreated cells, whereas 
there was a slight, not significant, increase in treated Ob-hA-MSCs (Figure 7) 
versus the untreated counterpart cells. Our results suggest that high levels of INF-
γ drive the up-regulation of CD13 expression in Co-h-MSCs, whereas its effect on 
Ob-h-MSCs CD13 expression during obesity is ambiguous. 
Figure 7. CD13 expression on Co- and Ob-hA-MSCs treated with 0.8 ng/mL or 12.5 ng/mL 
IFN-γ for 24 h. CD13 expression significantly increased on membrane of Co-hA-MSCs treated 
with 12.5 ng/mL IFN-γ (P=0.04) versus untreated, whereas slight even if not significant increase 
was observed in treated Ob-hA-MSCs respect to untreated.  
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DISCUSSION 
Human amniotic membrane is a readily available source of abundant fetal 
mesenchymal stem cells that are free from ethical concerns [Miki et al. 2005]. hA-
MSCs isolated from normal weight healthy women at delivery have been 
characterized [Parolini et al. 2008, Marioti et al. 2008, Roubelakis et al. 2012], but, 
to our knowledge, the features of hA-MSCs from obese women are largely 
unknown. In this study, we used flow cytometry to characterize hA-MSCs isolated 
at delivery from two groups of women: pre pregnancy normal weight and pre 
pregnancy severely obese women. The immunophenotypic characterization 
confirmed the mesenchymal origin of the isolated cells [Delorme et al. 2008]. In 
particular, the distribution of CD56 was in agreement with the placental origin of 
the isolated hA-MSCs. In fact, this marker is absent from bone marrow [Mariotti 
et al. 2008] and from adipose tissue-derived mesenchymal stem cells [Gronthos et 
al. 2001]. Similarly, the endothelial marker PECAM-1/CD31, and the 
hematopoietic antigens CD14, CD15, CD16, CD19, CD28, CD33, CD34, CD45 
and CD117 were absent from isolated Ob- and Co-hA-MSCs. Staining for the E-
cadherin/CD324 epithelial antigen was very weak in our Ob- and Co-hA-MSC 
preparations; the co-expression of epithelial, albeit at a low intensity, and 
mesenchymal markers on our h-AMSCs was in agreement with previous findings 
[Sakuragawa et al. 2004, Soncini et al. 2007]. Overall, our results are similar to 
those reported by Parolini et al. [2008] and/or Roubelakis et al. [2012] for the 
expressed (CD49d, CD90, HLA-ABC, CD13, CD56, CD105, CD166, CD10, 
CD29, CD44 and CD54) and not expressed (PECAM-1/CD31, HLA-DR, CD14, 
Prominin-1/CD133, NGFR/CD271, CD34 and CD45) membrane-bound antigens 
in hA-MSCs. We found that the Ob-hA-MSC immunophenotype is characterized 
by a significantly higher expression of the APN/CD13 antigen with respect to the 
Co-hA-MSC phenotype.  
Type II metalloprotease APN/CD13 (EC. 3.4.11.2) is a heavily 
glycosylated membrane-bound protein (~ 960aa, ~ 150 kDA) that is encoded by 
the human ANPEP gene located in chromosome 15 (q25-q26) [Watt and Willard 
1990]. This protein exists also in a soluble form. CD13 is a ubiquitous enzyme 
present in a wide variety of human organs, tissues and cell types including 
placenta, human umbilical vein endothelial cells, monocytes, lymphocytes T, 
hypothalamus, and epithelial intestinal cells [Osorio et al. 2008]. It has various 
mechanisms of action: enzymatic cleavage of peptides, endocytosis and signal 
transduction [Luan et al. 2007]. CD13 is involved in inflammation, cellular 
differentiation and proliferation, apoptosis, cell adhesion and motility [Osorio et 
al. 2008]. Dysregulated expression of membrane and/or soluble forms of CD13 
has been observed in many diseases [Luan et al. 2007], but until now it has never 
been associated with obesity. Here, we provide the first demonstration that the 
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CD13 antigen is increased on hA-MSCs during obesity and could play a role in 
adipogenesis. In fact, we first detected a higher adipogenic potential in Ob- than in 
Co-hA-MSCs after 14 days of adipogenic differentiation and then observed that 
the adipogenic potential of Ob-hA-MSCs was comparable to that of Co-hA-MSCs 
after CD13 silencing. Conversely, the adipogenic potential increased in Co-hA-
MSCs after CD13 overexpression. Further, we showed evidence that INFγ
upregulated CD13 expression also in Co-hA-MSCs.  
Intriguingly, in Ob-pregnant women CD13 serum levels at delivery were 
higher than in Co-pregnant women and correlated with CD13 surface Ob-hA-MSC 
expression (r
2
=0.89, P<0.0001) supporting that the placenta is the major source of 
the high CD13 levels measured in maternal serum [Kawai et al. 2009]. Further 
increased biochemical markers in Ob-maternal serum at delivery were leptin 
concentration and the L/A ratio. This finding confirms the concept that these two 
parameters are obesity risk markers [Labruna et al. 2009, Labruna et al. 2011]. 
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CONCLUSIONS
The prevalence of obesity has increased in the world, in both men and 
women. Considering the prevalence of obese in women in reproductive age and 
that the pregnancy itself induces a state of insulin resistance and inflammation, 
maternal obesity may be the most common health risk for the developing foetus. 
Since the placenta is the main interface between foetus and mother, the study of 
changes in this tissue may help you understand how  it regulates intrauterine 
development and modulates adaptive responses to suboptimal in utero conditions. 
We succeeded in isolating and culturing mesenchymal cells from amnion. 
The fibroblast morphology of these cells in culture is characteristic to 
mesenchymal cells. The immunophenotypic characterization showed an antigen 
expressed differently in hA-MSCs isolated from obese compared to controls, and 
that this antigen, CD13, influences the adipogenic potential of these cells. CD13 
could be an in-utero risk factor for obesity. Furthermore, we find this antigen 
increased in the serum of obese women. 
Together, our data strengthen the hypothesis that high serum CD13 and 
mesenchymal stem cell CD13 are markers of obesity. 
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 INTRODUCTION 
 Celiac disease (CD) is a chronic disorder caused by the ingestion 
of the gluten prolamines of wheat, rye, and barley in genetically 
predisposed individuals ( 1 ). Although the pathogenesis of CD is 
not fully understood, it has been clearly shown that in the CD 
mucosa, gluten peptides deamidated by tissue transglutaminase 
trigger CD4  +  T cells to produce large amounts of interferon 
gamma (IFN- γ ) ( 2,3 ). " is mucosal in# ammatory response 
leads to a profound remodeling of the intestinal mucosa, up to 
complete villous atrophy. However, the spectrum of histological 
changes is quite wide and there are CD patients, indicated as 
potential CD, who present the genetic and immunological 
features of CD, but whose small-bowel mucosa is architecturally 
normal ( 4,5 ). 
 In addition to the " 1 response, it has highlighted the funda-
mental role of other pro-in# ammatory cytokines, such as inter-
leukin 15 (IL-15) ( 6 ). More recently, also other cytokines, such 
as IL-21, bridging innate, and adaptive immunity, have been 
found to have an important role ( 6 ). In these studies, an impor-
tant contribution to the comprehension of the mechanisms 
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leading to disease has come from  in vitro studies based on 
 ex vivo organ cultures of intestinal biopsies taken from CD 
patients on a gluten-free diet ( 6 ). 
 CD can be seen as the result of a break of tolerance in which 
the regulation of the mucosal immune response to dietary gliadin 
might be altered. Several Tregs subsets are involved in immune tole-
rance ( 7 ). " ese subsets include natural Treg cells expressing the 
forkhead box P3 (Foxp3) transcription factor that is able to main-
tain tolerance to self components, and antigen-induced Foxp3  + 
cells that are able to contain the activity of " 1 and " 17 cells ( 8 ). 
Tr1 cells that downregulate naive and memory T-cell responses 
upon local secretion of IL-10 and transforming growth factor- β 
(TGF- β ) ( 9 ), and TGF β -producing Treg cells (" 3) ( 10 ) are other 
important subsets that possess regulatory properties. Many factors 
may interfere with the function of Treg cells. For CD, it is relevant 
to know that IL-15, largely expressed in the CD mucosa, interferes 
with immune regulation, functioning on TGF- β 1 activity, thus 
contributing to the loss of intestinal homeostasis and promoting 
chronic in# ammation ( 11 ). Nevertheless, concomitantly with this 
pro-in# ammatory response, high amount of the anti-in# ammatory 
cytokines IL-10 and IL-4 are also produced in the untreated CD 
intestinal mucosa ( 12 ). " is apparent paradoxical milieu of both 
pro-in# ammatory and suppressive cytokines strongly suggests 
that regulatory mechanisms might operate to counterbalance 
the gliadin-triggered, abnormal immune activation in untreated 
mucosa ( 13 ). Our recent studies have revealed that the treatment 
with IL-10 of small intestinal mucosa from CD patients in remis-
sion prevents the massive immune activation induced by gliadin 
challenge ( 14 ). Moreover, we have observed that celiac intestinal 
mucosa harbors a subset of Treg cells, Tr1 cells, which, through the 
release of both IL-10 and TGF- β , inhibit the pathogenic response 
to  in vitro gliadin challenge ( 15 ). Although Tr1 cells, identi$ ed in 
CD, have some properties similar to that of Treg cells, they do not 
express Foxp3 ( 16 ). " is suggests that they are functionally distinct 
and may represent another level of regulation of the in# ammatory 
response. Several studies have found that the number of Foxp3  + 
T cells is signi$ cantly increased in the small intestinal mucosa with 
active CD ( 17 – 19 ). Futhermore, although the functional activity 
of circulating CD4  +  CD25  +  T cells from CD patients has been 
recently investigated ( 20 – 22 ), the suppressive capacity relative to 
their intestinal counterparts has never been reported. 
 " e aim of our study was to investigate the presence of Foxp3 
cells in the celiac small intestinal mucosa and their correlation 
with the disease state by combined immunohistochemistry and 
# ow cytometry (FACS)  ex vivo analysis. Furthermore, we used an 
 in vitro organ culture to investigate the induction of Foxp3 by 
gluten. Finally, we evaluated the functional capacity of intestinal 
Treg cells from celiac patients, and the e% ects that IL-15 exerts on 
their suppressive function. 
 METHODS 
 Patients and controls 
 Biopsy specimens were obtained from the distal duodenum of 25 
untreated CD patients (seven male and eighteen female patients; 
median age, 29 years; range 17 – 54). " ey were snap-frozen in liquid 
nitrogen or immediately processed. Diagnosis was based on typical 
mucosal lesions with crypt cell hyperplasia and total villous atrophy. 
All untreated CD patients were positive for serum anti-endomy-
sial antibodies. Duodenal biopsy samples were also obtained from 
15 treated CD patients (seven male and eight female patients; 
median age 35 years; range 21 – 51), who were in clinical and his-
tological remission, and negative for anti-endomysial antibod-
ies. Finally, 10 non-celiac individuals (six male and four female 
patients; median age 41 years; range 25 – 57) with normal intes-
tinal mucosa and negative serology for anti-endomysial were 
recruited. Functional studies were performed on both intesti-
nal CD4  +  CD25  +  T cells, isolated from biopsy samples of nine 
untreated CD patients, and on peripheral blood CD4  +  CD25  + 
T cells, puri$ ed from $ ve untreated CD patients and four non-CD 
controls. " e study received approval from a local ethics commit-
tee (Hospital Moscati, Avellino, Italy). 
 Immunohistochemistry 
 Acetone-$ xed sections (5  µ m), from biopsy samples that were 
not cultured or a& er culture, were individually incubated for 1  h 
with mouse monoclonal antibodies (see  Supplementary Table 1 
online), followed by incubation (20  min) in the dark with rabbit 
anti-mouse tetramethyl-rhodamine isothiocyanate-conjugated 
(Vector 1:200) antibodies. Costaining experiments were set up 
by mixing rat anti-human Foxp3 with mouse anti-CD3, -CD8, or 
-CD4, and incubating the cryosections individually for 1  h with 
each single mixture. A& er incubation with primary antibodies, 
the cryosections were incubated with a mixture of goat anti-rat 
tetramethyl-rhodamine isothiocyanate-conjugated antibody and 
horse anti-mouse # uorescein isothiocyanate-conjugated anti-
body for 30  min. Finally, all the sections were counterstained with 
ToPro-3 (Molecular Probes, Leiden, " e Netherlands), mounted in 
phosphate-bu% ered saline:glycerol (1:1), and imaged with a Leica 
SP confocal microscope (Heidelberg, Germany). Non-immune 
mouse immunoglobulins were used as isotype controls of primary 
antibodies. " e density of cells expressing Foxp3 in the lamina 
propria was evaluated within a total area of 1  mm 2 of lamina pro-
pria. Slides were analyzed by two observers who were blinded. 
 Organ culture 
 " e mucosal specimens were cultured as described elsewhere ( 22 ). 
Brie# y, biopsy samples taken from 10 patients with inactive CD 
and from six control patients were placed on iron grids, with the 
mucosal face upwards in the central well of an organ culture dish. 
Cultures were prepared with or without the addition of 1  mg / ml of 
peptic – tryptic digest (Frazer III fraction) of gliadin (PT-gliadin; 
Sigma, St Louis, MO), and were placed in a tight container with 
95 % O 
2
 / 5 % CO 
2
 at 37  ° C, at 1 bar. A& er 24  h of culture, the tissue 
was embedded in Optimal Cutting Temperature and snap-frozen 
in liquid nitrogen. 
 Ex vivo cytofl uorimetric analysis 
 Mucosal explants from nine healthy donors, nine CD patients 
and four gluten-free diet, either following 24  h of gliadin chal-
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lenge or freshly processed, were digested with collagenase-A. 
Immediately a& er the digestion, the cells were passed through 
a cell strainer (40  µ m Nylon, Becton Dickinson (BD), Bedford, 
MA) and isolated from mucosal explants. A total of 5 – 10 × 10 4 
cells obtained from fresh biopsy  samples were washed in phos-
phate-bu% ered saline and labelled with a pre-titrated optimal 
dilution of each # uorochrome- conjugated mouse monoclonal 
anti bodies against surface antigens (see  Supplementary Table 1 
online). Appropriate isotype-matched control antibodies (BD) 
were included in all experiments.  Intracellular cytokine produc-
tion was detected by using a triple-staining technique and by FACS 
analysis. Brie# y, a& er washing twice with phosphate-bu% ered 
saline, cells were $ xed and permeabilized with Cyto$ x / cytoperm 
(BD), according to the manufacturer ’ s instructions, followed by 
staining with # uorescein isothiocyanate (FITC)-anti-Foxp3 anti-
body (PCH101; eBioscience, San Diego, CA) in permeabilization 
bu% er. Cells were then analyzed by a # ow cytometer (FACSCalibur 
and CellQuest So& ware, BD), using a live gate set around viable lym-
phocytes based on their forward-scatter / side-scatter characteristics. 
 IL-15 receptor- α surface expression (IL-15R α ) was evaluated 
by incubating peripheral blood mononuclear cells (PBMCs) with 
optimal concentration of phycoerythrin-conjugated mouse mAb 
against CD4 (BD Pharmingen, San Jose, CA), phycoerythrin-Cy5-
conjugated mAb against CD25 (BD Pharmingen), anti-IL-15R α 
goat IgG (R & D System, Minneapolis, MN, USA and Alexa Fluo 
488, R & D System), and donkey anti-goat as a secondary mAb 
(R & D System). Cells were also incubated with the respective 
mouse isotype controls. A& er two washings, the cells were $ xed 
with 2 % paraformaldehyde and analyzed by # ow cytometry. 
 Purifi cation of T cell subsets 
 Autologous PBMCs isolated by heparinized blood obtained from 
patients with active CD and healthy donors were puri$ ed by 
density-gradient centrifugation (Ficoll, MP Biomedicals, LLC, 
Solon, OH). However, freshly isolated mucosal cells were proc-
essed from intestinal mucosal explants a& er collagenase digestion. 
CD4  +  CD25  +  T cells and CD4  +  CD25  −  T cells were separated 
using the Dynabeads Regulatory CD4  +  CD25  +  T cell kit (Dynal-
Biothec, AS, Oslo, Norway). In the $ rst step, CD4  +  cells were sep-
arated by negative selection, using the Antibody Mix Human CD4 
(Dynal-Biothec, AS, Oslo, Norway). In the second step, Depletion 
MyOne Dynabeads (Dynal-Biothec, AS, Oslo, Norway) was added 
to remove the non-CD4 cells. In the third step, Dynabeads CD25 
(Dynal-Biothec, AS, Oslo, Norway) was added to CD4  +  T cells to 
capture the CD4  +  CD25  +  T cells and the remaining fraction was 
used as CD4  +  CD25  −  T cells. In the last step, Dynabeads CD25 
was removed from the cells. All puri$ cation steps were performed 
according to the manufacturer ’ s instructions and collected cells 
were found to be   >  95 % pure by # ow cytometry. 
 Suppression assay 
 " e CD4  +  CD25  +  (Treg) and CD4  +  CD25  −  responder T cells 
(Tresp) were cultured, respectively, at di% erent ratios in the sup-
pression experiments (1:1, 1:0.5, 1:0.25, 1:0.125, 1:0). Cells were 
cultured (1 – 2 × 10 4 cells / well) in U-bottom 96-well plates with 
RPMI medium supplemented with 2-m M L -glutamine, 100-U / ml 
penicillin, 100- µ g streptomycin, and 10 % fetal bovine serum. Cells 
were stimulated for 3 days in the presence of Treg suppression 
Inspector (Miltenyi Biotec, Bergisch Gladbach, Germany) that 
consists of Anti-Biotin MACSi Bead Particles that are pre-loaded 
with biotinylated CD2, CD3, and CD28 antibodies. As additional 
control, Tresp cells were cultured alone with and without the Treg 
suppression Inspector (Miltenyi Biotec) and Treg cells were cul-
tured alone with Treg suppression Inspector (Miltenyi Biotec). 
Furthermore, the cocultured Tresp / Treg cells were stimulated 
with 10-ng / ml of IL-15 (R & D System). On the last day,  3 H-thy-
midine (1  uCi / well; Amersham-Pharmacia Biotec, Uppsala, 
Sweden) was added to the cultures and incubated for 16  h. Radio-
activity was assessed with a  β -counter (1600 TP, Hewlet Packard 
California, San Francisco, CA, USA). Percentage proliferation 
was determined as (cpm incorporated in the coculture) / (cpm of 
responder population alone) × 100 % . Percentage of inhibition was 
calculated as (1  −  number of cells in coculture that divide / number 
of responder cells that divide) × 100. 
 Cytokine assay 
 At the end of the cell culture, supernatants were collected and ana-
lyzed for the content of IFN- γ by enzyme-linked immunosorbent 
assay. Brie# y, 96-well plates (Immunoplate MaxiSorp, Nunc, Merel-
beke, Belgium) were coated by incubating with anti-human IFN- γ 
monoclonal antibody (Endogen) overnight at 4  ° C. A& er washing, 
wells were blocked by incubation with phosphate-bu% ered saline 
a b c
 Figure 1 .  Phenotyping of forkhead box P3 (Foxp3  +  ) cells on jejunal biopsy samples from untreated celiac disease (CD). Immunofl uorescence costaining 
experiments revealed that all the Foxp3  +  cells were CD3  +  ( a ), CD4  +  ( b ), and CD8  −  ( c ). Pink indicates the Foxp3 molecule staining, green indicates the 
CD3, CD4 and CD8 molecule staining, and blue indicates the nuclei counterstaining by using ToPro-3. Original magnifi cation:  × 40. 
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 Intestinal Regulatory T Cells and Celiac Disease 
solution containing 2 % bovine serum albumin. Supernatants were 
added and incubated for 1  h at room temperature. A& er two washes, 
the wells were incubated with biotinylated anti-human IFN- γ 
monoclonal antibody (Endogen) for 30  min at room temperature. 
Finally, the wells were incubated with streptavidin-horseradish 
peroxidase (BD Pharmingen) and then was added 100  µ l of TMB 
(3,3 ′ ,5,5 ′ -tetramethylbenzidine; Sigma) , a chromogenic substrate 
for horseradish peroxidase. Absorbances were read on an enzyme-
linked immunosorbent assay reader at 450  nm. 
 Statistical analysis 
 Data are presented as mean values ± s.d.; paired two-tailed Student ’ s 
 t- test was used to calculate  P -values within the same individuals 
and unpaired two-tailed Student ’ s- t test was used to calculate 
 P -values between study groups.  P -values   <  0.05 were considered 
statistically signi$ cant. 
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 Figure 2 .  Increased CD4  +  CD25  +  forkhead box P3 (Foxp3  +  ) intestinal T cells in untreated celiac disease (CD) patients as compared with treated-CD and 
non-CD control. Freshly isolated human intestinal cells were collected, stained, and analyzed by fl ow cytometry, as described in Methods, and assessed 
by a FACSCalibur (BD). Upper panel, representative dot plot from one experiment from non-CD control, treated-CD, and untreated-CD intestinal cells each 
is shown. Lymphocytes gated on forward- and side-scatter properties to exclude dead and / or granular cells, representative gates of CD4 populations are 
shown. Dot plot of Foxp3  +  CD25  +  are gated on CD4  +  cells. Foxp3  +  staining was performed after cell permeabilization. Lower panel, the mean percentages 
of the intestinal whole Foxp3   +   CD25   +   T cells in total CD4   +   cells isolated from non-CD control patients ( n  =  9), untreated patients ( n  =  9), and treated patients 
( n  =  4) was presented in each scatter plot. Horizontal bars represent mean values.  * * * P  <  0.0001 comparing the non-CD control vs. untreated-CD patients. 
 RESULTS 
 Increased expression of Foxp3 T cells in untreated CD mucosa 
 To localize the anatomical site of cells expressing Foxp3, we per-
formed immunohistochemical analysis of untreated CD, treated 
CD, and non-CD control duodenal sections, using a mouse anti-
human Foxp3 antibody. In untreated CD, the number of cells / mm 2 
of lamina propria expressing the transcription factor Foxp3  +  was 
signi$ cantly higher (mean ± s.d.: 91 ± 24) in comparison with treated 
CD (8 ± 2,  P  <  0.001) and non-CD controls (6 ± 3,  P  <  0.001; see  Supple-
mentary Figure 1 online upper panel online). Foxp3 cells exhibit a 
nuclear localization in positive cells (see  Supplementary Figure 1 
online lower panel). " ose cells were not found in the epithelium 
layer, but only in the lamina propria, particularly in the subepi-
thelial compartment (see  Supplementary Figure 1 online lower 
panel). No signi$ cant di% erences were noted in the number of 
Foxp3  +  cells in biopsy samples of treated CD in comparison with 
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 Foxp3  +  cell expansion in treated-CD biopsy samples cultured 
with gliadin 
 An  in vitro gliadin-challenge system was used, which reproduces 
many features of the mucosal immune response that occurs in the 
established celiac lesion ( 23 ). In the lamina propria of treated-
CD biopsy specimens cultured in the presence of PT gliadin, the 
number of cells / mm 2 expressing Foxp3 (16 ± 9) was signi$ cantly 
higher ( P  <  0.01) than in those cultured in medium alone (6 ± 4; 
 Figure 3 , upper le&  panel). By contrast, no statistically signi$ -
cant di% erences were noted in the number of Foxp3  +  cells, when 
biopsy samples obtained from non-CD controls were cultured in 
the presence of PT-gliadin (5 ± 1), compared with those cultured 
in medium alone (5 ± 2;  Figure 3 , upper le&  panel). As seen in 
uncultured biopsy samples taken from untreated CD, Foxp3  + 
cells in PT-gliadin-challenged mucosa were not found in the epi-
thelium layer, but were found only in the lamina propria, mainly 
localized beneath the epithelium ( Figure 3 , upper right panel). 
biopsy samples of non-CD controls (see  Supplementary Figure 1 
online upper panel). We next explored the phenotype of Foxp3  + 
cells, with antibodies to CD3, CD4, and CD8, by costaining experi-
ments. Herein, we demonstrated that all the intestinal Foxp3  + 
cells, in untreated CD, treated CD, and non-CD control duodenal 
sections, expressed a CD3  +  CD4  +  double-positive phenotype 
( Figure 1a, b ), whereas CD8  +  T cells expressing Foxp3 were not 
found ( Figure 1c ). 
 FACS con$ rmed the $ ndings obtained by immunohistochemis-
try. Speci$ cally, we analyzed the frequency of Foxp3  +  CD25  +  cells 
in a CD4  +  population. As shown in  Figure 2 , the percentage of 
Foxp3  +  CD25  +  CD4  +  cells was signi$ cantly higher in untreated 
celiac patients (mean ± s.d.: 14.1 ± 2.7 % ) compared with treated CD 
patients (8.9 ± 3.4 % ,  P  <  0,01) and non-CD controls (6.8 ± 2.4 % , 
 P  <  0,001;  Figure 2 ). No signi$ cant di% erences were noted in the 
percentage of Foxp3  +  CD25  +  CD4  +  cells in treated CD in com-
parison with non-CD controls ( Figure 2 ). 
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 Figure 3 .  PT-gliadin challenge increased Foxp3  +  cells in the jejunal biopsy specimens from treated-celiac disease (CD) patients. Upper left panel, number 
of forkhead box P3 (Foxp3) cells analyzed by immunohistochemistry, in mucosal explants from non-CD controls and treated CD cultured  in vitro with 
medium alone or with PT-gliadin. Foxp3  +  cells were counted per square millimeter of lamina propria. Dashes indicate the mean values. Statistical signifi cance 
was evaluated by comparing responses to PT-gliadin with responses to medium alone for each group of subjects.  * P  <  0.05. Upper right panel, Foxp3  +  
cells in the jejunal mucosa from a celiac patient cultured  in vitro with medium only or with a PT-gliadin. In the later, increased numbers of immunostained 
cells are evident particularly in the subepithelial region (arrows). Original magnifi cation:  × 20. Lower panel, CD4  +  CD25  +  Foxp3  +  cells, analyzed on FAC-
SCalibur, in intestinal biopsies from treated CD patients (left panel) and non-CD controls (right panel) cultured for 24  h in the presence of only medium or 
PT-gliadin. Data represent the mean of percentages of CD25  +  Foxp3  +  cells in the CD4  +  population. Each scatter plot is representative of mean of three or 
six independent experiments, respectively. Statistical signifi cance was evaluated for lower panel as indicated in the upper left panel.  * P  <  0.05. 
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 " e FACS analysis of the frequency of Foxp3  +  CD25  +  cells 
before and a& er challenge with PT-gliadin in CD4  +  population, 
con$ rmed the immunohistochemical data. As shown in  Figure 3 , 
lower le&  panel, there was a signi$ cantly higher ( P  <  0,01) 
 frequency of Foxp3  +  CD25  +  T cells in treated-CD biopsy samples 
cultured with PT-gliadin (21.4 ± 17.9 % ) than in those cultured in 
medium alone (10.8 ± 7.9 % ). No signi$ cant di% erences were noted 
in the percentage of Foxp3  +  CD25  +  CD4  +  cells in biopsy sam-
ples of non-CD controls cultured with PT-gliadin (4.2 ± 0.87 % ), 
in comparison with biopsy samples cultured with medium alone 
(3.7 ± 2.1 % ;  Figure 3 , lower right panel). 
 Intestinal CD4  +  CD25  +  cells in CD are regulatory T cells 
 " e high Foxp3 expression by CD4  +  CD25  +  cells from the mucosal 
explants of active CD raised the possibility that these cells may be 
Treg cells. " erefore, we co-cultured intestinal CD4  +  CD25  +  T 
cells from untreated CD patients with CD4  +  CD25  −  peripheral 
Tresp at a ratio of 1:1, in the presence of a polyclonal stimulus. A& er 
3 days, CD4  +  CD25  +  T cells showed a hypoproliferative response 
(anergy), whereas Tresp cells proliferated vigorously ( Figure 4a ). 
In coculture, intestinal CD4  +  CD25  +  T cells signi$ cantly sup-
pressed the proliferation of Tresp cells ( Figure 4a )( P  <  0.005) in 
a cell dose-dependent manner, and induced a signi$ cant decrease 
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 Figure 4 .  In coculture, CD4  +  CD25  +  cells isolated from intestinal or peripheral blood of untreated-celiac disease (CD) patients signifi cantly suppressed the 
proliferation and interferon gamma (IFN- γ ) production of responder T cells (Tresp). Proliferative responses were measured by [ 3 H]thymidine uptake. IFN- γ 
secretion was evaluated in supernatants of cocultures by an enzyme-linked immunosorbent assay test. Upper panel,  in vitro study evaluating the suppres-
sive capacity of CD4  +  CD25  +  T cells, purifi ed from intestinal biopsy of seven active CD patients, on the proliferation ( a ) and IFN- γ production ( b ) by Tresp 
cells. Results are from at least three independent experiments.  * * P  <  0.005 and  * * * P  <  0.001 comparing the 1:0 vs. 1:1 ratio). Lower panel,  in vitro study 
evaluating the suppressive capacity of CD4  +  CD25  +  T cells, purifi ed from peripheral blood of four active CD patients, on the proliferation ( c ) and IFN- γ 
production ( d ) by Tresp cells. Results are from at least three independent experiments.  * P  <  0.05 comparing the 1:0 vs. 1:1 ratio. 
of IFN- γ production ( P  <  0,001;  Figure 4b ). Moreover, in line with 
previous reports  (21), we have shown that the peripheral blood 
CD4  +  CD25  +  T cells of untreated CD patients were Treg cells, 
being capable of suppressing a signi$ cantly autologous responder 
CD4  +  CD25 − stimulated by anti-CD3 / anti-CD28 in a cell  dose-
dependent manner, in both terms of proliferation ( P  <  0.05; 
 Figure 4c ) and IFN- γ secretion ( P  <  0.05) ( Figure 4d ). 
 Ability of IL-15 to overcome Treg-mediated immunosuppression 
in CD patients 
 As our data show increased number of Foxp3  +  cells and a satis-
factory suppressive activity to explain the strong in# ammatory 
response in untreated CD patients, we hypothesized that IL-15 
hyperexpressed in the untreated CD mucosa could impair such 
suppression. " erefore, we assessed whether IL-15 could alter Treg-
mediated immunosuppression. Freshly isolated Treg cells from intes-
tinal or peripheral blood of untreated CD patients were cocultured, 
with Tresp at a ratio of 1:1, in a medium containing anti-CD3 / CD28, 
in the presence or absence of IL-15 (10  ng / ml). In CD patients, IL-15 
was e% ective in counteracting both intestinal and peripheral blood 
Treg cell-mediated suppression of anti-CD3-activated Tresp cells, 
partially in terms of proliferation ( Figure 5a, b , respectively) and 
completely in terms of IFN- γ production ( Figure 5c ). 
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with active CD compared with both treated CD and non-CD 
controls. " ese cells were not found in the epithelium layer, but 
were mainly localized in the subepithelial layer of the lamina 
propria. " e data obtained in biopsies from active celiac patients 
are in agreement with recent observations ( 17 – 19 ), indicating 
an increased density of Foxp3  +  cells by immunohistochemis-
try. In our study, we have con$ rmed these results also by FACS 
 ex vivo analysis. 
 In general, these data suggest that Foxp3 expression is linked 
to the Th1-driven mucosal immune response to gliadin. In fact, 
the expansion of this subset proportional to the intensity of 
local inflammation, could have a role in the negative  feedback 
loop of T-cell activation. In support of this hypothesis, we 
found in three CD patients with a partially healed mucosal 
tissue, an increased number of Foxp3  +  cells when compared 
with the normal mucosa of both treated CD and non-CD 
controls, but lower with respect to the density found in the 
mucosa of untreated CD (data not shown). Moreover, the data 
that we are collecting on duodenal biopsies from  “ potential ” 
CD patients (patients with positive CD serology, and low local 
inflammation) point in the same direction. Thus, the increased 
density of Foxp3  +  cells seems to be correlated with the histo-
logical lesion, suggesting that the immune system is actively 
trying to downregulate ongoing inflammation either through 
the rapid redistribution of Treg cells from the circulation to 
the inflamed site, or through the local proliferation of these 
regulatory cells. 
 To test whether the inhibitive e% ect of IL-15 on Treg cells 
was unique to CD patients, we performed analysis on non-CD 
 controls. We cocultured only peripheral blood CD4  +  CD25  +  T 
cells with Tresp cells, with or without IL-15, as CD4  +  CD25  +  T 
cells isolated from the intestinal biopsy samples of non-CD control 
patients were not enough for functional studies. Our data dem-
onstrated that the phenomenon was nonspeci$ c for CD patients 
as in non-CD controls IL-15 partially prevented the inhibition of 
IFN- γ secretion ( Figure 5d ). However, it did not overcome the 
Treg cell-mediated block of Tresp cell proliferation ( Figure 5e ). 
 Finally, we wondered whether the greater sensitivity to IL-15 
seen in CD patients could be explained by an increased expression 
of its receptor. Cell-surface IL-15R α was then monitored by FACS 
in peripheral blood Treg and Tresp cells of both CD patients and 
non-CD controls. We found that IL-15R α was highly expressed 
on Treg cells in both CD patients and non-CD controls ( Figure 
6 ), whereas it was moderately detectable in Tresp cells ( Figure 6 ). 
However, a direct comparison of Treg cells from CD patients and 
non-CD controls revealed that the surface density of IL-15R α 
was signi$ cantly higher ( P  <  0.05) in Treg cells from CD patients 
(mean ± s.d.: 261 ± 150 and 33 ± 28, respectively;  Figure 6 ). 
 DISCUSSION 
 In this study, we found, by two complementary methods —
 immuno histochemistry and FACS  ex vivo analysis — an increased 
number of Foxp3  +  cells in the intestinal mucosa of patients 
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 Figure 5 .  Interleukin 15 (IL-15) impairs the suppressive activity of regulatory T cells (Treg). ( a, b ) Effect of IL-15 on suppressive capacity of Treg cells 
isolated, respectively, from intestinal biopsy and peripheral blood of fi ve active celiac disease (CD) patients assessed on proliferation. ( c ) Effect of IL-15 
on suppressive capacity of Treg cells isolated from peripheral blood of fi ve active CD patients assessed on IFN- γ production. Proliferative responses were 
measured by [ 3 H]thymidine uptake. Interferon gamma (IFN- γ ) secretion was evaluated in supernatants of cocultures by an enzyme-linked immunosorbent 
assay test. ( d and  e ) Effect of IL-15 on suppressive capacity of Treg cells isolated from peripheral blood of four non-CD controls assessed, respectively, on 
IFN- γ production and proliferation. Results are from four independent experiments. The Treg and responder T cells (Tresp) were cocultured at 1:1 ratio and 
stimulated with IL-15 (10  ng / ml).  * P  <  0.05,  * * P  <  0.005,  * * * P  <  0.001, when compared with the condition in presence of IL-15. 
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 In humans, the correlation between Foxp3 expression and 
suppressive capacity is not as clear as in the murine system. In 
fact, recently it has been shown that expression of Foxp3 does 
not exclusively occur in CD4  +  CD25  +  Treg cells, as in humans 
it can also be transiently induced in activated CD4  +  CD25  − 
T e% ector cells, which do not express Foxp3 in the resting state 
( 24,25 ). " erefore, the statement that CD patients are char-
acterized by accumulation of suppressive cells in the intesti-
nal mucosa must be considered carefully, in the absence of a 
functional suppressive assay. Although the functional activ-
ity of CD4  +  CD25  +  T cells isolated from peripheral blood of 
untreated-CD patients was recently investigated ( 20 – 22 ), the 
suppressive capacity of such T cells in the intestinal mucosa of 
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 Figure 6 .  Increased expression of interleukin-15 receptor alpha surface 
expression (IL-15R α ) on CD4  +  CD25  +  T cells from active celiac disease 
(CD) patients. Freshly isolated peripheral blood mononuclear cells 
(PBMCs) cells from active celiac patients and non-CD controls stained 
for CD4, CD25, and IL-15R α , and analyzed by fl ow cytometry (FACS). 
Representative dot plot from one experiment from active CD patients and 
non-CD control was shown. CD4  +  CD25  +  and CD4  +  CD25  −  T cells were 
analyzed for IL-15R α expression and mean fl uorescence intensity (MFI) of 
IL-15R α was indicated. The dot plot shows a higher intensity of IL-15R α 
on CD4  +  CD25  +  peripheral blood T cells from active CD patient than 
non-CD controls ( P  <  0.05). Numbers indicate the MFI of at least 
three experiments. 
CD patients has never been reported. Towards this aim, and to 
ascertain whether the observed Treg cells are indeed suppres-
sive, we isolated CD4  +  CD25  +  cells from biopsy samples of 
active CD and tested their suppressive capacity in an  in vitro 
coculture assay. Our data show that intestinal CD4  +  CD25  + 
T cells of CD patients are able to exert their regulatory e% ects  in 
vitro in terms of inhibition of proliferation and IFN- γ secretion 
of Tresp cells. Moreover, in line with recent report ( 21 ), we con-
$ rm the suppressive activity of peripheral blood CD4  +  CD25  + 
T cells of CD patients. " erefore, our current results suggest 
that intestinal and peripheral blood Treg cells of untreated 
CD patients are not functionally de$ cient and could be able to 
control the ongoing immune response to gluten and the conse-
quent in# ammation. 
 On the contrary, despite the increased frequency and suppres-
sive activity  in vitro , Treg cells fail to control the development of 
the in# ammation in the small intestinal mucosa with active CD. 
It is possible that the suppressor capacity of these cells may be 
abrogated  in vivo or it is insuY  cient to counterbalance the strong 
proin# ammatory response. Recently, it has been shown that IL-
15 not only has a pleiotropic role at the interface between innate 
and adaptive immunity in CD, but also exerts e% ects interfering 
with anti-in# ammatory pathways that are normally activated in 
the small intestinal mucosa by the cytokine TGF- β 1 ( 11 ). " e 
massive increase of the proin# ammatory cytokine IL-15 in CD 
led us to investigate whether IL-15 might interfere with the sup-
pressive activity of intestinal Treg cells. In active CD patients, we 
have shown that IL-15 impairs the functions of Treg cells making 
Tresp cells refractory to the regulatory e% ects of CD4  +  CD25  + 
T cells, in terms of proliferation and production of IFN- γ . " is 
phenomenon was nonspeci$ c for CD patients, as in non-CD con-
trols the addition of IL-15 to cocultures of Treg / Tresp cells pre-
vented the inhibition of IFN- γ secretion. Nevertheless, this e% ect 
was less marked than in CD. " e greater sensitivity to IL-15 of 
CD patients is likely to be due to their increased expression of 
IL-15 receptor. Recently, it has been observed that the mRNA 
expression of IL-15 receptor- α was increased in duodenal biopsy 
samples of untreated CD patients as compared with controls ( 26 ). 
How IL-15 can impair the suppressive activity of Treg cells in  vitro 
remains to be de$ ned. Previous data indicated that, in active CD, 
IL-15 was involved in the local downregulation of TGF- β signal-
ing ( 11 ), which is required to maintain the regulatory function 
of Treg cells ( 27 ). Studies are now in progress to address in our 
system whether and how IL-15 might interfere with the regula-
tory function of TGF- β . 
 Aside from evidence that natural Foxp3  +  Treg cells arise and 
mature in the thymus, there is mounting evidence that Foxp3  + 
Treg cells can develop extrathymically under certain conditions. 
As a consequence of this expansion, Treg cells cause downmodu-
lation of in# ammation associated with pathogen-speci$ c immune 
responses. Recently, it was observed that small intestine lamina 
propria dendritic cells promote  de novo generation of Foxp3 Treg 
cells through retinoic acid, which is a vitamin A metabolite that is 
highly expressed in gut associated lymphoid tissue ( 28 ). Together, 
these data demonstrate that the intestinal immune system has 
The American Journal of GASTROENTEROLOGY VOLUME 106 | JULY 2011   www.amjgastro.com
1316
 C
O
L
O
N
/S
M
A
L
L
 B
O
W
E
L
 
 Zanzi  et al. 
 Financial support: European Laboratory for the Investigation of 
Food-Induced Diseases, University Federico II, Naples, Italy. 
 Potential competing interests: None. 
 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE 
 3 Coeliac disease (CD) is a condition characterized by a 
dysregulated mucosal immune response to gliadin. 
 3 Increased number of Foxp3  +  T cells are present in the 
small-intestine biopsy samples from patients with active CD. 
 3 Suppressor capacity of circulating CD4  +  CD25  +  T cells 
from CD patients are reported, but no functional data are 
available for their intestinal counterparts. 
 WHAT IS NEW HERE 
 3 Intestinal CD4  +  CD25  +  T cells from CD patients are 
functionally suppressive. 
 3 IL-15 impairs the regulatory activity of both intestinal and 
peripheral blood Treg cells of CD patients. Their sensitivity 
to IL-15 is partly explained by the increased expression of 
IL-15R α . 
 3 CD4  +  CD25  +  Foxp3  +  T cells are induced  in situ 
by gliadin.  
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MicroRNA-449a Overexpression, Reduced NOTCH1
Signals and Scarce Goblet Cells Characterize the Small
Intestine of Celiac Patients
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Abstract
MiRNAs play a relevant role in regulating gene expression in a variety of physiological and pathological conditions including
autoimmune disorders. MiRNAs are also important in the differentiation and function of the mouse intestinal epithelium.
Our study was aimed to look for miRNA-based modulation of gene expression in celiac small intestine, and particularly for
genes involved in cell intestinal differentiation/proliferation mechanisms. A cohort of 40 children (20 with active CD, 9 on a
gluten-free diet (GFD), and 11 controls), were recruited at the Paediatrics Department (University of Naples Federico II). The
expression of 365 human miRNAs was quantified by TaqMan low-density arrays. We used bioinformatics to predict putative
target genes of miRNAs and to select biological pathways. The presence of NOTCH1, HES1, KLF4, MUC-2, Ki67 and beta-
catenin proteins in the small intestine of CD and control children was tested by immunohistochemistry. The expression of
about 20% of the miRNAs tested differed between CD and control children. We found that high miR-449a levels targeted
and reduced both NOTCH1 and KLF4 in HEK-293 cells. NOTCH1, KLF4 signals and the number of goblet cells were lower in
small intestine of children with active CD and in those on a GFD than in controls, whereas more nuclear beta-catenin
staining, as a sign of the WNT pathway activation, and more Ki67 staining, as sign of proliferation, were present in crypts
from CD patients than in controls. In conclusion we first demonstrate a miRNA mediated gene regulation in small intestine
of CD patients. We also highlighted a reduced NOTCH1 pathway in our patients, irrespective of whether the disease was
active or not. We suggest that NOTCH pathway could be constitutively altered in the celiac small intestine and could drive
the increased proliferation and the decreased differentiation of intestinal cells towards the secretory goblet cell lineage.
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Introduction
Celiac disease (CD) is an immunomediated enteropathy and
one of the most heritable complex diseases. The concordance rate
in monozygotic twins is 75% [1,2]. HLA DQ2/DQ8 haplotypes
confer the highest estimated heritability (,35%) [3] reported so
far.
Exposure to gliadin triggers an inappropriate immune response
in HLA-susceptible individuals. However, the presence of HLA-
risk alleles is a necessary but not sufficient condition for the
development of CD. In fact, about 30–40% of healthy subjects
carry HLA-risk alleles [4,5]. Attempts at identifying non-HLA
major genetic risk loci have been unsuccessful [6]. Gluten has also
been shown to affect epithelial differentiation-associated genes in
the small intestinal mucosa of celiac patients [7,8]. However, the
role of miRNA-based regulatory mechanisms in mediating gene
expression alteration in CD has not yet been investigated.
MicroRNAs (miRNAs) are small non-coding RNAs, 20–25 nt
long, that modulate gene expression through canonical base
pairing to complementary sequences in the 39UTR of target
mRNA [9]. Since their identification in 1993 [10], miRNAs have
been found to play a relevant role in regulating gene expression
in a variety of biological processes in physiological and
pathological conditions [11] including autoimmune disorders
[12]. They can be involved in the development of mature
immune cells and in the control of their function [13–15].
MiRNAs are also important in the differentiation and function of
the mouse intestinal epithelium [16].
In this study, we evaluated the miRNA expression pattern in the
small intestine of children affected by active CD, children with CD
on a gluten-free diet (GFD) and control children without CD. Our
aim was to look for miRNA-based modulation of gene expression
in celiac small intestine, and particularly for genes involved in cell
intestinal differentiation/proliferation mechanisms.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29094
Results
Clinical features of CD patients and controls
Clinical features of our CD patients and controls are reported in
Table 1. Villous atrophy was subtotal or total [TIIIB: n= 3 (15%)
and TIIIC: n= 17 (85%)] in all active CD patients. Only minor
histological abnormalities were present in GFD patients [T0: n= 5
(56%) and TI: n= 4 (44%)] and in control patients [T0: n= 7
(64%) and TI: n= 4 (36%)].
CD children and controls have a different miRNA
expression levels in small intestine
Figure 1 shows the miRNA expression in the small intestine of
children with active CD (panel A) and in children on a GFD (panel
B). Ninety of the 365 (25%) miRNAs tested were not expressed in
small intestine. Over 50% of miRNAs were expressed at similar
levels in the two groups of CD compared to controls. On the
contrary, the expression levels of about 20% of miRNAs (22% in
active CD and 19% in GFD) differed between CD and controls. In
particular, in active CD patients 27 and 55 miRNAs were
expressed respectively more (RQ$2.0) or less (RQ#0.5) than in
controls, whereas in GFD patients 22 and 49 miRNAs were
expressed respectively more (RQ$2.0) or less (RQ#0.5) than in
controls. The miRNAs that were differently expressed in the two
CD groups are listed in Table S1.
Two sets of miRNAs (one down-regulated and one up-
regulated compared to controls) show similar expression
levels in active and GFD CD patients, being miR-449a the
highest expressed miRNA
Among the miRNAs differently expressed between CD children
and controls, but with similar expression levels in active and in
GFD CD, 9 were up-regulated and 21 were down-regulated
(Table 2). Particularly, among the down-regulated miRNAs the set
of miR-124a, miR-189, miR-299-5p and miR-379, was previously
reported associated with autoimmune disorders [17]. Among the
up-regulated miRNAs the miR-449a was expressed at very high
levels in all active CD (55.18616.45 mean RQ6SEM) and GFD
children (15.4367.69 mean RQ6SEM). qRT-PCR confirmed the
expression levels both of miR-449a (active CD: 2.860.9 mean
RQ6SEM) and of 2 other tested miRNAs, the down-regulated
miR-124a (active CD:0.660.1 mean RQ6SEM) and the similar
to control expressed miR-564 (active CD:1.460.3 mean
RQ6SEM vs 1.260.1 at array).
Bioinformatic prediction of the target genes of miR-449a
Six of the 11 programs [Target Scan 5.1, PicTar, Miranda 1.9,
MirTarget2 (v2.0), PITA (Catalog version 3) and RNAhybrid (v2.2)],
which we used to predict putative target genes of miR-449a,
identified several proteins that are present in relevant biological
pathways. The biological pathways predicted to be deregulated by
miR-449a and sorted in functional groups are reported in Figure S1
(http://mirecords.biolead.org/interactions.php?species=Homo+sapiens
&mirna_acc=hsa-miR449a&targetgene_type=refseq_acc&targetgene_
info=&v=yes&search_int=Search (http://www.targetscan.org/cgi-bin
/targetscan/vert_50/targetscan.cgi?species=Human&gid=&mir_sc=
&mir_c=&mir_nc=&mirg=hsa-miR-449a). Among putative target
genes the programs identified NOTCH1, Krueppel-like factor 4
(KLF4), delta-like 1 (DLL1), lymphoid enhancer-binding factor 1
(LEF1) and numb homolog-like (NUMBL) proteins, which are all
involved in the Notch pathway. As this pathway plays a relevant role in
the control of intestinal cell fate in animal models we further examined
the interaction of miR-449a with Notch pathway [18].
MiR-449a binds to the 39 UTR of NOTCH1 and KLF4 and
inhibits their expression. We verified the interaction between
miR-449a and the 39 UTR of NOTCH1 and of KLF4 using the
luciferase reporter assay. In cells co-transfected with pRL-NOTCH1
vector and pre-miR-449a or with pRL-KLF4 vector, a pre-miR-
449a concentration of 100 nmol/L was sufficient to significantly
reduce (respectively, p=0.001 and p=0.002) Renilla luciferase
activity versus control values after 48 h (Figure S2A and S2B).This
finding confirms the interaction between miR-449a and the 39UTR
of both NOTCH1 and KLF4.
The direct interaction between miR-449a and the 39UTRs of
both NOTCH1 and KLF4 was further confirmed after mutating
the putative target sites in 39UTR of the two genes (See Materials
and Methods S1).
NOTCH1 and HES1 mRNAs are expressed in the small
intestine of CD patients
NOTCH1 and HES1 mRNA levels, tested by qRT-PCR, were
expressed in the small intestine of active CD patients (RQ6SEM:
3.461.3 and 1.460.2, respectively vs controls) and of GFD patients
(RQ6SEM: 6.564.7 and 0.760.1, respectively vs controls).
NOTCH1 and HES1 proteins are underexpressed in the
small intestine of CD patients
We next investigated the protein expression of NOTCH1 and of
HES1, which is a well known target gene of the Notch receptor
family, in small intestinal biopsies from CD patients and controls.
Figure 2 shows the results obtained for NOTCH1. NOTCH1 was
homogeneously distributed in the intestinal villi and crypts of
controls and higher expressed in crypts of controls than in crypts of
active and GFD CD patients (panel A, B).
In Figure 2 (panel C) are also the images converted for
automated analysis (white: unstained cells, yellow/orange: low/
moderately stained cells, brown: intensely stained cells). Signif-
icantly more intensely stained and less unstained cells (p = 0.02)
Table 1. General characteristics of studied celiac patients
(active CD and GFD) and control children (CTRL).
Characteristics# Subjects
Active CD
(n=20)
GFD‘
(n = 9)
CTRL
(n =11)
Sex Female (%) 55 55 45
Age (Years) 4.361.3 7.662.5 6.161.0
Clinical presentation:
Gastrointestinal symptoms (%) 80 22 82
Villous atrophy % (Marsh stage){ TIIIB 15 T0 56 T0 64
TIIIC 85 TI 44 TI 36
Positive tTG or EMA (IgA)1 19 3 0
Familiarity for:
CD (%) 20 22 0
Other autoimmune diseases (%) 5 11 0
#Data are expressed as percentage (%) or as mean 6 standard error of the
mean (SEM)
‘At gluten free diet from at least 2 years.
{According to [41].
1Only 1 active CD patient was negative for these antibodies but was positive for
both AGA IgG/IgA antibodies. Borderline tTG values in 3/9 GFD patients were
attributed to reported sporadic gluten ingestion.
doi:10.1371/journal.pone.0029094.t001
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were detected in controls than in the two groups of CD patients,
whereas no statistical significant difference was observed between
the two CD groups (Figure S3, panel A and Figure S4). These
results indicate that NOTCH1 is less expressed in the small
intestine of active and GFD CD patients than in controls.
Figure 3 shows the results obtained for HES1. HES1 was
homogeneously distributed in the intestinal villi and crypts of
controls and higher expressed in crypts of controls than in crypts
of active and GFD CD patients (panels A and B). In Figure 3
(panel C) are also the images converted for automated analysis
(white: unstained cells, yellow/orange: low/moderately stained
cells, brown: intensely stained cells). Significantly more intensely
stained cells were detected in controls than in CD patients
(p = 0.02) and significantly less unstained cells were detected in
controls than in active CD patients (p = 0.03), whereas no
statistical significant difference was observed between the two
CD groups (Figure S3, panel B and Figure S5). These results
indicate that HES1 is less expressed in the small intestine of
active and GFD CD patients with respect to controls. The above
findings confirm that NOTCH1 signaling is reduced in patients
affected by CD.
KLF4 protein is reduced and the number of goblet cells is
significantly lower in the small intestine of CD patients
versus controls
We also investigated the protein expression of KLF4, another
selected target gene of miR449a, in small intestinal villi from GFD
patients and controls, lacking the villous architecture in active CD
patients. We found that the levels of this protein (mean6SEM)
were significantly lower in villi from GFD patients vs controls,
respectively 29.065.0 vs 79.063.0 (p,0.0001) (Figure S6, panel
A). Since KLF4 negatively regulates cellular proliferation, we
examined the effect of inhibition of KLF4 on the proliferation of
intestinal crypts with the proliferation marker Ki67. The results
show that the number of Ki67 positive cells is higher in the crypts
of CD patients than in controls (Figure S6, panel B). Because
KLF4 is also involved in the differentiation and maturation of
secretory goblet cells we examined these cells by immunohisto-
chemistry and using anti-MUC-2 antibodies. We detected
statistically fewer MUC-2-stained cells (mean6SEM) in the crypts
of active CD patients (18.061.6) and GFD patients (15.063.0)
than in controls (35.067.7) (p = 0.04) (Figure 4A and B).
Moreover, there were fewer goblet cells in the villi of GFD
Figure 1. miRNA expression pattern in small intestine of CD patients. miRNA expression in the small intestine of patients with active CD
(Panel A) and of CD patients on a GFD (Panel B). Data are expressed as percentage of miRNAs tested (n = 365). White areas, miRNAs whose expression
levels were similar in the two CD groups and controls; gray areas, miRNAs not expressed; black areas, miRNAs whose expression levels differed
between CD patients and controls (up-regulated q(RQ$2.0) or down-regulated Q(RQ#0.5)).
doi:10.1371/journal.pone.0029094.g001
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patients (7.061.8) than in controls (20.064.9) (p = 0.04) (data not
shown). This finding demonstrates that the differentiation of the
secretory goblet cells is impaired in small intestine of CD patients.
Expression of beta-catenin
Because NOTCH1 and also KLF4 interact with the WNT
pathway to influence the intestinal stem cell fate, we investigated
the WNT pathway using beta-catenin antibodies. By counting the
beta-catenin positive nuclei/crypt for each patient we observed
higher even if not statistical significant mean percentage beta-
catenin positive nuclei/crypt in active CD and GFD patients than
in controls, respectively 57.0611.5 and 37.064.6 vs 27.064.6
(Figure S7). This finding suggests that cellular proliferation is
increased in the small intestine of CD patients.
Discussion
A very recent study established the importance of miRNAs in
the differentiation and function of the mouse intestinal epithelium
[16], whereas there are no data about miRNAs expression in
human CD small intestine. Our study reveals that the expression
of about 20% of miRNAs tested in the small intestine differed
among CD and control children irrespective of whether the
disease was active or not. Particularly, the miR-449a showed the
highest expression level in CD patients than in controls. The miR-
449 (a and b) cluster is embedded into an intronic sequence of the
mRNA-encoding gene CDC20B on Chr 5q11.2 [17]. MiR-449a
seems to be regulated through activation of its host gene, CDC20B,
and both were induced by the cell cycle regulator E2F1 [19]. The
mature miR-449a sequence is evolutionarily conserved across a
variety of species (monkey, horse, rodents, and dogs) and therefore
it probably exerts an important function [20]. The bioinformatics
search for putative target genes of miR-449a revealed about one
hundred proteins, among these several belonged to the Notch
pathway, i.e., NOTCH1, KLF4 (a NOTCH1 transcription factor)
[21], DLL1, LEF1 and NUMBL. Our strategy to choose
NOTCH1 gene among the other putative miRNA-target genes
was based on many studies highlighting that cellular formation of
the villi in small and large intestine is affected by signaling
pathways such as Notch, Wnt and BMP [22–25]. Notably,
deregulation of the intestinal epithelial formation has been
reported in several intestinal diseases such as Crohn, ulcerative
colitis and colon cancer [26]. Further, NOTCH1 and KLF4 genes
are both involved in the control of mouse intestinal epithelial
homeostasis [18,27]. In fact, in mouse intestine, also in
cooperation with WNT signals, NOTCH1 guides cell proliferation
and differentiation [18] and KLF4 inhibition by NOTCH1 or
KLF4 deletion was shown to reduce the differentiation and
maturation of goblet cells [21,27–29]. The Notch family is
constituted by single transmembrane receptors that, in mammals,
after interaction with ligands (DLL1,3,4 and Jagged 1–2) undergo
proteolytic cleavage and finally translocate into the nucleus where
they activate target gene transcription [30].
After confirmed the interaction between miR-449a and both
NOTCH1 and KLF4 mRNA, we measured the NOTCH1 and
KLF4 protein levels in small intestinal biopsies of CD children.
NOTCH1-positive cells were significantly fewer in biopsies from
active and GFD CD patients versus controls. Similar results were
also obtained for HES1, a target gene of NOTCH1 [31]. Globally,
these data indicate that the NOTCH1 pathway is deregulated in
intestinal epithelium of CD children, irrespective of whether the
disease is active or not, and that this alteration could be related to
the very high miR-449a expression. Accordingly, in a very recent
report miR449 by repressing the Delta/Notch pathway was
elegantly shown to control the human airway epithelium and
vertebrate multilciliogenesis [32]. In our patients we also observed
fewer KLF4-positive cells in small intestinal villi from GFD patients
than in controls, and, moreover, Ki67 signals were higher in crypts
from CD patients versus controls. These two results are in agree-
ment with data very recently reported in a mouse KLF4DELTAIS
model [27] and indicate a higher proliferation rate in our CD
patients in the presence of reduced KLF4 expression [27]. In
parallel the number of goblet cells was significantly lower in the two
CD groups than in control children. Ciacci et al [33] previously
reported fewer goblet cells/mm2 in untreated (29.1) and in treated
CD patients (42.2) than in controls (50.5), although the differences
were statistically significant only in untreated patients (p,0.02).
The WNT pathway in the small intestine of our CD patients,
evaluated based on beta-catenin expression level, did not differ
Table 2. List of miRNAs (n = 30) differently expressed in CD
patients and controls but with similar expression levels both
in active CD and GFD children.
MiRNA Active CD GFD
up-regulated miRNAs
miR-449a 55.18616.45 15.4367.69
miR-492 48.88614.56 26.8669.00
miR-644 47.8068.80 37.53618.85
miR-503 19.8462.36 20.5568.07
miR-196a 11.0662.84 8.4561.01
miR-504 5.5460.83 8.0262.86
miR-500 5.4960.70 7.8861.56
miR-330 3.8460.45 2.4860.11
miR-182 2.9560.42 2.7560.13
down-regulated miRNAs
miR-105 0.3760.03 0.2560.03
miR-409-5p 0.3560.04 0.3160.05
miR-631 0.3460.03 0.2760.04
miR-659 0.3360.03 0.3060.05
miR-379 0.3060.05 0.2360.10
miR-566 0.2960.02 0.2360.03
miR-512-3p 0.2760.03 0.2660.04
miR-614 0.2660.02 0.2160.02
miR-380-5p 0.2560.03 0.2860.04
miR-135a 0.2160.05 0.3860.05
miR-124a 0.2060.02 0.2160.05
miR-600 0.1960.02 0.2260.06
miR-618 0.1860.03 0.3260.07
miR-616 0.1760.04 0.1160.03
miR-189 0.1560.05 0.2160.06
miR-576 0.1560.04 0.4060.10
miR-412 0.1360.03 0.1860.01
miR-202 0.1260.06 0.1760.08
miR-299-5p 0.1160.01 0.1560.05
miR-323 0.1160.01 0.2360.08
miR-219 0.1060.01 0.2760.08
Data are reported as RQ# levels (mean6SEM).
#RQ=22delta deltaCT represents miRNA fold change in CD patients vs mean value
obtained in control patients.
doi:10.1371/journal.pone.0029094.t002
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from that of control children. This result is in agreement with the
western blot data reported by Ciccocioppo et al [34] and by Juuti-
Uusitalo et al [7]. However, we observed a more evident nuclear
localization of beta-catenin, albeit not statistically significant, in
the small intestinal crypts from our active and GFD CD patients
than in controls, which suggests activation of the WNT pathway.
The latter finding is in agreement with a previous study of human
CD [7] and with the increased mRNA levels of the genes in
the WNT pathway, including beta-catenin, observed in the
KLF4DELTAIS mouse [27]. Globally, our data support increased
cellular proliferation in the small intestinal epithelium in CD
patients. As it is well known, active CD is characterized by an
inversion of the differentiation/proliferation program of the
intestine with a reduction in the differentiated compartment, up
to complete villous atrophy, and an increase of the proliferative
compartment, with crypt hyperplasia [7,8]. Furthermore, although
GFD intestinal mucosa is characterized by an apparently normal
mucosal architecture, it can also be associated with increased crypt
cell proliferation (Barone M. V. et al., personal communication).
Our data are in contrast with those obtained in mouse models, in
which NOTCH1 activation resulted in a reduction of goblet cells
consequent to HES-1 dependent repression of Math1 (intestinal
secretory cell differentiation factor) [18] and in which NOTCH1
inhibited the expression of KLF4 [35]. However, our data are in
agreement with a recent report of increased proliferation, reduced
differentiation and goblet cells maturation associated with down-
regulation of the expression of components of the Notch pathway
(HES1, DLL1, JAG1) in the small intestine of the KLF4DELTAIS
mouse [27]. The authors for the latter article hypothesized that
KLF4 was involved in a feed-back loop by positively regulating
Notch signaling. Our results are suggestive that an altered
NOTCH1 and KLF4 expression could lead to the reduction of
goblet cells in the small intestine of CD patients. The maintenance
of a correct number of functional goblet cells is required for the
homeostasis of the intestinal mucosal environment, and deficien-
cies in the mucin composition renders the mucosa more
susceptible to damaging agents in the lumen [36–38]. In fact,
loss of goblet cell function leads to spontaneous colitis in mice [39].
Moreover, an altered mucous layer and increased rod-shaped
bacteria and interferon-gamma mRNA levels were found in
Figure 2. Decreased expression of NOTCH1 in small intestine of CD patients compared with controls. An example of NOTCH1
immunohistochemistry in small intestine. A. Low magnification picture of the intestinal sections (Original magnification 106). B. Intestinal crypts
(Original magnification 406). Note the homogeneous distribution of NOTCH1 in crypts and along the villi in control sample, whereas in active CD and
GFD samples the signals were prevalently detected in the crypts. Higher levels of NOTCH1 were detected in the intestinal crypts of controls than in
crypts of active and GFD CD samples. C. Images converted for automated analysis (white: unstained cells, yellow/orange: low/moderately stained
cells, brown: intensely stained cells). These results indicate that NOTCH1 is less expressed in the small intestine of active and GFD CD samples
compared with controls. (CTRL: controls; GFD: gluten free diet; CD: celiac disease).
doi:10.1371/journal.pone.0029094.g002
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intestine from CD patients [40]. Based on these experimental data,
we suggest that the mucus layer in our CD children could be
altered so deranging the protective function of the mucosal barrier
that interfaces with the environment. In our study, the observed
small intestine alterations are not related to inflammation; in fact,
they occurred in both the active CD and GFD patients. The major
criticism in our work is the gap between the results of the miRNA
array with NOTCH1 gene in a vivo system, however the lack of a
celiac animal model at moment, prevent us from this further
validation of our data. Nevertheless, our first description of
miRNA pattern in celiac disease and of the correlation of miRNA
449a over expression with NOTCH pathway could pave the way
for further research in this field. However, our choice to study
Notch pathway doesn’t exclude that other relevant biological
pathways in addition to it could be miRNA-deregulated in the
celiac intestine. Further deeper investigation are necessary to test
this hypothesis.
In conclusion we first demonstrate a miRNA mediated gene
regulation in small intestine of CD patients. We also highlighted a
reduced NOTCH1 pathway in our patients, irrespective of whether
Figure 3. Decreased expression of HES1 in small intestine of CD patients compared with controls. An example of HES1
immunohistochemistry in small intestine. A. Low magnification picture of the examined intestinal sections (Original magnification 106). B. Intestinal
crypts (Original magnification 406). Note the homogeneous distribution of HES1 in crypts and along the villi in control sample, whereas the signals
were prevalently detected in the crypts of active CD and GFD samples. Higher levels of HES1 were detected in the intestinal crypts of controls than in
crypts of active and GFD CD samples. C. Images converted for automated analysis (white: unstained cells, yellow/orange: low/moderately stained
cells, brown: intensely stained cells). These results indicate that HES1 is less expressed in the small intestine of active and GFD CD samples compared
with controls. (CTRL: controls; GFD: gluten free diet; CD: celiac disease).
doi:10.1371/journal.pone.0029094.g003
MiRNAs Expression in Celiac Small Intestine
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29094
the disease was active or not. We suggest that NOTCH pathway
could be constitutively altered in the celiac small intestine and could
drive the increased proliferation and the decreased differentiation of
intestinal cells towards the secretory goblet cell lineage.
Materials and Methods
Ethics approval
The study was conducted according to the Helsinki II
declaration and it was approved by the Ethics Committee of the
School of Medicine Federico II, Naples, Italy.
Written informed consent was obtained from the parent/guardian
of all children involved in our study before their enrollment.
Patients and controls
Forty-four children were recruited, in a two months period,
among patients attending the Department of Paediatrics of the
University of Naples Federico II where the European Laboratory
for the Investigation of Food-Induced Diseases (ELFID) is also
present. In our center about 40 biopsies are monthly performed
and about 50% of them are usually indicative of CD. Twenty/44
children were diagnosed celiacs according to the criteria
established by the European Society for Paediatric Gastroenter-
ology, Hepatology and Nutrition (ESPGHAN) [41]; the CD was
excluded based on both absence of CD antibodies and slight or no
abnormalities in the mucosal architecture in 15/44 children. In
four of these latter children (4/15) the final diagnoses were IgA
deficiency (2 cases), De George syndrome (1 case) and autoim-
mune thyroiditis (1 case), these subjects were excluded from the
study to avoid potentially confounding diseases. In the other 11/15
CD-negative children the final diagnoses were: Helicobacter pylori
infection, recurrent vomiting, food refusal or reflux esophagitis,
they were our enrolled controls. Nine out 44 children were CD
patients on gluten free diet for at least 2 years undergoing CD
Figure 4. Decreased expression of MUC2 in small intestine of CD patients compared with controls. Immunohistochemistry of goblet
cells in small intestine. A. An example of staining for MUC-2 shows fewer MUC-2 stained cells in active and in GFD CD samples than in controls.
(Original magnification 206). B. MUC2 stained cells evaluated in CD patients (6 active CD and 6 GFD patients) and in controls (n = 4). Data are
expressed as mean of the number of goblet cells/crypt measured in 10 crypts/children. Significantly fewer stained cells were detected in active and
GFD CD samples than in controls (p = 0.04). These results indicate that MUC2 is less expressed in small intestine of active and GFD CD patients
compared with controls. (CTRL: controls; GFD: gluten free diet; CD: celiac disease).
doi:10.1371/journal.pone.0029094.g004
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follow-up in the same study period of the active CD patients and
controls. There was no statistically significant difference in mean
age at diagnosis among the groups evaluated (4.361.3 years old in
active CD subjects, 7.662.5 in GFD subjects, and 6.161.0 in
controls [mean6SEM]). About 50% of each group was girls. From
all participants, we collected a fasting serum sample, a blood
sample with EDTA, and a small intestine biopsy sample.
Biochemical parameters
Anti-Endomysium IgA were detected by indirect immunofluo-
rescence on rhesus monkey esophagus substrate (Eurospital,
Trieste, Italy); tTG IgA, anti-gliadin (AGA) IgA/IgG were
analyzed by ELISA with human recombinant tTG as antigen
(DIA Medix Corp., Miami, FL, USA).
Histopathological analysis
Architectural abnormalities were classified according to the
modified Marsh classification: normal mucosa (T0), intraepithelial
lymphocytosis (TI), intraepithelial lymphocytosis and crypt hyper-
plasia (TII), intraepithelial lymphocytosis, crypt hyperplasia and
villous atrophy (partial TIIIA, subtotal TIIIB, total TIIIC) [42].
DNA and RNA extraction
Genomic DNA was extracted using the Nucleon BACC 2 kit
(Amersham Biosciences Europe, Milan, Italy). Total RNA,
including miRNAs, was extracted from small intestinal biopsy
samples using the Mirvana extraction kit (Applied Biosystems,
Foster City, CA, USA).
HLA typing
DQ2/DQ8 HLA CD-associated molecules were identified by
using primers and the PCR conditions of a commercial kit (BAG
Health care GmbH, Lich, Germany), which allows to identify the
HLA-alleles coding DQ2/DQ8 molecules.
MiRNAs evaluation
TaqMan low density arrays (TLDA), micro fluidic cards were
used to detect and quantify mature miRNAs (Applied Biosystems’
7900HT) according to manufacturer’s instructions (see Materials
and Methods S1 for details). We considered differently expressed
in CD vs controls, the miRNAs whose mean RQ levels were #0.5
(down-regulated) or $2.0 (up-regulated).
Bioinformatic approach
The prediction of putative target genes of miRNAs was
determined using miRecords (http://mirecords.biolead.org/),
which is an integration of 11 established miRNA target prediction
programs. The lists of target genes that were predicted by two or
more programs were then combined and analyzed using the Gene
Ontology Tree Machine (GOTM) (http://bioinfo.vanderbilt.edu/
gotm/) and KEGG database (http://www.genome.ad.jp/kegg/).
Finally, we identified the biological pathways that contained at
least two up- or down-regulated genes with a statistically
significant probability (p,0.01).
Quantitative real-time polymerase chain reaction (qRT-
PCR) of miRNAs and mRNAs
The levels of a group of deregulated miRNAs (up-regulated
miR-449a, down-regulated miR-124a, and similar to controls
expressed miR-564) were also evaluated with TaqMan miRNA
assays (Applied Biosystems) to validate the array results.
mRNA expression levels of neurogenic locus notch homolog
protein 1 (NOTCH1) and of hairy and enhancer of split 1 (HES1)
were measured in small intestinal tissues by qRT-PCR using single
TaqMan mRNA assays (Applied Biosystems) according to the
manufacturer’s instructions and using the housekeeping gene beta-
actin as control. Reverse transcription reactions were performed
with the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). The expression levels of miRNAs and mRNAs were
quantified using the ABI Prism 7900HT Sequence Detection
System 2.3 software.
Transfection and inhibition experiments
The oligonucleotides, plasmids (pGL3-control, pRL-NOTCH1-
encoding, pRL-KLF4-encoding and mutated pR-KLF4-encoding,
firefly luciferase and Renilla luciferase, respectively) and human
embryonic kidney cell lines (HEK293 cell line, ATCC number
CRL-1573, supplied by the Centre for Applied Microbiology and
Research, Salisbury, Wiltshire, UK) used for cell transfection
experiments are described in detail in the online Materials and
Methods S1.
Forty-eight hours after transfection, we measured firefly and
Renilla luciferase activities using a dual luciferase assay according
to the manufacturer’s instructions (Promega, Naples, Italy).
Protein evaluation by immunohistochemistry
Given the small amount of sample available for each patient (1–
2 mg of intestinal tissue/patient) we tested the expression of
selected proteins by immunohistochemistry instead of by western
blotting. The NOTCH1, HES1, MUC-2, KLF4, Ki67 and beta-
catenin proteins were identified on formalin-fixed paraffin-
embedded small intestinal tissue blocks in CD patients and in
controls. We randomly selected six active CD, six GFD and four
controls (see Materials and Methods S1 for details). We also tested
the specificity of our NOTCH1 and HES1 signals evaluating two
different human tissue samples where it is known NOTCH1 and
HES1 be present or absent respectively, that are colon cancer and
endothelial wall (Figure S8).
Scanning and automated image analysis of NOTCH1 and
HES1
To increase precision, we automated the quantification of the
immunohistochemical signals. Sections of the small intestine were
scanned with the NanoZoomer 2.0 system (Hamamatsu, Japan),
equipped with a 206, 0.7 Numerical Aperture Plan-Apochromat
lens, using a lens of 0.23 mm pixel size. The compressed jpeg files
were transferred to the Definiens Analyst LS5.0 system (Definiens
AG, Germany) that counted the NOTCH1, HES1 and beta-
catenin -positive and -negative cells and quantified the staining
signal (see materials and methods S1 for Definiens Analyst
software details). The Definiens Analyst software (Definiens AG,
Germany) is based on cognition network technology that is a
semantic network of objects and their mutual relationships. Two
rule sets, using cognition network language, were specifically
written for this evaluation to automatically detect and measure the
small intestinal area and to count positive and negative crypt cells.
The signal was classified as intensely stained, low/moderate
stained and unstained. Thus, both the percentage and intensity of
labeled cells were taken into account. The detection and exclusion
of areas not belonging to crypt were visually checked for all image
files. Ten crypts/patient were counted.
Immunohistochemical analysis of MUC-2, KLF4 and beta-
catenin
Because the MUC-2 staining of goblet cells was patchy, we
picked ten crypts from each slide and manually counted the
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number of goblet cells stained in each crypt. We also evaluated
MUC-2 staining of villi, when possible, i.e., in GFD patients and
controls. We also evaluated KLF4-positive villi (in GFD patients)
and both beta-catenin- and Ki67-positive nuclei/crypt in each
subject. Two independent observers evaluated the immunohisto-
chemical slides.
Statistics
All variables were expressed as mean6standard error of the
mean (SEM). Student t’s test and ANOVA were used to compare
group means and p values,0.05 were considered significant.
Statistically significant (p,0.01) miRNA-regulated pathways were
selected by the GOTM program.
Supporting Information
Materials and Methods S1
(DOC)
Figure S1 Bioinformatics analysis of miR-449a putative
target genes. miR-449a putative target genes with most favor-
able context score, selected by bioinformatics, were sorted into
pathways using GOTM(http://bioinfo.vanderbilt.edu/webgestalt/)
and then combined into functional groups. (http://mirecords.
biolead.org/interactions.php?species=Homo+sapiens&mirna_acc
=hsa-miR-449a&targetgene_type=refseq_acc&targetgene_info=&
v=yes&search_int=Search) (http://www.targetscan.org/cgibin/
targetscan/vert_50/targetscan.cgi?species=Human&gid=&mir_sc
=&mir_c=&mir_nc=&mirg=hsa-miR-449a). In each functional
group are reported the genes belonging to NOTCH pathway/
total gene number.
(TIF)
Figure S2 The luciferase assay confirms that miR-449a
inhibits the expression of NOTCH1 and KLF4. In
HEK293 cells co-transfected or with pRL-NOTCH1 vector
(panel A) or with pRL-KLF4 vector (panel B), a pre-miR-449a
concentration of 100 nmol/L was sufficient to significantly reduce
(respectively, p = 0.001 and p=0.002) Renilla luciferase activity
versus control values. No inhibition of the Renilla luciferase
expression was observed in mutant 39UTR of KLF4-mRNA with
miR-449a, so confirming the miR-449a/39UTR KLF4-mRNA
direct interaction (panel B). We didn’t verify the interaction miR-
449a/39UTR NOTCH1 being this latter recently validated by
Marcet B et al [32].
(TIF)
Figure S3 Automated Counts of NOTCH1 and HES1
stained/unstained cells. A. Automated counts of NOTCH1
stained/unstained cells (reported in Figure 2) in small intestine
from CD patients (6 active CD and 6 GFD patients) and from
controls (n = 4). Data are expressed as mean percent of intensely
stained, low-moderately stained and unstained cells of the total
intraepithelial cells (IECs) counted in ten crypts. The numbers of
intensely stained and unstained cells were significantly (p = 0.02)
higher and lower, respectively, in CTRL than in active CD and
in GFD patients. B. Automated counts of HES1 stained/
unstained cells (reported in Figure 3) in small intestine from
CD patients (6 active CD and 6 GFD patients) and from controls
(n = 4). Data are expressed as mean percent of intensely stained,
low-moderately stained and unstained cells of the total intraep-
ithelial cells (IECs) counted in ten crypts. The number of
intensely stained cells was significantly higher in controls versus
CD and GFD patients (p = 0.02) and the number of unstained
cells was significantly lower in CTRL than in active CD patients
(p = 0.03). (CTRL: controls; GFD: gluten free diet; CD: celiac
disease).
(TIF)
Figure S4 Other examples of NOTCH1 immunohisto-
chemistry in CD patients. Examples of NOTCH1 immuno-
histochemistry in 4 CD patients (2 active CD: TIII Marsh stage and 2
GFD: TI and T0 Marsh stage) and 2 controls (T0 Marsh stage). The
images show that the low expression levels of NOTCH1 in intestinal
mucosa fromCDpatients were always present fromTIII to T0Marsh
stage. (CTRL: controls; GFD: gluten free diet; CD: celiac disease).
(TIF)
Figure S5 Other examples of HES1 immunohistochem-
istry in CD patients. Examples of HES1 immunohistochemistry
in 4 CD patients (2 active CD: TIII Marsh stage and 2 GFD: TI and
T0 Marsh stage) and 2 controls (T0 Marsh stage). The images show
that the low expression levels of HES1 in intestinal mucosa from CD
patients were always present from TIII to T0 Marsh stage. (CTRL:
controls; GFD: gluten free diet; CD: celiac disease).
(TIF)
Figure S6 Decreased KLF4 and increased Ki67 expres-
sion in small intestine from CD patients compared with
controls. A. KLF4 staining of small intestinal villi in GFD
patients and Controls (Original magnification 206). A statistically
significant reduced KLF4-positive cells/villi were counted in GFD
patients than in controls, respectively 29.065.0 vs 79.063.0
(mean6SEM) (p,0.0001). B. Increased Ki67 signal is present in
small intestinal crypts of active CD, GFD patients than in controls
(Original magnification 206). (CTRL: controls; GFD: gluten free
diet; CD: celiac disease).
(TIF)
Figure S7 Increased expression of beta-catenin in small
intestine from CD patients compared with controls.
Immunostaining with beta-catenin in small intestinal crypts from
active CD, GFD and controls. We counted the beta-catenin
labeled nuclei. Similar counts of beta-catenin labelled nuclei were
detected in the crypts of the small intestine in all groups. However,
higher even if not statistical significant mean percentage counts
(beta-catenin positive nuclei/crypt) were obtained in active CD
and GFD than in controls, respectively 57.0611.5 and 37.064.6
vs 27.064.6 (Original magnification 636). (CTRL: controls; GFD:
gluten free diet; CD: celiac disease).
(TIF)
Figure S8 Specificity of NOTCH1 and HES1 signals by
immunohistochemistry. Specificity controls of NOTCH1 and
HES1 antibodies. Positive NOTCH1 (A) and HES1 (B) immuno-
staining signals obtained in human colon cancer and negative
NOTCH1 (C) and HES1 (D) immunostaining signals obtained in
human endothelial wall.
(TIF)
Table S1 MiRNAs differently expressed in active and
GFD CD patients.
(DOC)
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ABSTRACT: Adipose tissues show selective gene expression patterns, to
whom microRNAs (miRNAs) may contribute. We evaluated in visceral
adipose tissue (VAT) from obese and nonobese females, both miRNA and
protein expression proﬁles, to identify miRNA/protein target pairs associated
with obesity (metabolic pathways miRNA-deregulated during obesity). Obese
and nonobese females [BMI 42.2 ± 1.6 and 23.7 ± 1.2 kg/m2 (mean ± SEM),
respectively] were enrolled in this study. Notably, most miRNAs were down-
expressed in obese tissues, whereas most of the proteins from the investigated
spots were up-expressed. Bioinformatics integration of miRNA expression and
proteomic data highlighted two potential miRNA/protein target pairs: miR-
141/YWHAG (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, gamma polypeptide) and miR-520e/RAB11A (Ras-related
protein RAB-11A); the functional interaction between these miRNAs and
their target sequences on the corresponding mRNAs was conﬁrmed by luciferase assays. Both RAB11A and YWHAG proteins
are involved in glucose homeostasis; YWHAG is also involved in lipid metabolism. Hence, the identiﬁed miRNA/protein target
pairs are potential players in the obese phenotype.
KEYWORDS: obesity, visceral adipose tissue, miRNAs, 2D-DIGE
■ INTRODUCTION
Obesity is an epidemic health problem worldwide that causes
morbidity and mortality associated with increased risk of
cardiovascular disease, metabolic syndrome, and cancer.1,2 In
particular, central obesity, i.e., fat accumulated in visceral
adipose tissue (VAT), is the major risk factor for obesity-related
disorders.3,4 VAT represents up to 10−20% of total fat in men
and 5−8% in females. It is anatomically present in the
mesentery and omentum, and it drains directly to the liver
through the portal vein. This characteristic allows the direct
access of the free fatty acids and of adipokines released from fat
to the liver.4 In addition, adipose tissues show selective gene
expression patterns,2,3,5,6 to whom microRNAs (miRNAs) may
contribute.7 miRNAs are small noncoding RNAs ∼21
nucleotides long that bind speciﬁc regions of mRNA targets to
mediate their cleavage or translational repression, and they regulate
about 50% of human genes.8 In mammals, miRNAs have been also
shown to modulate adipocyte diﬀerentiation.9 Previous work from
our laboratory showed that up-expression of miR-519d in
subcutaneous adipose tissue (SAT) from obese patients was
associated with down-expression of the PPARA protein.10 There
are biological diﬀerences between VAT and SAT. In fact, compared
with SAT, VAT contains more large and insulin-resistant
adipocytes and inﬂammatory cells such as macrophages that
secrete pro-inﬂammatory cytokines (TNF-α, IL-6, and CRP).4
In the present study, we evaluated miRNA and protein
signatures using transcriptomic and proteomic approaches,
respectively, in VAT from the women studied previously. Our
aim was to investigate for metabolic pathways miRNA-
regulated in VAT that could be altered during obesity. Our
results indeed show that VAT from obese females is
characterized by peculiar miRNA and protein expression
signatures. Most of the tested miRNAs are down-expressed in
VAT from obese females. Accordingly, most of proteins in VAT
from the obese group showed increased levels by proteomic
proﬁle. Finally, the functional association of the transcriptomic
and proteomic proﬁles revealed two potential miRNA/protein
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target pairs in VAT, namely, miR-141/YWHAG (tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation pro-
tein, gamma polypeptide) and miR-520e/RAB11A (Ras-related
protein RAB-11A), which may contribute to altered gene
expression in obesity.
■ EXPERIMENTAL SECTION
Subjects and Experimental Design
Fifteen obese females (age range: 19−65 years, BMI [mean ±
SEM] 42.2 ± 1.6 kg/m2) and 10 nonobese females (age range:
19−57 years, BMI [mean ± SEM] 23.7 ± 1.2 kg/m2) were
enrolled in the study. During surgery (gastric banding or
laparoscopic cholecystectomy for obese and nonobese females,
respectively), a bioptic sample of VAT was collected and frozen
in liquid nitrogen. The main anamnestic, clinical, and general
characteristics of the enrolled subjects were recorded at
admission. The day before surgery, a fasted blood sample was
collected from all subjects and tested for the main biochemical
parameters (glucose, cholesterol, triglycerides, AST, ALT, ALP,
GGT) by routine methods (Table 1). Written informed consent
was obtained from all recruited subjects, and the study was
approved by the Ethics Committee of our Faculty of Medicine.
RNA Isolation
Total RNA (including miRNAs) was isolated from the VAT of
all subjects using the mirVana miRNA isolation kit (Ambion,
Austin, TX, USA) according to the manufacturer’s instructions.
RNA concentration was evaluated using the NanoDrop ND-
1000 UV−vis spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA).
The total RNA isolated from nonobese females was pooled
to serve as control in the comparison of the miRNA expression
proﬁles of the obese females.
miRNA Expression Proﬁle
We used the commercially available TaqMan Array Human
MicroRNA Panel v1.0 (Applied Biosystems Inc., Foster City,
CA, USA) to measure miRNA expression proﬁle in 10/15
obese and 4/10 nonobese females. The panel contains 365
diﬀerent human miRNA assays in addition to two small
nucleolar RNAs (snoRNAs) that function as endogenous
controls for data normalization. We used 80 ng of total RNA
for reverse transcription. RT-PCR was performed using the
7900 HT real-time PCR system (Applied Biosystems). The
miRNA expression values were normalized to RNU48
(endogenous control), and relative expression values were obtained
using the ΔΔCT method (relative quantiﬁcation, RQ = 2−ΔΔCT)
with sequence detection system (SDS) v2.3 and RQ Manager 1.2
software (Applied Biosystems). To further normalize our miRNA
data and to minimize interindividual variability, we considered
diﬀerently expressed the miRNAs whose mean RQ levels were
<0.5 (down-expressed) or >2.0 (up-expressed) in at least 6/10
obese females.
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR) of miRNAs and mRNAs
The expression levels of some selected miRNAs (miR-141,
miR-200c, miR-520e, and miR-520d) were also validated by
TaqMan miRNA assays (Applied Biosystems) in accordance
with the manufacturer’s instructions on the 7900 HT real-time
PCR system (Applied Biosystems). The expression of one of
these selected miRNAs, namely, miR-141, was preliminarily
tested in each nonobese control, and after ensuring that the
expression was comparable among these individuals, we pooled
their RNAs to obtain a control against which to compare
miRNA levels in obese females.
The expression levels of the selected miRNAs (miR-141,
miR-200c, miR-520e, and miR-520d) were ﬁrst normalized to
the endogenous control (RNU48), and then the relative
expression values were obtained versus the nonobese control
pool using the ΔΔCT method (relative quantiﬁcation, RQ =
2−ΔΔCT) with SDS v2.3 and RQ Manager 1.2 software (Applied
Biosystems).
Real-time RT-PCR of RAB11A and YWHAG mRNAs was
performed using gene- speciﬁc primers (RAB11a, forward:
AACATCAGCATATTATCGTGGA and reverse: GAT-
CACTCTTATTGCCCACA; YWHAG, forward: AGACC-
CAGCCCCGCGAAGAT and reverse: TCTGTCACGTTCT-
TCATGGCCGC), the Power SYBR Green PCR Master Mix
(Applied Biosystems) and the PRISM 7900HT sequence
detection system (Applied Biosystems).
Bioinformatic Analysis
Biological targets of miRNAs diﬀerently expressed in obese vs
nonobese females were predicted using the TargetScan Release
5.0 algorithm (http://www.targetscan.org). This algorithm
assigns a “total context score” for each predicted target. Target
genes with a “total context score” < −0.30 were further
analyzed using the KEGG database (http://www.genome.ad.
jp/kegg/) to identify the pathways that involve the target genes
of miRNAs and then using the Gene Ontology (GO) database
(http://www.geneontology.org/ontologies) to identify the
biological processes in which the proteins identiﬁed by DIGE
participate. Gene ontology classiﬁcation of the diﬀerentially
expressed proteins revealed by 2D-DIGE analysis was
performed in the web-accessible DAVID (v 6.7) annotation
system (http://david.abcc.ncifcrf.gov/home.jsp).11,12
Table 1. General Characteristics of the Obese (n = 15) and
Nonobese (n = 10) Females Enrolled in the Studya
females
obese nonobese
subjects (n) 15 10
age (years) 41.6 (4.4) 38.0 (3.5)
weight (kg)†b 115.2 (6.3) 62.5 (2.6)
height (m) 1.7 (0.04) 1.6 (0.01)
BMI (kg/m2)‡b 42.2 (1.6) 23.7 (1.2)
systolic blood pressure (mmHg) 133.6 (6.7) 115 (4.5)
diastolic blood pressure (mmHg)c 80.0 (80.0−90.0) 80.0 (70.0−80.0)
cardiac frequencyd 80.0 (2.2) 67.6 (3.7)
glucose (mmol/L)e 4.9 (0.2) 4.3 (0.2)
cholesterol (mmol/L) 5.9 (0.5) 5.8 (0.6)
triglycerides (mmol/L) 1.4 (0.1) 0.9 (0.1)
AST (U/L)c 18.5 (16.0−21.0) 18.0 (13.5−19.0)
ALT (U/L)c 17.0 (13.0−28.5) 14.0 (12.0−21.0)
ALP (U/L) 79.3 (5.8) 89.2 (19.3)
GGT (U/L) 28.5 (4.7) 17.3 (3.5)
aData are expressed as mean (SEM) value (unless speciﬁed otherwise)
and interquartile range (nonparametric distributions). bStatistically
signiﬁcant diﬀerences (designated by † and ‡) at Student's t test
p < 0.0001. cData are expressed as median value. dp = 0.01. ep = 0.03.
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Preparation of Protein Extracts and Two-Dimensional
Fluorescence Diﬀerence Gel Electrophoresis (2D-DIGE)
Analysis
Protein extracts from VAT samples of 6/15 obese and 3/10
nonobese females were prepared using a lysis buﬀer containing
2% SDS, 10% glycerol, 6.25 mM Tris-HCl pH 6.8, 0.5 mM
EDTA, 20 mM NaF, 1 mM Na3VO4 (Santa Cruz Biotech-
nology, Santa Cruz, CA), and the Sigma-Aldrich cocktail of
protease inhibitors. The suspensions were shaken in Tissue
Lyser II (Qiagen) for 4 min at maximum frequency. After
30 min on ice, samples were centrifuged at 15000g for 10 min
at 4 °C. The clear interface of each sample was recovered and
was transferred to a clean tube. Protein concentrations were
determined by the Bradford method using BioRad protein
reagent (Bio-Rad Laboratories, Hercules, CA). For 2D-DIGE
analysis, proteins extracted from VAT were precipitated for
16 h at −20 °C with 9 volumes of a mix composed of acetone
and methanol (9:1) and then centrifuged at 15000g for 30 min
at 4 °C; protein pellets were solubilized in a buﬀer, UTC,
containing 7 M urea, 2 M thiourea, 4% CHAPS (3-[(3-
cholamidopropyl)dimethylammonium]-1-propane sulfonate) in
30 mM Tris-HCl. Protein concentrations were redetermined
after precipitation by using BioRad protein reagent. Thirty
micrograms of each protein extract were labeled with 240 pmol
of Cy3 or Cy5 ﬂuorescent dye on ice, in the dark for 30 min.
To exclude preferential binding of a label to a set of proteins,
we dye-swapped the samples. The internal standard containing
equal amounts of proteins from each sample was labeled with
Cy2. The same internal standard was run in all gels to
normalize the experiments and to reduce gel-to-gel variations.
Labeling reactions were stopped by adding 1 mM lysine.
Sample pairs labeled with Cy3 and Cy5 and the internal
standard were combined and used to hydrate passively
individual strips as follows: each mix of labeled samples was
diluted in UTC solution containing 130 mM DTT, 2% IPG
Buﬀer pH 3−10 NL (GE Healthcare, Buckinghamshire, UK),
2.8% DeStreak reagent (GE Healthcare) in a ﬁnal volume of
400 μL. The mixtures were used to hydrate 24 cm IPG strips
pH 3−10NL required for protein separation in the ﬁrst
dimension. Isoelectric focusing (IEF) was run in an IPGphor II
apparatus (GE Healthcare) according to this voltage protocol:
300 V for 3 h, linear gradient to 600 V in 3 h, linear gradient to
1000 V in 3 h, linear gradient to 8000 V in 5 h, 8000 V for 6 h.
After the ﬁrst dimension, the strips were equilibrated in
equilibration buﬀer (100 mM Tris-HCl, 6 M urea, 30% (v/v)
glycerol, 2% (w/v) SDS, and trace of bromophenol blue,
pH 8.0) containing 0.5% (w/v) DTT for 15 min and thereafter
in equilibration buﬀer containing 4.5% (w/v) iodoacetamide for
a further 15 min. The equilibrated strips were transferred onto
12% polyacrylamide gels for the second dimension (Ettan Dalt
six electrophoresis system, GE Healthcare). The SDS-PAGE
electrophoresis was run using a Peltier-cooled DALT II
Electrophoresis unit (GE Healthcare) at 30W. After the
electrophoresis, the gels were scanned with a Typhoon 9400
variable mode imager (GE Healthcare) at 100 μm resolution,
using appropriated individual excitation/emission wavelengths:
488/520 for Cy2, 532/580 for Cy3 and 633/670 for Cy5. The
images were captured with Image Quant software and were
analyzed with DeCyder software (GE Healthcare). We chose
the most representative gel as master gel to compare results
obtained from other samples. Globally we analyzed VAT
samples from 6 randomly selected obese (mean BMI 38.7) and
3 nonobese females (mean BMI 23.5). We used the Student’s t
test to determine the fold change between obese and nonobese
females. Only protein spots with a p < 0.05 were investigated
further.
Protein Identiﬁcation with Liquid
Chromatography−Tandem Mass Spectrometry
(LC−MS/MS)
We used 250 μg of protein sample for the preparative gel. After
2D-electrophoresis, performed under the conditions reported
for the analytical experiment, the gel was stained with SYPRO
Ruby ready-to-use formula (BIORAD), and the spot map so
obtained was matched with the analytical reference gel. The
spots diﬀerentially expressed in obese and nonobese females
were excised from the preparative gel using the Ettan Spot
Picker robotic system (GE Healthcare). The excised spots were
analyzed with LC−MS/MS (Functional and Structural
Proteomics Facility, CEINGE−Biotecnologie Avanzate, Italy).
The excised spots were washed in 50 mM ammonium
bicarbonate pH 8.0 in 50% acetonitrile to a complete
destaining. The gel pieces were resuspended in 50 mM
ammonium bicarbonate pH 8.0 containing 100 ng of trypsin
and incubated for 2 h at 4 °C and overnight at 37 °C. The
supernatant containing the resulting peptide mixtures was
removed, and the gel pieces were re-extracted with acetonitrile.
The two fractions were then collected and freeze-dried. The
peptide mixtures were further analyzed by LC−MS/MS using
the LC−MSD Trap XCT Ultra apparatus (Agilent Technolo-
gies, Palo Alto, CA, USA) equipped with a 1100 HPLC system
and a chip cube (Agilent Technologies). After loading, the
peptide mixture (8 μL in 0.5% TFA) was ﬁrst concentrated at 4
μL/min in 40 nL enrichment column (Agilent Technologies
chip), with 0.1% formic acid as eluent. The sample was then
fractionated on a C18 reverse-phase capillary column (75 μm ×
43 mm in the Agilent Technologies chip) at a ﬂow rate of 300
nL/min, with a linear gradient of eluent B (0.1% formic acid in
acetonitrile) in eluent A (0.1% formic acid) from 7 to 50% in
35 min. Elution was monitored on the mass spectrometer
without a splitting device. Peptide analysis was performed using
data-dependent acquisition of one MS scan (m/z range from
400 to 2000 Da/e) followed by MS/MS scans of the three most
abundant ions in each MS scan. Dynamic exclusion was used to
acquire a more complete survey of the peptides by automatic
recognition and temporary exclusion (2 min) of ions from
which deﬁnitive mass spectral data had previously been
acquired. A permanent exclusion list of the most frequent
peptide contaminants (keratins and trypsin peptides) was
included in the acquisition method in order to focus on
signiﬁcant data. Mass spectral data obtained from the LC−MS/
MS analyses were used to search a nonredundant protein
database using an in-house version of the Mascot v. 2.1 (Matrix
Science, Boston, MA, USA) software and NCBI database
(221,338 human sequences, timestamp: March and April,
2009). Peptide mass values and sequence information from the
LC−MS/MS experiments were used in the MS/MS ion search
taking into account the Carbamidomethyl-Cys as ﬁxed
modiﬁcation, Met oxidized, Pyro-Carbamidomethyl-Cys (with
N-term Carbamidomethyl-Cys) and Pyro-Glu (with N-term E)
as variable modiﬁcations. The maximum missed cleavage of 1,
and a precursor ion and fragment ion mass tolerance of ±600
ppm and 0.6 Da, respectively, were used. In agreement with the
proposed Guidelines for the Analysis and Documentations of
Peptide and Protein Identiﬁcations (Paris Consensus), we
report the number of identiﬁed peptides whose individual ion
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score (as provided by Mascot) was higher than the designated
conﬁdence level (95%)/protein sequence coverage (%). The
sequences and charge state of the peptides used for protein
identiﬁcation of each DIGE spot obtained by LC−MS/MS are
reported in Supporting Information Table S1.
Western Blot
Protein evaluation by Western blot was performed in 8/15
obese and 7/10 nonobese females with 35 μg of total proteins
separated by SDS-PAGE (13% polyacrylamide gel) and
electroblotted onto hydrophobic polyvinylidene diﬂuoride
(PVDF) membranes (Amersham) for 19 h at 33 V. Blots
were blocked with 5% BSA in TBS buﬀer with 0.1% Tween 20
for 2 h at room temperature. Immunoblotting was performed
with the speciﬁc polyclonal antibody: rabbit anti-14-3-3γ
(dilution 1:800), rabbit anti-RAB11A (1 μg/mL), and rabbit
antiactin (dilution 1:800) (Abcam, Cambridge, UK) for 4 h.
For the following incubation with primary antibody, membrane
was washed in TBS buﬀer with 0.1% Tween 20 and incubated
for 45 min IgG-HRP-conjugated secondary antibody (dilution
1:10000 for anti-14-3-3γ and antiactin; 1:50000 for anti-
RAB11A). Immunoreactive bands were visualized with the
chemiluminescence reagent kit (ECL Western blotting
detection reagents, GE Healthcare). We used the same
membrane for each immunoblot, washing it in TBS buﬀer
with 0.1% Tween 20 for 10 min after each experiment.
After each immunoblot, the membrane was exposed to X-ray
ﬁlm (Amersham) for diﬀerent times. The images of three
diﬀerent exposures were captured by Gel Doc XR (Bio-Rad)
and quantitated with the Quantity One software (Bio-Rad).
Each protein band was contained within a rectangular area,
identical for each sample, and background values were
subtracted from each band. The triplicate sample values were
normalized to the corresponding triplicate actin values. Then,
the mean values from the diﬀerent ratio calculations were
calculated for each sample. The data were expressed as percent
relative expression, the sample with the highest expression of
either RAB11A or YWHAG having been set as 100%. The data
obtained were used to obtain the corresponding box plots and
p-values (Student’s t test) in the Microsoft Excel software.
Oligonucleotides and Plasmids
Chemically modiﬁed double-stranded RNA molecules (micro-
RNA precursor molecules: pre-miR-520e and pre-miR-141)
and pre-miR-negative control were purchased from Ambion
(Austin, TX, USA). The ﬁnal concentration of pre-miR
molecules and the corresponding pre-miR negative control
were 100 nM each. The plasmids used were pGL3-control
(Promega Corp., Madison, WI, USA) encoding for ﬁreﬂy
luciferase and pRL-CMV encoding for Renilla luciferase
(Promega Corp., Madison, WI, USA). The 3′UTRs of
RAB11A (1258−1264 bp 3′UTR) and of YWHAG (2489−
2495 bp 3′UTR) genes, containing respectively the miR-520e
and miR-141 binding sites, as well as the mutated 3′UTRs of
these two genes (three bases of each seed region were changed
by complementary bases), were obtained from genomic DNA
by PCR with a sense and antisense primers carrying a XbaI
restriction site and cloned downstream to Renilla luciferase
gene in pRL-CMV vector in XbaI site.
Cell Culture, Transfection, and Luciferase Assay
Human embryonic kidney (HEK) 293 cells were cultured in
DMEM (Invitrogen) supplemented with 2 mM glutamine
(Invitrogen), 100 U/mL penicillin/streptomycin (Invitrogen),
and 10% FBS (Invitrogen). The day before transfection, cells
were plated in 24-well plates to allow adherence and to reach
70−90% conﬂuence at the time of transfection. Transfection of
plasmids, carrying wild-type or mutant 3′UTRs, with pGL3-
control and each pre-miRNAs or pre-miR negative control
(Ambion, Austin, TX, USA) in HEK293 was performed using
Lipofectamine 2000 following the manufacturer’s instructions.
Fireﬂy and Renilla luciferase activities were measured 48 h after
transfection, with the dual-luciferase reporter system (Prom-
ega) in a Sirius Luminometer (Berthold Detection Systems,
Huntsville, AL, USA). All transfection experiments were done
in triplicate.
Statistical Analysis
The investigated parameters were expressed as mean ±
standard error of the mean (SEM) (parametric distribution)
or as median value and interquartile range (nonparametric
distributions). Student’s t test was used to compare group
means, and a p-level < 0.05 was considered statistically signiﬁcant.
Statistical analyses were carried out with the PASW package for
Windows (Ver.18; SPSS Inc. Headquarters, Chicago, Ill).
■ RESULTS
miRNA Expression Signature in Visceral Adipose Tissue
from Obese Females
Expression proﬁle showed that a large set of the tested miRNAs
was expressed in VAT from both obese and nonobese females
(243/365, 66%). A small set (50/365, 14%) was not expressed,
whereas 72/365 (20%) miRNAs were expressed only in VAT
from one or more obese females. On the basis of the
normalization criteria reported above (see the Experimental
Section), namely, miRNAs whose expression levels versus
controls were up- or down-expressed (respectively, RQ > 2 or <
0.5) in at least 6/10 obese females, we found that 61/243 (25%)
miRNAs were down-expressed, and 10/243 (4.1%) miRNAs were
up-expressed (Table 2). The search for gene targets of these
diﬀerentially expressed miRNAs was performed by TargetScan
5.0 algorithm and their assembly in metabolic pathways by
Kegg database. The main signiﬁcant (p < 0.01) pathways
predicted to be aﬀected by miRNAs in VAT samples during
obesity are reported in Supplementary Figure 1.
Protein Expression Signature in VAT from Obese Females
We studied the protein expression signature of VAT samples
from obese and nonobese subjects using 2D-DIGE analysis.
Figure 1A shows the master gel used to match the whole set of
the 2-DE proﬁles obtained. The analysis performed with
DeCyder Software detected approximately 2700 protein spots
per gel in a 3−10 pH range, with a molecular mass of 10−120
kDa. Approximately 1500 spots were matched throughout the
gels. The DeCyder statistical analysis revealed 172 spots
diﬀerentially expressed in obese vs nonobese VAT samples with
average ratio ≥ 1.50 for up-expressed protein spots and ≤
−1.50 for down-expressed spots (p < 0.05). Some spots were
excluded from further evaluation, i.e., those at the extreme right
and left sides of the gel and those (30 spots) representing
contaminating serum proteins. Furthermore, many spots were
not objected to further investigation, because of their low
abundance on the analytical gel or on the preparative gel. As a
result, we focused on 33 spots with optimal features.
Figure 1B shows the position of the 33 selected spots on the
preparative gel. The latter was stained with SYPRO Ruby
protein stain and used for automated spot picking. The isolated
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spots were digested with trypsin and then analyzed by LC−
MS/MS, followed by database search. The relative expression
ratios (in obese vs nonobese VAT) for each of the 33 spots and
their statistical values are listed in Table 3. Interestingly, most
(32/33) of the spots were increased, and only 1 spot (number
2312) was decreased.
Globally, a total of 67 proteins, after the exclusion of very
abundant proteins that we considered not informative, were
identiﬁed in these spots (http://pubs.acs.org/paragonplus/
submission/jprobs/jprobs_proteomics_guidelines.pdf) (Table
3). Most of these proteins were bioinformatically predicted
by DAVID database to be functionally annotated in two main
clusters (Figure 2). Annotation cluster 1 (Figure 2A) was con-
stituted by the following: (i) 5 members of the 14.3.3 family of
proteins, namely, YWHAB, YWHAE, YWHAG, YWHAH, and
YWHAZ; (ii) 9 proteins (YWHAB, YWHAE, YWHAZ,
RAB11A, RAB7A, ANXA7, ARCN1, FLOT1, and SERPINF1)
involved in the GOTERM_CC_FAT vesicle pathway, on the
basis of their subcellular localization; and (iii) 7 regulated
proteins involved in intracellular protein transport (YWHAB,
YWHAE, YWHAH, YWHAG, YWHAZ, RAB11A, and
ARCN1). Annotation cluster 2 (Figure 2B) was constituted
by a predominance of metabolic enzymes clustered in the
KEGG pathways: valine, leucine, and isoleucine degradation
(6 members, ACAT2, ACADS, ALDH2, BCKDHA, ECHS1, and
HADHB), butanoate metabolism (5 members, ACAT2, ACADS,
ALDH2, ECHS1, and PDHAD1) and fatty acid metabolism
(5 members, ACAT2, ACADS, ALDH2, ECHS1, and HADHB).
miRNA/Protein Target Pairs in VAT from Obese Females
To ﬁnd potential miRNA/protein target pairs, we integrated
miRNA expression and proteomic data. Speciﬁcally, we
combined the list of the identiﬁed protein spots with the
miRNAs predicted to possess the ability to target the proteins
we identiﬁed. The last column of Table 3 shows the potential
miRNA counterparts of the identiﬁed proteins, as revealed by
bioinformatics tools (TargetScan). Among the potential
miRNA/protein target pairs deriving from this analysis, we
Table 2. Diﬀerentially Expressed miRNAs in Visceral Adipose Tissue from Obese Vs Nonobese Females Identiﬁed with the
TaqMan Array Human MicroRNA Panel v1.0a
RQ value
down-expressed miRNAs mean SEM
hsa-miR-514-4373240 0.007 0.002
hsa-miR-520e-4373255 0.014 0.005
hsa-miR-520f-4373256 0.029 0.010
hsa-miR-184-4373113 0.030 0.010
hsa-miR-518d-4373248 0.057 0.021
hsa-miR-196a-4373104 0.059 0.019
hsa-miR-337-4373044 0.065 0.025
hsa-miR-520d-4373254 0.066 0.022
hsa-miR-490-4373215 0.067 0.025
hsa-miR-508-4373233 0.069 0.022
hsa-miR-519c-4373251 0.073 0.026
hsa-miR-369-3p-4373032 0.075 0.025
hsa-miR-202-4378075 0.078 0.027
hsa-miR-141-4373137 0.079 0.025
hsa-miR-562-4380939 0.080 0.030
hsa-miR-591-4380955 0.085 0.028
hsa-miR-580-4381024 0.086 0.029
hsa-miR-380-5p-4373021 0.086 0.029
hsa-miR-518a-4373186 0.092 0.035
hsa-miR-618-4380996 0.096 0.034
hsa-miR-494-4373219 0.097 0.037
hsa-miR-624-4380964 0.099 0.035
hsa-miR-519b-4373250 0.102 0.032
hsa-miR-185-4373181 0.113 0.043
hsa-miR-219-4373080 0.120 0.042
hsa-miR-509-4373234 0.124 0.039
hsa-miR-548d-4381008 0.125 0.047
hsa-miR-206-4373092 0.126 0.042
hsa-miR-200c-4373096 0.130 0.041
hsa-miR-196b-4373103 0.166 0.055
hsa-miR-653-4381012 0.168 0.068
hsa-miR-493-4373218 0.178 0.059
hsa-miR-629-4380969 0.181 0.074
hsa-miR-198-4373101 0.187 0.062
hsa-miR-450-4373208 0.199 0.070
hsa-miR-375-4373027 0.202 0.071
hsa-miR-518b-4373246 0.208 0.069
RQ value
down-expressed miRNAs mean SEM
hsa-miR-137-4373174 0.222 0.091
hsa-miR-649-4381005 0.224 0.079
hsa-miR-189-4378067 0.226 0.080
hsa-miR-489-4373214 0.240 0.085
hsa-miR-451-4373209 0.242 0.099
hsa-miR-615-4380991 0.248 0.083
hsa-miR-335-4373045 0.250 0.088
hsa-miR-215-4373084 0.264 0.088
hsa-miR-422b-4373016 0.271 0.090
hsa-miR-500-4373225 0.271 0.111
hsa-miR-601-4380965 0.285 0.108
hsa-miR-203-4373095 0.298 0.122
hsa-miR-410-4378093 0.298 0.122
hsa-miR-330-4373047 0.320 0.121
hsa-miR-30a-5p-4373061 0.324 0.122
hsa-miR-486-4378096 0.327 0.133
hsa-miR-22-4373079 0.332 0.125
hsa-miR-181c-4373115 0.332 0.117
hsa-miR-30d-4373059 0.334 0.126
hsa-miR-101-4373159 0.346 0.141
hsa-miR-376a-4373026 0.372 0.152
hsa-miR-191-4373109 0.386 0.146
hsa-miR-99a-4373008 0.393 0.161
hsa-miR-7-4373014 0.396 0.162
RQ value
up-expressed miRNAs mean SEM
hsa-miR-433-4373205 21.563 7.624
hsa-miR-520 h-4373258 13.617 5.559
hsa-miR-153-4373125 12.447 4.705
hsa-miR-579-4381023 12.047 4.553
hsa-miR-520b-4373252 9.400 3.553
hsa-miR-616-4380992 3.954 1.495
hsa-miR-296-4373066 3.872 1.463
hsa-miR-517c-4373264 3.342 1.365
hsa-miR-501-4373226 3.068 1.160
hsa-miR-594-4380958 2.714 1.108
aThe normalization criteria are detailed in the Experimental Section. Data are expressed as RQ. RQ value was calculated as 2−ΔΔCt (see the
Experimental Section for details), and it is reported as mean and SEM.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr300152z | J. Proteome Res. 2012, 11, 3358−33693362
selected those including miRNAs down-expressed in almost all
VAT samples (9/10 or 10/10): miR-206/ARCN1 (spot 751);
miR-141/YWHAG and miR-200c/YWHAG (spot 2005); miR-
206/YWHAZ (spot 2054); miR-520d/RAB11A and miR-520e/
RAB11A (spot 2229) (bold characters in Table 3).
The expression levels of the above miRNAs (miR-206, miR-
141, miR-200c, miR-520e, and -520d) were further validated by
qRT-PCR. The qRT-PCR results, except slight diﬀerences due
to the two diﬀerent methodologies, were in close agreement
with those obtained by TaqMan array (respectively, mean RQ
± SEM): miR-206 (0.209 ± 0.066 vs 0.126 ± 0.042), miR-141
(0.099 ± 0.032 vs 0.079 ± 0.025), miR-200c (0.138 ± 0.044 vs
0.130 ± 0.041), miR-520e (0.554 ± 0.175 vs 0.014 ± 0.005),
except for miR-520d, whose results did not diﬀer from controls
in the qRT-PCR validation (0.944 ± 0.299 vs 0.066 ± 0.022).
Consequently the miR-520d was discarded in our following
evaluations.
All the miRNA/protein target pairs reported above warrant
further investigation. However, functional annotation clustering
in the DAVID database revealed that ARCN1, YWHAG,
YWHAZ, and RAB11A are present in the annotation cluster
intracellular protein transport (Figure 2A), which may be
involved in the physiopathology of the adipose tissue. Among
the miRNAs associated to these targets, miR-141 and miR-520e
were accordingly regulated in the complete set of RNA samples
(10/10) from obese VAT. Thus, we selected the functional
pairs miR-141/YWHAG and miR-520e/RAB11A for further
analysis.
Since the eﬀects of miRNA down-regulations may result in
increased mRNA stability and/or mRNA translation, we tested
the transcript levels for RAB11A and YWHAG by qRT-PCR.
We indeed observed that both mRNAs were more abundantly
expressed in VAT of obese women (RQ ± SEM: 6.1 ± 2.6 and
4.8 ± 0.7, respectively) compared to control VAT mRNA
samples (data not shown). Next, we tested YWHAG and
RAB11A protein expression by Western blot in VAT from a
subset of obese (8/15) and nonobese (7/10) females whose
samples were available. These samples were also probed with an
actin antibody for protein normalization. As shown in Figure 3,
both YWHAG and RAB11A proteins were signiﬁcantly (p = 0.001
and p = 0.00001, respectively) up-expressed in obese than in
nonobese VAT tissues.
Taken together, our data suggest that in VAT from obese
females, there is a functional interplay between the mRNAs of
two up-expressed proteins (YWHAG and RAB11A, as emerged
from 2D-DIGE analysis, qRT-PCR, and Western blot
validations) and two down-expressed miRNAs (miR-141 and
miR-520e, respectively, as revealed by the transcriptomic
screening and qRT-PCR analysis). Thus, to determine whether
the mRNAs of YWHAG and RAB11A are targets of miR-141
and miR-520e, respectively, we cloned the regions encompass-
ing the 3′UTRs of the two mRNAs downstream the Renilla
luciferase gene, under the transcriptional control of the
cytomegalovirus promoter. The constructs were cotransfected
with the pre-miRNAs for miR-141 or miR-520e, and as a
transfection control, we used a pGL3-control that expresses
ﬁreﬂy luciferase. As shown in Figure 4, both pre-miR-520e (A)
and pre-miR-141 (B) signiﬁcantly reduced the normalized
Renilla luciferase activities of the constructs containing
respectively the RAB11A (p = 0.004) and the YWHAG
3′UTRs (p = 0.02). No inhibition was observed in mutant
3′UTR of RAB11A (A) and YWHAG (B) constructs. These
data are consistent with a functional interaction between the
selected miRNAs and the 3′UTRs of their mRNA targets,
thereby suggesting that changes in the levels of these two
miRNAs may modulate the expression of RAB11A and
YWHAG.
■ DISCUSSION
Understanding the molecular mechanisms underpinning
obesity could pave the way for new therapeutic strategies to
contrast obesity-related metabolic disorders. miRNAs, which
Figure 1. 2D-DIGE of visceral adipose tissue (VAT) proteins. (A) Scan of master gel used to match protein spots from the diﬀerent gels used for the
analysis. This gel is constituted by three overlapped images: (1) VAT proteins of a nonobese female labeled with Cy3 (green), (2) VAT proteins of
an obese female labeled with Cy5 (red), and (3) VAT proteins from a mixture of the random selected samples (used for normalization) labeled with
Cy2 (blue). (B) Scan of preparative gel of VAT proteins from a mixture of samples stained with SYPRO Ruby protein stain. Numbers correspond to
diﬀerentially expressed protein spots as indicated in Table 3.
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Table 3. Identiﬁcation and Characterization of Proteins Diﬀerently Expressed in Visceral Adipose Tissue from Obese Vs
Nonobese Females by 2D-DIGE Analysis Followed by LC−MS/MS
spot no.a
DIGE
(p-value)b
DIGE
obese/
controlc accession no.d protein name
MW
(Da)e pIf
no. of qualified
peptides/
coverage (%)g scoreh gene symboli miRNAj
B1_750 0.035 1.7 gi/5031875 Lamin A/C isoform 2 65153 6.40 13/25 743 LMNA
gi/20127454 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase/IMP
cyclohydrolase
65089 6.27 7/16.5 440 ATIC
gi/5803181 Stress induced phosphoprotein 1 63227 6.40 4/9 228 STIP1
C1_751 0.023 1.73 gi/55960506 Chaperonin containing TCP1, subunit 3
(gamma)
58505 6.46 17/43 1043 CCT3
gi/4503377 Dihydropyrimidinase −like 2 62711 5.95 7/19 465 DPYSL2
gi/11863154 Archain isoform 1 57630 5.89 9/19 503 ARCN1* mir-206
gi/189926 Phosphoglucomutase 1 61674 6.35 4/9 208 PGM1* mir-30a,
-30d
gi/6009626 Brain carboxylesterase hBr1 47100 6.02 3/8 189 CES1
D1_ 976 0.004 1.67 gi/5453603 Chaperonin containing TCP1, subunit 2 57794 6.01 17/50 1271 CCT2
gi/178390 Aldehyde dehydrogenase 56858 7.00 6/15 387 ALDH2
gi/2183299 Aldehyde dehydrogenase 1 55427 6.30 5/12 319 ALDH1
gi/5771523 3-phosphoglycerate dehydrogenase 57370 6.29 4/9 225 PHGDH
E1_993 0.011 1.78 gi/16306550 Selenium binding protein 1 52928 5.93 13/37 711 SELENBP1
F1_1021 0.008 2.01 gi/15620780 Glutamate carboxypeptidase 53161 5.71 3/7 143 CNDP2
G1_1092 0.039 1.88 gi/5174529 Methionine adenosyltransferase II, alpha 43975 6.05 2/7 143 MAT2A* mir-30a,
-30d,-22
H1_1119 0.007 1.43 gi/4504169 Glutathione synthetase 52523 5.67 7/23 458 GSS
gi/1049219 Gamma-aminobutyraldehyde
dehydrogenase
54410 6.01 5/11 306 E3
gi/21410323 Perilipin 56216 5.82 2/5 112 PLIN
A2_1154 0.003 1.61 gi/21361144 Proteasome 26S ATPase subunit 3 49458 5.13 15/50 843 PSMC3
gi/340219 Vimentin 53738 5.03 4/9 273 VIM
gi/7106299 Ataxin 10 54196 5.12 4/4 241 ATXN10
B2_1158 0.011 1.48 gi/4503571 Enolase 1 47481 7.01 13/46 906 ENOI
gi/40068518 Phosphogluconate dehydrogenase 53619 6.8 6/17 427 PGD
C2_1173 0.003 1.87 gi/4503481 Eukaryotic translation elongation factor 1
gamma
50429 6.25 10/34 576 EEF1G
gi/496902 Translation initiation factor 47088 6.08 5/7 297 E2F1
gi/4504327 Mitochondrial trifunctional protein, beta
subunit precursor
51547 9.45 4/9 207 HADHB* mir-203
D2_1174 0.006 2.08 gi/5031699 Flotillin 1 47554 7.08 4/12 265 FLOT1
E2_1182 0.002 2.01 gi/4502111 Annexin VII isoform 1 50569 6.25 9/24 526 ANXA7
gi/7546384 Chain A, Human branched- chain Alpha-
Keto Acid Dehydrogenase
45770 6.32 4/11 213 BCKDHA
gi/4099506 ErbB3 binding protein EBP1 38321 7.15 4/15 211 PA2G4
gi/18379349 Vesicle amine transport protein 1 42122 5.88 2/8 121 VAT1
F2_1202 0.012 1.85 gi/39725934 Serine (or cysteine) proteinase inhibitor,
clade F member 1
46454 5.97 11/38 695 SERPINF1
gi/9836652 BSCv 47887 5.78 5/13 305 C20ORF3
gi/285975 Human rab GDI 51088 5.94 2/5 116 GDI
gi/515634 Ubiquinol-cytochrome C reductase core I
protein
53270 5.94 2/4 122 UQCRC1
gi/338695 Beta-tubulin 50240 4.75 2/5 121 TUBB
G2_1221 0.045 2.61 gi/4503529 Eukaryotic translation initiation factor 4A
isoform 1
46353 5.32 8/27 487 EIF4A1
H2_1268 0.013 1.6 gi/181914 DNA-binding protein 36086 9.20 2/7 122
A3_1271 0.002 1.54 gi/33415057 Transformation-related protein 14 43248 5.49 5/19 309 TRG14
B3_1272 0.010 1.99 gi/4557809 Ornithine aminotransferase precursor 48846 6.57 7/23 435 OAT
gi/387011 Pyruvate dehydrogenase E1-alpha
precursor
47098 8.79 4/9 265 PDHA1* mir-203
gi/3641398 NADP-dependent isocitrate dehydrogenase 46944 6.34 2/7 86 IDH1* mir-30a,
-30d
C3_1299 0.004 1.81 gi/24308406 Secernin 2 46989 5.44 4/16 231 SCRN2
gi/6678271 TAR DNA binding protein 45053 5.85 2/7 162 TARDBP* mir-137,
-203
D3_1352 0.006 1.67 not identified
E3_1410 0.023 1.59 gi/4557233 Acyl-Coenzyme A dehydrogenase, C-2 to
C-3 short chain precursor
44611 8.13 8/30 436 ACADS
gi/148539872 Acetyl-Coenzyme A acetyltransferase 2 41783 6.47 2/8 99 ACAT2
F3_1521 0.006 1.64 gi/7661704 Osteoglycin preprotein 34243 5.46 5/18 307 OGN* mir-22
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have been involved in the regulation of a variety of biological
processes, including appetite regulation, adipocyte diﬀer-
entiation, and insulin secretion,13 are interesting candidate
molecules to be investigated in adipose tissues as potential
mediators of metabolic pathway alterations in obesity. We
previously reported that miRNA expression was altered in SAT
from morbidly obese patients, and that up-expressed miR-519d
plays a role in adipocyte lipid metabolism.10 We now describe
the miRNA and proteome VAT signatures in morbidly obese
females and show several miRNAs and proteins diﬀerentially
expressed between obese and nonobese females.
Globally, our miRNA expression proﬁle revealed that 71
miRNAs were deregulated in the VAT from obese females.
Interestingly, most of these miRNAs (61/71) were down-
expressed. This latter ﬁnding coincides with a report of a similar
global down-expression of miRNAs in VAT from obese
individuals with nonalcoholic steatohepatitis than those with
nonalcoholic fatty liver disease that, moreover, was correlated
with enhanced expression of inﬂammatory adipocytokines.14
Eleven of the 61 largely down-expressed miRNAs in the VAT
of our obese females were also found in the above report;14 in
particular, we previously reported 7/11 of these miRNAs (miR-
200c, miR-519b, miR-206, miR-618, miR-30a, miR-181c, and
miR-7) down-expressed in SAT from the same obese females.10
In a mouse model, Xie et al.15 reported an inverse correlation
of miRNA expression between adipogenesis and obesity.15 In
fact, they observed that up-expressed miRNAs during adipo-
genesis tended to be down-expressed in the mouse epididymal
fat pads, and vice versa, and suggested that these changes could
be linked to the chronic local inﬂammation environment in the
fat mouse obese tissue. Lastly, Kloting et al.7 reported that miR-198,
one of our down-expressed miRNAs, was inversely correlated with
omental adipocyte diameter during obesity.7
Our 2D-DIGE analysis showed that 172 protein spots were
diﬀerentially expressed in VAT from obese vs nonobese
females. Analysis of 33 of these protein spots, those with
optimal features, led to the identiﬁcation of 67 proteins because
most spots were related to more than one protein. Our data
conﬁrm, and also integrate, proteomic data previously obtained
in VAT.3,16,17 In particular, we detected high levels of EIF4A1,
CES1, SELENBP1, ALDH1, ALDH2, GSTP1, HSPB1 proteins
that were previously reported to be increased in the omental vs
Table 3. continued
spot no.a
DIGE
(p-value)b
DIGE
obese/
controlc accession no.d protein name
MW
(Da)e pIf
no. of qualified
peptides/
coverage (%)g scoreh gene symboli miRNAj
gi/25453472 Eukaryotic translation elongation factor
1delta
31217 4.90 4/17 277 EFF1D
G3_1560 0.033 1.69 gi/194373515 Unnamed protein product (Corrisp. in
Sprot a P68363 Tubulin alpha-1B chain)
33856 4.88 2/8 151 DNAJB2
gi/157833780 Chain A, human Annexin V with Proline
substitution by thioproline
36041 4.94 3/11 153 ANXA5
H3_1908 0.001 1.67 gi/24119203 Tropomyosin 3 isoform 2 29243 4.75 11/40 598 TPM3
gi/4507651 Tropomyosin 4 28619 4.67 2/9 104 TPM4
gi/13236577 Thiamine triphosphatase 25721 4.75 3/15 165 THTPA
A4_1948 0.001 1.68 gi/5803225 Tyrosine 3/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
29326 4.63 15/65 943 YWHAE
B4_2005 0.001 1.91 gi/21464101 Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
gamma polypeptide
28456 4.80 5/21 329 YWHAG* mir-141,
-200c,
gi/119598039 Tropomyosin 1 (alpha), isoform Cra_m 28730 4.78 4/17 215 TPM1
C4_2054 0.010 1.64 gi/4507953 Tyrosine 3/tryptophan 5-
monooxygenase activation protein, zeta
polypeptide
27899 4.73 9/52 629 YWHAZ* mir-206,
-30a,
-30d, -22
D4_2065 0.001 1.72 gi/4507949 Tyrosine 3/tryptophan 5-monooxygenase
activation protein, beta polypeptide
28179 4.76 5/29 310 YWHAB
gi/4507951 Tyrosine 3/tryptophan 5-monooxygenase
activation protein, eta polypeptide
28372 4.76 3/15 225 YWHAH
E4_2087 0.038 1.7 gi/4504517 Heat shock protein beta-1 22826 5.98 6/27 330 HSPB1
gi/1922287 EnoylCoA hydratase 31807 8.34 5/23 330 ECHS1
F4_ 2229 0.007 1.64 gi/4758984 Ras-related protein Rab-11A 24492 6.12 2/11 99 RAB11A* mir-520e,
-520d,
G4_2245 0.039 1.51 gi/2204207 Glutathione S-transferase 23595 5.43 6/38 372 GSTP1
gi/1174149 Small GTP binding protein Rab 7 23732 6.40 2/12 101 RAB7A* mir-30a,
-30d
H4_2291 0.008 1.65 gi/14249382 Abhydrolase domain containing 14B 22446 5.94 5/32 264 ABHD14B
A5_2312 >0.001 −2.12 gi/5020074 Glyoxalase-I 20934 5.24 3/16 166 GLO I
gi/17986273 Fast skeletal myosin alkali light chain 1
isoform 1f
21189 4.97 3/18 215 MYL1
B5_2417 0.024 2.27 not identified
aSpot numbering as shown in 2-DE gel in Figure 1. bp-value at Student's t test. cAverage abundance ratio (obeses/controls) as calculated by
DeCyder Analysis. dProtein accession number from NCBI. eTheoretical molecular weight (Da). fTheoretical pI. gAccording to the Proposed
Guidelines for the Analysis and Documentation of Peptide and Protein Identiﬁcations (Paris consensus), we included in this table the complete
ﬁgures of merit regarding the MS identiﬁcation as the number of identiﬁed peptides whose individual ion score (as provided by Mascot) was higher
than the designated conﬁdence level (95%)/protein sequence coverage (%). hIdentiﬁcation score indicating a probabilistic measure of the goodness
of the MS protein identiﬁcation. iGene symbol from NCBI. jDown-expressed miRNAs in at least 6/10 obese females, which targeted 3′UTR-mRNA
regions of asterisk genes. In bold are indicated down-expressed miRNAs in VAT from 9 or 10/10 obese females and their targeted proteins.
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SAT in an obese population, or proteins that were diﬀerently
expressed in VAT from obese vs nonobese females, such as
ACADS, LMNA, VIM,17 which indicates that VAT is not only a
lipid storage site, but also a highly active metabolic tissue.3
Furthermore, Peŕez-Peŕez et al.3 suggested that EIF4A1 could
be involved in the altered protein synthesis pathways preceding
insulin resistance and/or type 2 diabetes.3 In agreement with
another study,18 we detected high levels of E2F1, which could
play a role in glucose metabolism.18 We also identiﬁed proteins
involved in intracellular traﬃcking, i.e., ARCN1 (or COPI),
PLIN, RAB11A, and RAB14, in agreement with earlier
reports.19,20 Furthermore, we observed an up-expression of
proteins involved in antioxidant activity and in apoptosis,
namely, GSS, ANXA5, ANXA7, PRDX3, and GSTP1, some of
which were reported by Coŕton et al.16 in a proteomic study of
VAT from obese females with or without polycystic ovary
syndrome.16
A novelty of our study is that we evaluated simultaneously
the miRNome and the proteome of VAT in obese and
nonobese women to identify potential biological mechanisms,
based on the concerted action of miRNA and protein targets,
associated with obesity. To this aim, we intersected the list of
the bioinformatically predicted protein targets of the
deregulated miRNAs with the whole set of identiﬁed proteins
from the experimental comparison of the VAT proteomes. This
screening enabled us to identify in the obese VAT samples a
potential miRNA-based mechanism for the up-expression of
some proteins, in particular YWHAG and RAB11A, which was
associated with down-expression of miR-141 and miR-520e,
respectively. The functional luciferase assay conﬁrmed the
binding of these miRNAs to the 3′UTRs of the YWHAG and
RAB11A transcripts. We investigated YWHAG and RAB11A
because they are involved in glucose homeostasis,21−23 and
YWHAG also in lipid metabolism,24,25 and hence are potential
actors in the obese phenotype.
Rab proteins are a large family of small GTPases that are
involved in vesicular traﬃcking, in cytoskeleton organization,
and in the control of cell proliferation and diﬀerentiation.20
Members of the Rab family, which includes about 70 proteins
in humans, continuously cycle between the cytosol and
diﬀerent membranes as inactive GDP-bound or active GTP-
bound forms, assisted by diﬀerent Rab-associated proteins.26
Defects in Rab-associated proteins lead to abnormal intra-
cellular traﬃcking and have been associated with several
monogenic inherited disorders and multigenic conditions such
as type 2 diabetes.26,27 Several Rab GTPases have been
implicated in GLUT4 traﬃcking in relation to the cell type
studied; among these, RAB10, RAB11, and RAB14 have been
identiﬁed in adipocytes.28 An additional player in GLUT4
traﬃcking is the GTPase-activating protein AS160. The latter,
under basal conditions contributes to cytosolic retention of
GLUT4, whereas, upon insulin stimulation, it is phosphorylated
at Thr642 by AKT kinase and inactivated, so that AS160
dissociates from GLUT4 vesicles to favor an increase in the
GTP-bound form of RAB. This event facilitates the transport of
GLUT4 from storage vesicles toward cell surface.21
YWHAG (14-3-3γ) protein belongs to a seven-member
protein family in mammals. These proteins, by interacting with
target proteins, typically at phospho-residues, regulate a variety
of functions, including subcellular redistribution.22 Studies
conducted in animal models and/or in cellular systems have
shown that 14-3-3 plays a relevant role in both cellular insulin-
mediated glucose transport and lipid metabolism. In fact, in
mice, insulin-stimulated YWHAG binding to AS160 at
phospho-Thr649 (equivalent to Thr642 in human AS160)
normally regulates GLUT4 traﬃcking from storage vesicles to
plasma membrane, thereby inﬂuencing glucose uptake.23
AS160-Thr649Ala knock-in mice (Ala: nonphosphorylable
residue) display impaired glucosal and insulin sensitivity.23
Furthermore, in 3T3-L1 adipocytes, the up-expression of
14-3-3 promotes the cytoplasmic localization of Lipin1, a
bifunctional protein involved in lipid metabolism.24 The
subcellular localization of this protein is relevant to its
activities; in fact, its nuclear isoform promotes the activation
Figure 2. VAT proteins, overexpressed in obese females and identiﬁed by LC−MS/MS, were bioinformatically predicted by DAVID database to be
functionally annotated in two main clusters: (A) annotation cluster 1 and (B) annotation cluster 2.
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of genes involved in oxidative metabolism. In the cytosol, its
insulin-mediated phosphorylation leads to the conversion of
phosphatidate (PA) to diacylglycerol (DAG), a precursor of
triacylglycerol (TAG).25
Figure 4. Validation of interaction between miR-520e and miR-141 with respectively wild-type or mutant 3′UTR of RAB11A or YWHAG. HEK-293
cells were transfected with wild-type or mutant 3′UTR of RAB11A, pGL3-control, pre-miR-520e, or pre-miR-negative control (A) and with wild-type
or mutant 3′UTR of YWHAG, pGL3-control, pre-miR-141, or pre-miR-negative control (B). Pre-miR-520e and the pre-miR-141 signiﬁcantly
inhibited the expression of a Renilla luciferase-expressing construct that contains the 3′UTR region of the RAB11A (p = 0.004) and YWHAG
(p = 0.02), respectively. No inhibition was observed in mutant 3′UTR of RAB11A (A) and YWHAG (B) constructs. All experiments were done in
triplicate. Error bars denote SEM.
Figure 3. (A) An example of the Western blot evaluation of YWHAG and RAB11A proteins from VAT of randomly selected obese females (TO01, TO02,
TO03, TO04) and controls (TC01, TC02, TC03). (B) The box plots of the data normalized to actin content, after densitometric analysis of YWHAG and
RAB11A immunoblots. The data are expressed as percent relative expression, the sample with the highest expression of either RAB11A (p = 0.00001) or
YWHAG (p = 0.001) having been set as 100%. The bottom and top of each box represent the 25th and 75th percentile, respectively; the thick band inside
each box shows the 50th percentile (the median). The ends of the whiskers represent the minimum and maximum values of each group of data.
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On the basis of above-mentioned mechanisms, we
hypothesize (Figure 5) that in VAT from obese subjects, low
expression levels of some miRNAs, including miR-520e and
miR-141, by modulating the up-expression of RAB11A and
YWHAG proteins, respectively, may lead to increased glucose
uptake and to increased triglyceride synthesis. This could then
contribute to worsening the obese phenotype by increasing the
accumulation of adipose tissue. Obviously, the analysis of suitable
cellular systems is required to provide mechanistic details for the
proposed model and clarify the role of insulin as an independent,
or co-operative model, linked to the observed miRNA down-
expression and protein target up-expression in obesity.
Furthermore, studies on larger cohorts of obese and
nonobese subjects are necessary to verify our results on the
expression of miR-520e and miR-141, as well as of YWHAG
and RAB11A proteins, in obesity risk assessment.
Lastly, we did not study the 72/365 miRNAs that were
expressed only in VAT from obese females. Further investigations
are necessary to test if these miRNAs may play a role in obesity
insurgence and/or in the metabolic-associated alterations.
In conclusion, our study provides an integrated view of both
miRNAs and protein expression proﬁles in VAT during obesity
and gives clues as to the metabolic pathways that may be
involved in adipose tissue accumulation.
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J. A.; Camafeita, E.; Ricart, W.; Fernańdez-Real, J. M.; Peral, B.
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Abstract  
Maternal obesity is associated to increased fetal risk of obesity and other metabolic diseases. Human 
amniotic mesenchymal stem cells (hA-MSC) have not been characterized in obese women. The aim of 
this study was to isolate and compare hA-MSC immunophenotypes from obese (Ob-) and normal 
weight control (Co-) women to identify alterations possibly predisposing the fetus to obesity. We 
enrolled 16 Ob- and 7 Co-women at delivery (mean/SEM pre-pregnancy BMI: 40.3/1.8 kg/m
2
 and 
22.4/1.0 kg/m
2
, respectively) and 32 not pregnant women. hA-MSCs were phenotyped by flow 
cytometry; several maternal and newborn clinical and biochemical parameters were also measured. The 
expression of membrane antigen CD13 was higher on Ob-hA-MSCs than on Co-hA-MSCs (P=0.0043). 
Also serum levels of CD13 at delivery were higher in Ob- versus Co-pregnant women and correlated 
with CD13 antigen expression on Ob-hA-MSCs (r
2
=0.84, P<0.0001). Adipogenesis induction 
experiments revealed that Ob-hA-MSCs had a higher adipogenic potential than Co-hA-MSCs as 
witnessed by higher PPARg and aP2 mRNA levels (P=0.02 and P=0.03, respectively) at post-induction 
day 14 associated with increased CD13 mRNA levels from baseline to day 4 post-induction (P<0.05). 
Adipogenesis was similar in the two sets of hA-MSCs after CD13 silencing, whereas it was increased 
in Co-hA-MSCs after CD13 overexpression. CD13 expression was high also in Ob-h-MSCs from 
umbilical cords or visceral adipose tissue of not pregnant women. In conclusion, antigen CD13, by 
influencing the adipogenic potential of hA-MSCs could be an in-utero risk factor for obesity. Our data 
strengthen the hypothesis that high levels of serum and MSC CD13 are obesity markers.  
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Introduction  
The increase in the incidence of obesity in pregnant women in the last two decades has paralleled that  
observed in the general population [1-3]. Although maternal fat stores increase in all pregnant women, 
irrespective of pre-pregnancy weight [4], the storage capacity of subcutaneous adipose tissue (SAT) is 
impaired, and fat predominantly accumulates in visceral adipose tissue (VAT) [5]. VAT is an important 
risk factor for metabolic imbalance in human subjects, also during pregnancy [6-8]. In fact, maternal 
obesity is related to offspring obesity [9], and there is an increased risk of adverse outcomes for both 
mother and child [10-13]. Moreover, the risk of childhood obesity was quadrupled if the mother was 
obese before pregnancy [14], which suggests that the in utero environment is obesogenic. In mammals, 
the placenta is the main interface between fetus and mother; it regulates intrauterine development and 
modulates adaptive responses to suboptimal in utero conditions [15,16]. 
Placenta is also an important source of stem/progenitor cells [17-19]. In particular, human 
amniotic mesenchymal stem cells (hA-MSCs) have been shown to differentiate into cell types of 
mesenchymal origin such as chondrocytes, adipocytes and osteocytes [20-22]. The phenotype of hA-
MSCs from normal pregnant women has been characterized and found to differ in terms of cytokine 
expression from that of pregnant women affected by preeclampsia [23]. Thus far, little is known about 
hA-MSCs from obese women.  
The aim of this study was to characterize hA-MSCs from term placenta of obese (Ob-) women and 
to test their adipogenic potential with respect to that of normal weight control (Co-) women. We also 
measured several maternal and newborn clinical and biochemical parameters, and looked for 
correlations between these parameters with the hA-MSC immunophenotype. We found that the Ob-hA-
MSC immunophenotype was characterized by increased expression levels of the CD13 surface antigen 
that correlated with maternal CD13 serum levels. Adipogenesis was higher in Ob-hA-MSCs than in  
Co-hA-MSCs, and returned to the control value after CD13 silencing. On the other hand, CD13 
 Page 3 of 36 
S
te
m
 C
el
ls
 a
n
d
 D
ev
el
o
p
m
en
t
H
ig
h
 A
m
in
o
p
ep
ti
d
as
e 
N
/C
D
1
3
 L
ev
el
s 
C
h
ar
ac
te
ri
ze
 H
u
m
an
 A
m
n
io
ti
c 
M
es
en
ch
y
m
al
 S
te
m
 C
el
ls
 a
n
d
 D
ri
v
e 
T
h
ei
r 
In
cr
ea
se
d
 A
d
ip
o
g
en
ic
 P
o
te
n
ti
al
 i
n
 O
b
es
e 
W
o
m
en
 (
d
o
i:
 1
0
.1
0
8
9
/s
cd
.2
0
1
2
.0
4
9
9
)
T
h
is
 a
rt
ic
le
 h
as
 b
ee
n
 p
ee
r-
re
v
ie
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
li
ca
ti
o
n
, 
b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
g
o
 c
o
p
y
ed
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. 
T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
4 
4 
 
overexpression increased the adipogenic potential of Co-hA-MSCs. Our findings suggest that CD13 
could contribute to obesity programming in the fetus and indicates that maternal serum CD13 is an 
obesity risk marker.  
 
Materials and methods 
Patients and controls 
Sixteen Ob- (age range: 26–39 years) and seven Co-pregnant women, (age range: 26–38 years), pre-
pregnancy BMI (mean/SEM) 40.3/1.8 kg/m
2 
and 22.4/1.0 kg/m
2
, respectively and thirty-two not 
pregnant women (16 obese and 16 normal weight, BMI >30 kg/m
2 
and <25 kg/m
2
, respectively) were 
recruited at the Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, 
University of Naples “Federico II”. The clinical, personal and family history of the 23 women was 
recorded during a medical interview conducted by an expert upon hospitalization. Data relative to each 
pregnancy follow-up and delivery were also recorded. The general characteristics of the newborn and 
clinical data (birth weight, length, head circumference, Apgar score) were recorded at birth.  
 
Sample collection  
Two fasting peripheral blood samples were collected in the morning from not pregnant women and 
from Ob- and Co-pregnant women, immediately before delivery. One sample was used for DNA 
extraction, whereas the other was centrifuged at 2,500 rpm for 15 min and serum was stored at -80°C 
until further processing. At delivery, placentas were collected by C-section from each enrolled women 
and immediately processed. Bioptic samples of visceral adipose tissue (VAT) were also collected from 
not pregnant obese and control women during obstetric surgery (ovarian cysts). All patients and 
controls gave their informed consent to the study and both parents gave consent for their newborns. 
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The study was performed according to the Helsinki II Declaration and was approved by the Ethics 
Committee of our Faculty.  
 
Biochemical evaluations  
The main serum biochemical parameters were evaluated by routine assays. Leptin and adiponectin 
were measured in maternal serum with Luminex xMAP Technology on a BioRad Multiplex 
Suspension Array System (Bio-Rad, Hemel Hempstead, Herts., UK), according to the manufacturer’s 
instructions. The ratio leptin/adiponectin (L/A) was also calculated.  
 
Aminopeptidase N/CD13 ELISA assay  
Aminopeptidase N (APN)/CD13 serum levels were measured by ELISA (Life Science, Houston). 
Briefly, the microtiter plate was pre-coated with a specific anti-CD13 antibody. Standards or samples 
were then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody 
preparation specific for CD13. Next, avidin conjugated to horseradish peroxidase was added to each 
microplate well and incubated for 15 min at room temperature. A TMB substrate solution (3,3´,5,5´-
tetramethylbenzidine) was then added to each well. The enzyme-substrate reaction was terminated by 
the addition of a sulphuric acid solution and the color change was measured spectrophotometrically at a 
wavelength of 450 nm. The amount of CD13 in each sample was determined by comparing the 
absorbance of the sample to a standard curve. 
 
Cell isolation from placenta tissue 
Placentas were collected and immediately processed, according to Parolini et al. [24]. After removal of 
the maternal decidua, the amnion was manually separated from the chorion and extensively washed 5 
times in 40 mL of phosphate-buffered saline (PBS) containing 100 U/mL penicillin, 100 μg/mL 
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streptomycin and 250 μg/mL amphotericin B (all from Sigma-Aldrich, Missouri) after which it was 
mechanically minced into small pieces [24]. Amnion fragments were digested overnight at 4°C in 
ACCUMAX
®
 reagent (Innovative Cell Technology, San Diego), a combination of DNase, protease and 
collagenolytic enzymes [25], containing 100 U/mL penicillin, 100 μg/mL streptomycin and 250 μg/mL 
amphotericin B. The next day, digestion enzymes were inactivated with complete culture medium 
constituted by low glucose D-MEM (Sigma-Aldrich) supplemented with 10% of heat-inactivated 
bovine serum (FBS), 1% of non-essential amino acids and 2% of Ultraglutamine (all from Lonza, 
Basel, Switzerland). After centrifugation at 300g for 10 min, cell pellets and digested tissue fragments 
were seeded in a cell culture dish (BD Falcon, New York) in complete culture medium and incubated at 
37°C in 5% CO2. One week later, digested tissue pieces were removed from the dish and discarded, and 
isolated cells formed distinct fibroblast colony-forming units. When the colonies reached 70% 
confluence, they were washed with PBS and detached with trypsin/EDTA (Sigma-Aldrich), counted 
and reseeded in complete medium for expansion at a concentration of about 5,000/cm
2 
[24].  
 
Cell preparation  
hA-MSCs were expanded for several passages. Absence of mycoplasma contamination was assessed as 
described previously [26]. The population-doubling level was calculated for each subcultivation with 
the following equation: population doubling= [log10 (NH) ─ log10 (NI)]/ log10 (2), where NI is the cell 
inoculum number and NH is cell harvest number [27]. The increase in population doubling was added 
to the population doubling levels of the previous passages to yield the cumulative population doubling 
level. When 70%-80% confluent cultures reached about 4 population doublings they were detached 
with trypsin/EDTA, resuspended in PBS with 10% FBS, and processed for flow cytometry, DNA and 
RNA extraction. Cellular viability was assessed by both Trypan blue dye exclusion and the analysis of 
light scatter proprieties in flow cytometry, and it was never lower than 90%.  
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Using the above cell isolation and preparation procedures, h-MSCs were also isolated from umbilical 
cord (hUC-MSCs) of one obese and one control pregnant woman. 
 
Isolation of visceral adipose tissue mesenchymal stem cells (hVAT-MSCs) 
Briefly, VAT bioptic samples were washed with phosphate buffered saline (PBS) containing 100 U/mL 
penicillin, 100 μg/mL streptomycin and 250 μg/mL amphotericin B (all from Sigma-Aldrich), minced 
into small pieces and digested with 1.5 mg/ml collagenase type I (GIBCO, USA) at 37C°. The 
digestion enzymes were inactivated with FBS. After centrifugation at 1500g for 5 min, cell pellets and 
digested tissue fragments were washed and seeded in a cell culture dish (BD Falcon, New York) in 
complete culture medium and incubated at 37°C in 5% CO2. When the colonies reached 60-70% 
confluence, they were washed with PBS and detached with trypsin/EDTA (Sigma-Aldrich), counted 
and reseeded in complete medium for expansion at a concentration of about 5,000/cm
2 
[28]. 
 
DNA typing  
The fetal origin of both amnion and hA-MSCs was verified by DNA typing. Genomic DNA was 
extracted from the mother’s peripheral blood, from amnion samples and from hA-MSCs using the 
Nucleon BACC2 extraction kit (Illustra DNA Extraction Kit BACC2, GE Healthcare, Calfont St. Giles, 
Bucks., UK). DNA concentration was evaluated using the NanoDrop® ND-1000 UV-Vis 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). Genomic DNA (1 ng) was amplified in 
a final volume of 25 µL using the AmpFlSTR® Identifiler™ PCR Amplification Kit (Applied 
Biosystems, Foster City). The AmpFlSTR® Identifiler™ PCR Amplification Kit is a short tandem 
repeat (STR) multiplex assay that amplifies 15 repeat loci and the Amelogenin gender determining 
marker in a single PCR amplification using a primer set labeled with four fluorescent molecules. The 
amplification was performed with the GeneAmp PCR System 9700 (Applied Biosystems) instrument. 
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PCR products were then analyzed by capillary electrophoresis on the ABI Prism 3130 Genetic 
Analyzer (Applied Biosystems) together with an allelic ladder that contained all the most common 
alleles for the analyzed loci that were present in Caucasian populations and both a negative- and a 
positive-quality control sample. Typically, 1µL of each sample was diluted in 18.7µL of deionized 
formamide; each sample was supplemented with 0.3µL of an internal size standard (LIZ 500 Applied 
Biosystems) labeled with an additional fluorophore. The samples were denatured at 95 °C for 4 min 
and then placed in the auto sampler tray (maximum of 96 samples) on the ABI Prism 3130 for 
automatic injection in the capillaries. The data were analyzed by Gene Mapper Software (Applied 
Biosystems). 
 
Immunophenotyping of h-MSCs by flow cytometry 
We analyzed the expression of 38 hematopoietic, mesenchymal, endothelial, epithelial and no-lineage 
membrane antigens on the surface of hA-MSCs, hUC-MSCs and hVAT-MSCs by four-color flow 
cytometry (Table 1). The antibody cocktails contained in each tube are detailed in Supplementary 
Table 1. All monoclonal antibodies (MoAbs) were from Becton Dickinson (San Jose) except anti-
CD338-APC, which was from R&D (Minneapolis), anti-CD-133-PE and anti-CD271-APC MoAbs, 
which were from Milenyi Biotec (Bergisch Gladbach, Germany). For all antibody staining 
experiments, at least 1x10
5 
hA-MSCs isolated from each placenta sample were incubated at 4°C for 20 
min with the appropriate amount of MoAbs, washed twice with PBS and finally analyzed with an 
unmodified Becton-Dickinson FACSCanto II flow cytometer (Becton-Dickinson, San Jose), that was 
set up according to published guidelines [29]. For each sample the respective control was prepared in 
order to determine the level of background cellular autofluorescence without antibody staining. 
CaliBRITE beads (Becton-Dickinson, catalog no. 340486) were used as quality controls across the 
study as described elsewhere [30, 31], according to the manufacturer’s instructions. Daily control of 
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CaliBRITE intensity showed no change in instrument sensitivity throughout the study. The relative 
voltage range for each detector was assessed una tantum using the “eight-peak” technology (Rainbow 
Calibration Particles, Becton-Dickinson, catalog no. 559123) at the beginning of the study. 
Compensation was set in the FACS-DiVa (Becton-Dickinson) software, and compensated samples 
were analyzed. Samples were acquired immediately after staining using the FACSCanto II instrument, 
and at least 10,000 events were recorded for each monoclonal combination. Levels of CD antigen 
expression were displayed as median fluorescence intensity (MFI). The FACS-DiVa software (Becton-
Dickinson) was used for cytometric analysis. 
 
Differentiation potential towards the adipogenic lineage 
hA-MSCs and hVAT-MSCs were cultured in low glucose D-MEM (Sigma-Aldrich) supplemented 
with 10% of FBS, 2% of ultraglutamine and 1% of non-essential amino acids at 37°C in 5% CO2 (all 
from Lonza, Basel, Switzerland). The cells were passaged twice before the addition of differentiation 
medium composed of DMEM with the addition of 10% FBS, 1 µM dexamethasone, 0.5 mM 3-
isobutyl-1-methylxhantine, 200 µM indomethacin and 10 mg/mL insulin. Media were changed every 
two days and cells were either stained or collected for RNA extraction. 
 
CD13 RNA interference and overexpression 
hA-MSCs plated at a density of 5,000 cells/cm
2
 were transfected using 20 mL Lipofectamine 2000 
according to the manufacturer’s instructions (Invitrogen, Paisley, UK) with 8 mg short hairpin RNAs 
(shRNAs)-expressing plasmids (Open Biosystem, Huntsville) or with 8 mg pCMV-Sport 6 Vector 
(Invitrogen, Paisley, UK), to silence or to overexpress CD13 mRNA, respectively. Transfected cells 
were induced to differentiate towards the adipogenic lineage up to 4 days.  
 
 Page 9 of 36 
S
te
m
 C
el
ls
 a
n
d
 D
ev
el
o
p
m
en
t
H
ig
h
 A
m
in
o
p
ep
ti
d
as
e 
N
/C
D
1
3
 L
ev
el
s 
C
h
ar
ac
te
ri
ze
 H
u
m
an
 A
m
n
io
ti
c 
M
es
en
ch
y
m
al
 S
te
m
 C
el
ls
 a
n
d
 D
ri
v
e 
T
h
ei
r 
In
cr
ea
se
d
 A
d
ip
o
g
en
ic
 P
o
te
n
ti
al
 i
n
 O
b
es
e 
W
o
m
en
 (
d
o
i:
 1
0
.1
0
8
9
/s
cd
.2
0
1
2
.0
4
9
9
)
T
h
is
 a
rt
ic
le
 h
as
 b
ee
n
 p
ee
r-
re
v
ie
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
li
ca
ti
o
n
, 
b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
g
o
 c
o
p
y
ed
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. 
T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
10 
10 
 
Effect of IFN-g on the expression of CD13 on the surface of h-MSCs 
The expression of CD13 on the surface of Co- and of Ob-h-MSCs isolated from amnion, umbilical cord 
and VAT was measured after exposure of cells to 0.8 and 12.5 ng/mL IFN-g at 37° C for 24 h, using 
untreated Co- and Ob-h-MSCs as controls. At the end of incubation, the cells were harvested by 
trypsin, washed in PBS, counted, and adjusted to the same concentrations of 1x10
5 
h-MSCs. 
Subsequently, their immunophenotype was examined by flow cytometry. 
 
Adipocyte staining  
After 14 days of differentiation, the adipocyte cultures were stained for lipid droplets, which are an 
index of differentiation. The cells were washed in PBS and fixed in 10% formalin for 1 h. Then they 
were washed in PBS and the lipids were stained for 15 min with Oil-red-O prepared by mixing 
vigorously three parts of stock solution (0.5% Oil-red-O in 98% isopropanol) with two parts of water 
and then eliminating undissolved particles with a 0.4-mm filter. Cells were then washed with water and 
the number of adipocytes was evaluated with a microscope. Relative lipid levels were assessed by 
redissolving the Oil-Red-O present in stained cells in 98% isopropanol and then determining 
absorbance at 550 nm. 
 
RNA isolation 
Total RNA was purified from hA-MSCs isolated from term placentas of Co- and of Ob-pregnant 
women using the mirVana
TM
 miRNA isolation kit (Ambion, Austin) and its concentration was 
evaluated with the NanoDrop® ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, 
Wilmington).  
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Quantitative real-time polymerase chain reaction (qRT-PCR) of mRNAs 
Real-time quantitative PCR was carried out on the Applied Biosystems 7900HT Sequence Detection 
system (Applied Biosystems). cDNAs were synthesized from 2 mg of total RNA using hexamer random 
primers and M-MuLV Reverse Transcriptase (New England BioLabs, Beverly). The PCR reaction was 
performed in a 20 µL final volume containing cDNA, 1X SYBR Green PCR mix, 10 µM of each 
specific primer. Supplementary Table 2 lists the oligonucleotide primers used for PCR of selected 
genes: peroxisome proliferator-activated receptor gamma (PPARg), CD13, protein homologous to 
myelin P2 (aP2), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The PCR conditions for 
reverse transcription were: stage 1: 50°C, 2 min; stage 2: 95°C, 10 min; stage 3: 95°C, 15 s; 60°C, 1 
min/40 cycles; and stage 4: 95°C, 15 s; 60°C, 1 min. Levels of target genes were quantified using 
specific oligonucleotide primers and normalized for GAPDH expression. 
 
Statistical analysis  
The parameters investigated were expressed as mean and standard error of the mean (SEM) (parametric 
distributions) or as median value and 25
th
 and 75
th
 percentiles (non parametric distributions). Student’s 
“t” and Mann-Whitney tests were used to compare parametric and nonparametric data, respectively. P 
values <0.05 were considered statistically significant. Correlation analysis was performed with the 
SPSS package for Windows (ver. 18; SPSS Inc., Headquarters, Chicago). 
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Results 
The clinical and biochemical characteristics of the mothers and their newborns are reported in Table 2 
(A and B, respectively). Weight gain was lower (P=0.025) and diastolic blood pressure was higher 
(P=0.039) in Ob- than in Co-pregnant women. Both leptin concentration (P<0.0001) and the L/A ratio 
(P<0.0001) were higher in Ob- than in Co-pregnant women at delivery. Biometric characteristics did 
not differ significantly between Ob- and Co-newborns. 
 
Isolation of hA-MSCs 
We isolated hA-MSCs from the mesenchymal layer of amniotic membranes obtained from our Ob- and 
Co-pregnant women at delivery. The fetal origin of all isolated hA-MSCs was confirmed by STR 
typing of DNA of the mother and of the hA-MSCs. Mycoplasma contamination of cultures was 
checked and excluded (data not shown). All isolated hA-MSCs were characterized by a high 
proliferation potential and collected after 4 population doublings. Morphologically, cultured Ob- and 
Co-hA-MSCs showed a similar fibroblastic-like morphology after 4 population doublings 
(Supplementary Fig. 1).  
 
Immunophenotyping of h-MSCs 
The antigenic mosaic displayed by Ob- and Co-hA-MSCs is shown in Table 3. Seventeen of the 38 
antigens investigated were not expressed on the surface of hA-MSCs (hematopoietic antigens: CD14, 
CD15, CD16, CD19, CD28, CD33, CD34, CD45 and CD117; the endothelial marker PECAM-1/CD31; 
and no-lineage markers: thrombospondin receptor/CD36, Bp50/CD40, Prominin-1/CD133, MDR-
1/CD243, NGFR/CD271, ABCG-2/CD338 and HLA-DR). Both Ob- and Co-hA-MSCs were positive 
for the following mesenchymal markers: CD9, CD10, CD13, CD26, CD29, CD44, CD47, CD49d, 
CD54, CD56, CD58, CD71, CD81, CD90, CD99, CD105, CD151, CD166, CD200 and HLA-ABC. A 
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very weak positivity for the epithelial antigen E-cadherin/CD324 was also observed. Interestingly, 
CD13 expression was significantly higher in Ob-hA-MSCs than in Co-hA-MSCs, i.e., MFI: 9,802.0 
and 3,950.0, respectively (P=0.0043) (Table 3 and Fig. 1A). The immunophenotype characterization 
confirmed the mesenchymal origin and the higher CD13 expression in hVAT-MSCs and hUC-MSCs 
from Ob- than from Co-women (hVAT-MSCs - MFI: 8,200.0 vs 1,100.0 and hUC-MSCs - MFI: 
4,965.0 vs 3,155.0, respectively). 
 
APN/CD13 serum levels  
We first measured baseline serum levels of CD13 in a small group of not pregnant obese and normal 
weight women and found significantly higher values in the obese subset (medians: 6.00 U/L and 1.00 
U/L, P=0.02, respectively) (Fig. 1B). The serum levels of CD13 were also significantly higher in Ob- 
than in Co-pregnant women at delivery (medians: 24.00 U/L and 7 U/L, P=0.002, respectively), (Fig. 
1B). CD13 levels were significantly higher in Ob- and Co-pregnant women than in not pregnant Ob- 
and Co-women: 4 (P=0.0003) and 7 times (P=0.003), respectively. Furthermore, in Ob-pregnant 
women, serum CD13 levels were significantly correlated to the levels of CD13 on the surface of hA-
MSCs (r
2
=0.84; P<0.0001) (Fig. 1C).  
 
CD13 h-MSC expression and adipogenic differentiation 
To investigate whether CD13 is involved in adipogenesis, we cultured Ob- and Co-hA-MSCs for 14 
days in adipogenic induction medium. At the end of incubation, the adipogenic potential, as measured 
by PPARg and aP2 mRNA levels, was higher in Ob- than in Co-hA-MSCs. In fact, as shown in Fig. 2A 
and 2B, the mean RQs at day 14 were 0.04 and 0.02, respectively for PPARγ (P=0.02), and 0.02 and 
0.01, respectively for aP2 (P=0.03). The same results were obtained with Oil-Red staining; in fact, 
staining was more intense in Ob- than in Co-hA-MSCs at day 14 of differentiation [Abs (550 nm) = 0.6 
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and 0.4, P=0.02, respectively] (Fig. 2C). During adipogenesis, CD13 mRNA levels remained higher in 
Ob- than in Co-hA-MSCs. CD13 silencing by shRNA in Ob-hA-MSCs resulted in a switch-off of 
CD13 mRNA expression, as evaluated by RT-PCR (Fig. 3A), and, at the same time, the adipogenic 
potential of these cells did not differ from that observed in Co-hA-MSCs, as shown by similar 
PPARg mRNA levels measured in silenced Ob-hA-MSCs and in Co-hA-MSCs (P=0.71) (Fig. 3B). In 
agreement to CD13 involvement in adipogenesis, we overexpressed CD13 in Co-hA-MSCs (mRNA 
CD13 mean RQ=7.23) and observed at day 4 of differentiation that PPARg mRNA levels were higher 
in treated (mean RQ=0.015) than in untreated (mean RQ=0.001) Co-hA-MSCs. The adipogenic 
potential at day 14 was also higher in Ob- than in Co-hVAT-MSCs isolated from not pregnant women 
[aP2: RQs were 0.050 and 0.036; Oil-red-O Abs (550 nm): 0.559 and 0.437, respectively].  
 
Upregulation of CD13 h-MSC expression by IFN-g 
We next evaluated if CD13 expression could be upregulated in h-MSCs by IFN-g as occurs in murine 
cellular models [32]. To this aim, we treated the Co- and Ob-hA-MSCs with 0.8 ng/mL or 12.5 ng/mL 
IFN-g for 24 h. We found that CD13 expression was significantly higher on membranes of Co-hA-
MSCs treated with 12.5 ng/mL IFN-g (P=0.04) than in untreated cells, whereas there was a slight, not 
significant, increase in treated Ob-hA-MSCs (Supplementary Fig. 2) versus the untreated counterpart 
cells. In addition, IFN-g treatment (12.5 ng/mL at 37° C for 24 h) induced the increase of CD13 
membrane expression in hVAT-MSCs (Ob- and Co-MSCs: 39% and 8%, respectively) and in Co-hUC-
MSCs (4%) versus the untreated counterpart cells, but not in Ob-hUC-MSCs. Our results suggest that 
high levels of INF-g drive the up-regulation of CD13 expression in Co-h-MSCs, irrespective of their 
source and of pregnancy, whereas its effect on Ob-h-MSCs CD13 expression during obesity is 
ambiguous.  
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Discussion 
Human amniotic membrane is a readily available source of abundant fetal MSCs that are free from 
ethical concerns [33]. hA-MSCs isolated from normal weight healthy women at delivery have been 
characterized [24, 34, 35], but, to our knowledge, the features of hA-MSCs from obese women are 
largely unknown. In this study, we used flow cytometry to characterize hA-MSCs isolated at delivery 
from two groups of women: pre-pregnancy normal weight and pre-pregnancy severely obese women. 
The immunophenotypic characterization confirmed the mesenchymal origin of the isolated cells [36]. 
In particular, the distribution of CD56 was in agreement with the placental origin of the isolated hA-
MSCs. In fact, this marker is absent from bone marrow [34] and from adipose tissue-derived 
mesenchymal stem cells [37]. Similarly, the endothelial marker PECAM-1/CD31, and the 
hematopoietic antigens CD14, CD15, CD16, CD19, CD28, CD33, CD34, CD45 and CD117 were 
absent from isolated Ob- and Co-hA-MSCs. Staining for the E-cadherin/CD324 epithelial antigen was 
very weak in our Ob- and Co-hA-MSC preparations; the co-expression of epithelial, albeit at a low 
intensity, and mesenchymal markers on our h-AMSCs was in agreement with previous findings [38, 
39]. Overall, our results are similar to those reported by Parolini et al. [24] and/or Roubelakis [35] 
regarding the expressed (CD49d, CD90, HLA-ABC, CD13, CD56, CD105, CD166, CD10, CD29, 
CD44 and CD54) and not expressed (PECAM-1/CD31, HLA-DR, CD14, Prominin-1/CD133, 
NGFR/CD271, CD34 and CD45) membrane-bound antigens in hA-MSCs. We found that the Ob-hA-
MSC immunophenotype is characterized by a significantly higher expression of the APN/CD13 antigen 
with respect to the Co-hA-MSC phenotype. Besides amnion, CD13 was overexpressed in h-MSCs 
isolated from umbilical cord in obese womenand in those isolated from VAT in not pregnant women.  
Type II metalloprotease APN/CD13 (EC. 3.4.11.2) is a heavily glycosylated membrane-bound 
protein (~ 960aa, ~ 150 kDA) that is encoded by the human ANPEP gene located on chromosome 15 
(q25-q26) [40]. This protein exists also in a soluble form. APN/CD13 is a ubiquitous enzyme present in 
 Page 15 of 36 
S
te
m
 C
el
ls
 a
n
d
 D
ev
el
o
p
m
en
t
H
ig
h
 A
m
in
o
p
ep
ti
d
as
e 
N
/C
D
1
3
 L
ev
el
s 
C
h
ar
ac
te
ri
ze
 H
u
m
an
 A
m
n
io
ti
c 
M
es
en
ch
y
m
al
 S
te
m
 C
el
ls
 a
n
d
 D
ri
v
e 
T
h
ei
r 
In
cr
ea
se
d
 A
d
ip
o
g
en
ic
 P
o
te
n
ti
al
 i
n
 O
b
es
e 
W
o
m
en
 (
d
o
i:
 1
0
.1
0
8
9
/s
cd
.2
0
1
2
.0
4
9
9
)
T
h
is
 a
rt
ic
le
 h
as
 b
ee
n
 p
ee
r-
re
v
ie
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
li
ca
ti
o
n
, 
b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
g
o
 c
o
p
y
ed
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. 
T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
16 
16 
 
a wide variety of human organs, tissues and cell types including placenta, human umbilical vein 
endothelial cells, monocytes, lymphocytes T, hypothalamus, and epithelial intestinal cells [41]. It has 
various mechanisms of action: enzymatic cleavage of peptides, endocytosis and signal transduction 
[42]. APN/CD13 is involved in inflammation, cellular differentiation and proliferation, apoptosis, cell 
adhesion and motility [42]. Dysregulated expression of membrane and/or soluble forms of APN/CD13 
has been observed in many diseases [43], but until now it has never been associated with obesity. Here, 
we provide the first demonstration that the CD13 antigen is increased on hA-MSCs during obesity and 
could play a role in adipogenesis. In fact, we first detected a higher adipogenic potential in Ob- than in 
Co-hA-MSCs after 14 days of adipogenic differentiation and then observed that the adipogenic 
potential of Ob-hA-MSCs was comparable to that of Co-hA-MSCs after CD13 silencing. Conversely, 
the adipogenic potential increased in Co-hA-MSCs after CD13 overexpression. Furthermore, we 
provide evidence that INFg upregulated CD13 expression in Co-hA-MSCs.  
Intriguingly, in Ob-pregnant women APN/CD13 serum levels at delivery were higher than in Co-
pregnant women and correlated with CD13 surface Ob-hA-MSC expression (r
2
=0.89, P<0.0001), 
which support the hypothesis that the placenta is the major source of the high CD13 levels measured in 
maternal serum [44]. We also found that leptin concentration and the L/A ratio were increased in Ob-
maternal serum at delivery. This finding confirms the concept that these two parameters are obesity risk 
markers [45, 46]. 
In conclusion, this characterization of Ob-hA-MSCs shows that antigen CD13, by influencing the 
adipogenic potential of these cells, could be  an in-utero risk factor for obesity. Our data strengthen the 
hypothesis that high serum CD13 and mesenchymal stem cell CD13 are markers of obesity.  
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Legends  
FIG. 1. Expression of CD13 antigen in control (Co-) and obese (Ob-) pregnant women. A: Ob-hA-
MSCs expressed significantly higher amounts (at Mann-Whitney test) of CD13 surface antigen 
compared with Co-hA-MSCs (P=0.0043); B: serum levels of CD13 were significantly higher both in 
Ob- than in Co-not pregnant women (P=0.02) and in Ob- than in Co-women at delivery (P=0.002); C: 
Serum CD13 levels were correlated with CD13 surface expression levels in Ob-pregnant women 
(r
2
=0,84; P<0.0001). The box plots provide a vertical view of the data expressed as median, 25th 
percentile, 75th percentile and extreme values. 
 
FIG. 2. Adipogenic potential in Ob-hA-MSCs and in Co-hA-MSCs. The statistically significant 
higher mRNA expression levels of PPARg (P=0.02) (A) and of aP2 (P=0.03) (B) measured 14 days 
after the adipogenic induction, indicated increased adipogenesis in Ob- versus Co-hA-MSCs. (C) The 
higher adipogenesis in Ob- than in Co-hA-MSCs was also confirmed by Oil-Red staining [Abs (550 
nm) = 0.6 and 0.4, P=0.02, respectively].  
 
FIG. 3. Role of CD13 in adipogenesis. (A) mRNA expression levels of CD13 were significantly 
higher in Ob- than in Co-hA-MSCs at day 0 (P=0.02), day 2 (P=0.02) and day 4 (P=0.04) when 
cultured with adipogenic medium. CD13 mRNA expression was switched-off in Ob-hA-MSCs after 
CD13 silencing with shRNA. (B) At day 4 of adipogenic induction, PPARg mRNA expression levels 
that were significantly higher in Ob-hA-MSCs than in Co-hA-MSCs (P=0.01), decreased to the levels 
detected in Co-hA-MSCs after CD13 silencing (P=0.71), which indicates that CD13 enhances 
adipogenesis in hA-MSCs. n.s.: not statistically significant difference. 
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Table 1. Surface immunophenotypic profile investigated in hA-MSCs by flow cytometry 
Fluorochrome CD 
Antigen 
Other Names Molecular 
Weight 
(kDa) 
Cell expression Function 
FITC CD9 Tspan-29 24-26 Platelets, pre-B cells, activated T cells Adhesion, migration, platelet activation 
APC CD10 CALLA 100 B/T precursors, stromal cells Endopeptidase 
PE CD13 APN 150 Granulocytes, monocytes and their precursors, 
endothelial cells, epithelial cells, mesenchymal stem 
cells 
Metalloproteinase 
PE CD14 LPS-R 53-55 Monocytes, macrophages Receptor for LPS/LPB complex  
APC CD15 Lewis X _ Granulocyte, monocyte, epithelial cells Cell adhesion 
PE CD16 FCγRIIIa 50-65 Neutrophils, NK, macrophages Low affinity with FCγ receptor, mediates 
phagocytosis 
APC CD19 Bgp95 95 B cells, not on plasma cells Signal transduction 
FITC CD26 DPP IV 110 Mature thymocytes, T, B, NK cells Exoprotease, co-stimulation  
APC CD28 Tp44 44 Most T cells, thymocytes, NKs and plasma cells Co-stimulation 
APC CD29 VLA β1-chain 130 T, B, granulocytes, monocytes, fibroblasts, 
endothelial cells, NKs , platelet 
Adhesion activation, embryogenesis and 
development 
FITC CD31 PECAM-1 130-140 Monocytes, platelets, granulocytes and endothelial 
cells 
Cell adhesion 
APC CD33 My9 67 Monocytes, granulocytes, mastocytes and myeloid 
progenitors 
Cell adhesion 
APC CD34 My10 105-120 Hematopoietic stem cells and progenitors, endothelial 
cells 
Cell adhesion 
APC CD36 Platelet GPIV 85 Platelets, monocytes, macrophages, endothelial cells, 
erythroid precursors 
Adhesion and phagocytosis 
FITC CD40 Bp50 48 Monocytes, macrophages, B cells, endothelial cells, 
fibroblasts, keratinocytes 
Co-stimulation to B cells, growth, 
differentiation and isotype switching 
APC CD44 H-CAM 90 Leukocytes, erythrocytes and epithelial cells Rolling, homing and aggregation 
Per Cp CD45 LCA 180-220 Hematopoietic cells, except erythrocytes and platelets Critical for T and B cell receptor 
mediated activation 
FITC CD47 IAP I 50-55 Hematopoietic, epithelial, endothelial and brain 
mesenchymal cells 
 Adhesion 
FITC CD49d VLA-4 150 B cells, T cells, monocytes, eosinophils, basophils, 
NKs, dendritic cells 
Adhesion, migration, homing, activation 
APC CD54 ICAM-1 80-114 Epithelial and endothelial cells monocyte. Low on 
resting lymphocytes, upregulate on activated 
T cell activation 
PE CD56 NCAM 175-220 Neural,  tumors, embryonic tissue, NK Homophilic and heterophilic adhesion 
PE CD58 LFA-3 40-70 Leucocytes, erythrocytes, epithelial endothelial cells 
and fibroblasts 
Costimulation 
FITC CD71 Transferrin recepor 95 Reticulocytes, erythroid precursor Controls iron intake during cell 
proliferation 
APC CD81 TAPA-1 26 B and T cells, monocytes, endothelial cells Signal transduction 
FITC CD90 Thy-1 25-35 Hematopoietic stem cells, neurons, mesenchymal 
stem cells 
Inhibition of hematopoietic stem cells 
and neuron differentiation 
PE CD99 MIC2 32 Leucocyte, NK, monocytes, endothelial and epithelial 
cells 
Leucocyte migration, T cell activation, 
cell adhesion 
PE CD105 Endoglin 90 Endothelial and  mesenchymal stem cells, erythroid 
precursors, monocytes  
Angiogenesis, modulates cellular 
response to TGFβ1 
PE CD117 c-kit 145 Hematopoietic stem cells and progenitors Crucial for hematopoietic stem cells  
PE CD133 Prominin-1 120 Hematopoietic stem cell, endothelial, epithelial and 
neural precursors 
Unknown function, stem cell marker 
PE CD151 PETA-3 32 Endothelial and epithelial cells, megakaryocytes, 
platelets 
Adhesion 
PE CD166 ALCAM 100-105 Neurons, activated T cells, epithelial cells, 
mesenchymal stem cells 
Adhesion, T cell activation 
PE CD200 OX-2 33 B cells, activated T cells, thymocytes, neurons 
endothelium 
Down-regulatory signal for myeloid cell 
functions 
FITC CD243 MDR-1 170 Stem cells, multi drug resistant tumors Influences the up-take, distribution, 
elimination of drugs  
APC CD271 NGFR 75 Neurons, stromal and dendritic follicular cells Low affinity for NGF receptor 
APC CD324 E-cadherin 120 Epithelial, keratinocytes, platelet Adhesion, growth, differentiation 
APC CD338 ABCG-2 72 Hematopoietic stem cells, liver, kidney, intestine, side 
population of stem cells 
Absorption and excretion of xenobiotics 
FITC HLA-
ABC 
Class I MHC 46 All nucleated cells and platelets Antigen presentation   
FITC HLA-DR Class II MHC 30 B cells, monocytes, myeloid progenitors, activated T 
and dendritic cells  
Antigen presentation   
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Table 2. Clinical and biochemical characteristics of obese (Ob-) and normal weight control (Co-) pregnant 
women at delivery and their newborns. 
 
 
 
Data are expressed as mean (SEM) (parametric distributions). 
Statistically significant difference at Student t test: 
a
 P<0.0001, 
b
 P =0.025 and 
c
 P=0.039. 
d
 median value and 25
th
–75
th
 percentiles (non parametric distributions). 
A     
Mother’s parameters Ob-pregnant women (n=16) Co-pregnant women (n=7) 
Age (years) 32.6 (0.9) 30.7 (1.5) 
Weight (kg)
 a
 110.1 (5.4) 65.2 (3.6) 
Height (m) 163.3(1.6) 169.0 (1.7) 
BMI pre-pregnancy (kg/m
2
) 
a
 40.3 (1.8) 22.4 (1.0) 
Weight gain in pregnancy 
b
 8.4 (1.3) 14.3 (1.8) 
Systolic blood pressure (mmHg)  124.3 (2.7) 117.1 (5.1) 
Diastolic blood pressure (mmHg) 
c
 82.5 (2.2) 74.2 (2.0) 
Frequency cardiac 79.6 (1.7) 79.0 (3.7) 
Gestational age 38.4 (0.3) 38.7 (0.2) 
Glucose (mmol/L)  4.3 (0.1) 4.0 (0.3) 
Total cholesterol (mmol/L) 6.9 (0.4) 7.3 (0.1) 
Triglycerides (mmol/L) 2.8 (0.2) 2.3 (0.3) 
AST (U/L) 15
 d
 (12.2-26.5
d
) 14.8 (0.7) 
ALT (U/L) 13
 d
 (9.2-17.7
d
) 12.1 (1.1) 
ALP (U/L) 124.2 (11.1) 115.0 (12.6) 
GGT (U/L) 11.0 (1.7) 8.8 (1.5) 
Leptin (L) (ng/ml) 
a
 38.5 (2.2) 15.2 (3.3) 
Adiponectin (A) (mg/ml) 6.0 (0.7) 7.5 (1.4) 
L/A 
a
 7.7 (0.6) 2.6 (0.5) 
B     
Newborn features Ob-newborns (n=16) Co-newborns (n=7) 
Birth weight (kg) 3162 (0.1)  3401 (0.1) 
Length (cm) 49.6 (0.7)  50.8 (0.7) 
Head circumference (cm) 34.0 (0.4)  34.8 (0.3) 
Apgar 1’ 7.0
 d
 (7.0-8.0 
d
) 7.8 (0.2) 
Apgar 5’ 9.0
 d
 (8.5-9.0 
d
) 8.7 (0.1) 
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Table 3. Immunophenotyping of hA-MSCs isolated from obese (Ob-) and control (Co-) pregnant women 
 
 Ob-hA-MSCs  Co-hA-MSCs   
Not expressed antigens  
    
Fluorochrome  Antigen  MFI 25th-75th Percentiles   MFI 25th-75th  Percentiles p Value 
FITC CD31 364.0 278.3-511.3   306.5 286.8-368.0 0.3254 
  CD40 444.0 336.5-568.3 
 
388.0 357.0-457.8 0.4824 
  CD243 363.0 292.3-528.3 
 
307.5 274.0-378.3 0.2061 
  HLA-DR 355.0 283.8-530.0 
 
297.0 272.5-374.8 0.2415 
  NC  325.0 250.0-516.3   279.0 218.8-418.8 0.4260 
PE CD14 166.5 125.5-197.8   134.5 124.5-157.8 0.2815 
  CD16 36.0 11.5-71.7 
 
65.5 50.5-72.0 0.2407 
  CD117 142.5 109.5-189.3 
 
121.0 116.0-176.8 0.6065 
  CD133 95.5 80.5-112.8 
 
87.5 76.50-110.5 0.5423 
  NC  115.5 91.75-181.5   102.5 93.25-135.0 0.5427 
APC CD15 122.0 91.0-283.5   122.5 80.0-162.5 0.6065 
  CD36 241.5 194.0-388.5 
 
200.5 145.5-267.3 0.2417 
  CD271 208.0 127.0-296.5 
 
170.0 127.5-233.3 0.6065 
  CD338 200.5 106.5-373.0 
 
107.5 101.8-146.8 0.1223 
  CD19 192.0 154.0-241.3 
 
144.0 120.3-182.2 0,1012 
  CD28 91.0 5.2-228.5 
 
85.5 0-122.0 0.1722 
  CD33 147.5 10.0-189.5 
 
105.5 90.0-132.3 0.6734 
  CD34  186.5 105.0-241.5 
 
133.0 17.5-206.0 0.4250 
  NC  169.0 99.5-244.8   92.0 64.0-204.0 0.2061 
Per Cp CD45 215.5 133.8-251.3   167.0 146.0-208.0 0.6734 
  NC  305.0 252.0-483.3   288.5 261.3-348.8 0.7431 
Expressed antigens  
    
Fluorochrome  Antigen  MFI 25th-75th Percentiles   MFI 25th-75th  Percentiles p Value 
FITC CD9 3,538.0 2,172.0-6,871.0   2,156.0 1,743.0-3,495.0 0.2417 
  CD26 1,287.0 651.8-3,235.0 
 
1,308.0 742.3-1,920.0 0.9626 
  CD47 1,339.0 980.3-2,312.0 
 
1,287.0 1,106.0-1,344.0 0.4824 
  CD49d 1,185.0 946.8-1,393.0 
 
941.0 708.3-1,140.0 0.2061 
  CD71 1,271.0 796.5-2,147.0 
 
1,093.0 897.0-1,538.0 0.7431 
  CD90 37,140.0 22,740.0-52,690.0 
 
36,210.0 21,640.0-50,260.0 0.8149 
  CD324 517.0 463.0-551.0 
 
436.0 375.0-545.0 0.3027 
  HLA-ABC 9,363.0 4,033.0-14,180.0   5,424.0 3,987.0-6,539.0 0.1223 
 NC  325.0 250.0-516.3   279.0 218.8-418.8 0.4260 
PE CD13 9,802.0 6,786.0-17,130.0   3,950.0 3,634.0-4,961.0 0.0043 a 
  CD56 496.0 293.8-711.0 
 
528.0 151.0-1,048.0 0.9626 
  CD58 2,432.0 1,723.0-2,792.0 
 
2,009.0 1,798.0-2,459.0 0.5427 
  CD99 405.0 296.5-586.3 
 
467.5 360.5-651.0 0.3736 
  CD105 652.0 507.0-1,329.0 
 
790.0 746.0-847.8 0.6734 
  CD151 16,010.0 10,970.0-21,430.0 
 
19,410.0 11,090.0-23,690.0 0.4260 
  CD166 5,215.0 3,551.0-7,382.0 
 
4,634.0 3,962.0-5,608.0 0.6734 
 CD200 722.5 205.8-1,699.0   1,137.0 631.5-1,444.0 0.3736 
  NC  115.5 91.7-181.5   102.5 93.2-135.0 0.5427 
APC CD10 1,247.0 999.3-2,319.0   1,890.0 1,122.0-3,031.0 0.3736 
  CD29  45,150.0 25,130.0-54,610.0 
 
24,240.0 17,660.0-40,000.0 0.0832 
  CD44 11,440.0 8,186.0-16,290.0 
 
7,259.0 6,613.0-9,753.0 0.0678 
  CD54 9,910.0 5,404.0-14,260.0 
 
10,660.0 9,486.0-24,670.0 0.3736 
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FIG. 1. Expression of CD13 antigen in control (Co-) and obese (Ob-) pregnant women. A: Ob-hA-MSCs expressed significantly higher amounts (at Mann-
Whitney test) of CD13 surface antigen compared with Co-hA-MSCs (P=0.0043); B: serum levels of CD13 were significantly higher both in Ob- than in 
Co-not pregnant women (P=0.02) and in Ob- than in Co-women at delivery (P=0.002); C: Serum CD13 levels were correlated with CD13 surface 
expression levels in Ob-pregnant women (r<sup>2</sup>=0,84; P<0.0001). The box plots provide a vertical view of the data expressed as median, 25th 
percentile, 75th percentile and extreme values. 
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FIG. 2. Adipogenic potential in Ob-hA-MSCs and in Co-hA-MSCs. The statistically significant higher mRNA expression levels of PPARγ (P=0.02) (A) 
and of aP2 (P=0.03) (B) measured 14 days after the adipogenic induction, indicated increased adipogenesis in Ob- versus Co-hA-MSCs. (C) The higher 
adipogenesis in Ob- than in Co-hA-MSCs was also confirmed by Oil-Red staining [Abs (550 nm) = 0.6 and 0.4, P=0.02, respectively]. 
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FIG. 3. Role of CD13 in adipogenesis. (A) mRNA expression levels of CD13 were significantly higher in Ob- than in Co-hA-MSCs at day 0 (P=0.02), day 
2 (P=0.02) and day 4 (P=0.04) when cultured with adipogenic medium. CD13 mRNA expression was switched-off in Ob-hA-MSCs after CD13 silencing 
with shRNA. (B) At day 4 of adipogenic induction, PPARγmRNA expression levels that were significantly higher in Ob-hA-MSCs than in Co-hA-MSCs 
(P=0.01), decreased to the levels detected in Co-hA-MSCs after CD13 silencing (P=0.71), which indicates that CD13 enhances adipogenesis in hA-MSCs. 
n.s.: not statistically significant difference. 
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Supplementary Figures legend 
 
Supplementary Figure 1: Morphology of hA-MSCs isolated from pregnant women. A similar 
fibroblastic-like shape was observed in three Ob- (A) and three Co- (B) hA-MSCs  after 4 population 
doublings by phase contrast light microscopy (magnification 10x). 
 
Supplementary Figure 2: CD13 expression on Co- and Ob-hA-MSCs treated with 0.8 ng/mL or 
12.5 ng/mL IFN-g for 24 h. CD13 expression significantly increased on membranes of Co-hA-MSCs 
treated with 12.5 ng/mL IFN-g (P=0.04) versus untreated counterpart cells, whereas there was a slight, 
not significant increase, in treated Ob-hA-MSCs versus untreated cells.  
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Supplementary Table 1: Antibody cocktails contained in each tube for hA-MSCs 
immunophenotyping by flow cytometry. 
Tube CD Antigens 
1 Anti-CD90-FITC (clone 5E10)/anti-CD13-PE (clone L138)/anti-CD45-PerCP (clone 2D1)/anti-CD34-APC (clone 
8G12) 
2  Anti-HLA-DR-FITC (clone l243)/anti-CD14-PE (clone MΦP9)/anti-CD45-PerCP (clone 2D1)/anti-CD29-APC 
(clone MAR4) 
3 Anti-CD243-FITC (clone17F9)/anti-CD56-PE (clone MY31)/anti-CD45-PerCP (clone 2D1)/anti-CD44-APC (clone 
g44-26) 
4  Anti-CD324-FITC (clone 36)/anti-CD105-PE (clone 266)/anti-CD45-PerCP (clone 2D1)/anti-CD338-APC (clone 
5D3) 
5 Anti-CD71-FITC (clone L01.1)/anti-CD56-PE (clone MY31)/anti-CD45-PerCP (clone 2D1)/anti-CD28-APC (clone 
CD28.2) 
6 Anti-CD90-FITC (clone 5E10)/anti-CD200-PE (clone MRC OX-104)/anti- CD45-PerCP (clone 2D1)/anti-CD33-
APC (clone p67.6) 
7  Anti-HLA-A,B,C-FITC (clone G46-2.6)/anti-CD16-PE (clone B73.1)/anti-CD45-PerCP (clone 2D1)/anti-CD36-
APC (clone CB38 NL07) 
8 Anti-CD90-FITC (clone 5E10)/anti-CD200-PE (clone MRC OX-104)/anti-CD45-PerCP (clone 2D1)/anti-CD34-
APC (clone 8G12) 
9 Anti-CD9-FITC (clone ML-13)/anti-CD133-PE (clone ACC133/1)/anti-CD45-PerCP (clone 2D1)/anti-CD10-APC 
(clone HI10A) 
10 Anti-49d-FITC (clone R1-2)/anti-CD58-PE (clone L306.4)/anti-CD45-PerCP (clone 2D1)/anti-CD271-APC (clone 
ME20.4-1.H4) 
11 Anti-CD31-FITC (clone WM59)/anti-CD117-PE (clone 104D2)/anti-CD45-PerCP (clone 2D1)/anti-CD81-APC 
(clone JS-81) 
12 Anti-CD26-FITC (clone L272)/anti-CD99-PE (clone TU12)/anti-CD45-PerCP (clone 2D1)/anti-CD19-APC (clone 
SJ25C1) 
13 Anti-CD40-FITC (clone 53C)/anti-CD151-PE (clone 14A.H1)/anti-CD45-PerCP (clone 2D1)/anti-CD54-APC 
(clone HA58) 
14 Anti-CD47-FITC (clone B6H12)/anti-CD166-PE (clone 3A6)/anti-CD45-PerCP (clone 2D1)/anti-CD15-APC 
(clone HI98) 
  
FITC: fluorescein isothiocyanat; PE: R-Phycoerythrin; PerCP: peridinin-chlorophyll-protein complex; APC: 
allophycocyanin  
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